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Abstract
Long-term feeding studies in rats have been carried out with a 
number of compounds known to produce liv e r  enlargement in th is species, 
and sequential measurements of hepatic enzymes have been correlated 
with histochemical, histological and ultrastructural changes in the liv e r .
Administration of butylated hydroxytoluene (BHT) or safrole for 1 
week in the d iet at levels of 0.4 and 0.25% respectively produced liv e r  
enlargement and induction of the microsomal drug metabolising enzymes. 
During continued administration of BHT for up to 75 weeks this response 
was maintained unaltered and without production of liv e r  in ju ry .
However, in the case of safrole, drug metabolising enzyme a c tiv ity  fe ll  
to around control levels by week 8 but the liv e r  remained enlarged. 
Cytopathological changes, indicated histochemically by autophagy and 
depression of glucose-6-phosphatase, were observed at this stage. These 
.became progressively more severe leading to focal necrosis and the 
development around week 60 of nodular hepatic lesions. A s im ilar 
sequence of events was in itia te d  a fte r only 1 week in rats fed a d iet 
containing 1.0% Ponceau MX, a compound producing marked liv e r  
enlargement but only weak stimulation of drug metabolising enzyme 
a c tiv ity . Thus, where liv e r  enlargement is unaccompanied by drug 
metabolising enzyme induction, or where such enzyme induction is only 
transitory, gross pathological changes may develop in the enlarged liv e r .
The nodular hepatic lesions produced by safrole and Ponceau MX have 
been compared with hyperplastic liv e r  nodules induced by the 
hepatocarcinogen 2-acetyl aminofluorene and found to d if fe r  in some 
aspects o f th e ir biochemical and biological characteristics.
Finally , some in vitro  studies were conducted to explore the 
unusual interaction of safrole with hepatic microsomal cytochrome 
P450. The stable binding to cytochrome P450 of a species apparently 
formed during the metabolism of safrole could be reversed by certain  
alternative substrates of cytochrome P450 with the production of 
novel spectral changes.
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1.1 Chemically-Induced Liver Enlargement
The liv e r  is affected by the administration of foreign compounds 
more frequently than any other organ of the mammalian body (Rowe et a l . ,  
1959; Weil and McCollister, 1963). Thus, a very large number of 
compounds, d iffering  widely in pharmacological ac tiv ity  and chemical 
structure, produce an increase in the weight of the liv e r  when 
administered to experimental animals (Barka and Popper, 1967;
Golberg, 1966; Kunz et aj_., 1966a; S ilvestrin i et al_., 1966; Smyth et 
a l . ,  1952). Such liv e r  enlargement may or may not be associated w ith, 
or followed by, histopathological alterations depending upon the type of 
compound, the dose, the age and species of animal and the mode and 
frequency of administration. Accordingly, the response of the liv e r  to 
foreign compounds may range from enlargement without histological 
change to advanced structural changes, such as cirrhosis or hyperplastic 
nodules, and neoplasia. The induction of frank liv e r  cancer by such 
compounds as dimethylnitrosamine (Magee and Barnes, 1956) or aflatoxins  
(Lancaster et a jL , 1961), may present few problems of in terpretation  
from a pathological, and perhaps even a toxicological point of view. 
However, the interpretation of other chemically-induced hepatic e ffects , 
including some pathological changes such as hyperplasia following cell 
damage or death, remains a controversial issue (Bonser and Roe, 1970; 
Grasso et al_., 1969; 1974). Hyperplastic liv e r  nodules are often 
preceded by liv e r  enlargement without overt histological abnormalities 
but the mechanism of th e ir formation and th e ir toxicological 
significance is largely unknown. I t  was against this background that 
the work recorded in this thesis was undertaken. The observations 
made are in part relevant to liv e r  enlargement per se and i t  is  
therefore appropriate to b rie fly  review some aspects of this subject.
1.2 Types of Liver Enlargement
Chemically-induced liv e r  enlargement most frequently derives from 
changes in the parenchymal cel Is (hepatocytes) despite the fact that these 
comprise only 50-60% of the total cell population of normal mammalian 
l iv e r  (Steiner et aj_., 1966). These changes may involve an increase in 
the size of individual hepatocytes (hypertrophy)9 an increase in the 
number of hepatocytes as a result of m itotic division (hyperplasia), 
an increase in ploidy - also considered to represent hyperplasia (Barka 
and Popper, 1967) - or a combination of these processes to varying extents 
according to the particular compound administered (Koransky and Schulte- 
Hermann, 1970). The contribution of each or a ll of these processes to 
l iv e r  enlargement may vary for a particu lar compound depending upon the 
dose level and mode and frequency of administration. Less frequently the 
liv e r  may enlarge as a result of hypertrophy of the reticuloendothelial 
system with storage of macromolecular m aterial, e.g. iron dextran 
(Golberg, 1966), or of disproportionate p ro liferation  of non-parenchymal 
ce lls , e.g. b ile  ductular cells as in ethionine intoxication (Farber, 1956).
1.3 Metabolism of Foreign Compounds
Many of the compounds known to produce liv e r  enlargement are 
metabolised, at least to some extent, by a non-specific, NADPH- and 
oxygen-dependent enzyme system localised in the endoplasmic reticulum  
of the hepatocytes. This enzyme system catalyses the oxidation of a wide 
range of foreign compounds, mediating such reactions as aromatic and 
aliphatic  hydroxylation, N-, 0 -, and S- dealkylation, N- and S- 
oxidation, deamination and dehalogenation (G ille t te , 1971; G ille tte  and 
Brodie, 1970; Parke, 1968). The overall reaction sequence may be
summarised as
RH + NADPH + H+ + 02 — » ROH + NADP + H20
one atom of the oxygen molecule being incorporated into the substrate 
and the other into water (Hayashi, 1962). Hence the use of the terms 
mixed function oxidase (Mason, 1957) or monooxygenase (Hayashi, 1962) 
in describing this enzyme system, which is frequently referred to 
simply as the the drug metabolising enzyme system. Despite the 
chemical d iversity  of the substrates for this system, i t  appears that a 
single, integrated electron transport chain is involved, rather than a 
m u ltip lic ity  of d ifferen t enzymes, and some progress has been made in  
elucidating the mechanisms involved in mixed function oxidation.
I t  is firm ly established (Cooper ert a_l_., 1965; Diehl e t a \_., 1969) 
that the introduction of oxygen into the substrate is mediated by a b- 
type haemoprotein termed cytochrome P450 (Omura and Sato, 1964).
j
According to current theory, substrates combine with the oxidised form 
of cytochrome P450 and this binding may be visualised in liv e r  slices 
or microsomal suspensions by difference spectrophotometry (C inti and 
Schenkman, 1972; Schenkman et _al_., 1967). The spectral change produced 
by most substrates comprises a maximum at about 390 nm and a minimum at 
about 425 nm: this is termed a type 1 spectrum. A lim ited number of 
compounds, usually containing nitrogen, give rise  to a spectral maximum 
at about 430 nm and a minimum at about 390 nm: th is is termed a type I I  
spectrum. These and other less usual forms of substrate interaction  
spectra are the subject of an extensive lite ra tu re  (e .g . Mannering,
1971; Remmer et a l . ,  1969; Schenkman, 1970; Schenkman et al_., 1972b, 
1973; Temple, 1972). Spectrally detectable binding is not, however, a 
prerequisite for metabolism (Chaplin and Mannering, 1970; Leibman and
Estabrook, 1971) and conversely, some compounds produce interaction  
spectra but are not metabolised (Burke, 1972). In the presence of 
NADPH, metabolism proceeds with the reduction of the substrate- 
cytochrome P450 complex. The flavoprotein NADPH-cytochrome c 
reductase is known to be involved in this electron transfer (Masters 
et al_., 1973) but whether this or a separate en tity  constitutes NADPH- 
cytochrome P450 reductase remains uncertain. The reduced complex next 
reacts with oxygen to form a reduced cytochrome P450-substrate-oxygen 
complex. I t  is thought that a second electron is then introduced, 
either from NADPH via cytochrome c reductase or from NADH via 
cytochrome b5 reductase, resulting in the formation of an active oxygen 
intermediate which decomposes to liberate  the oxidised substrate and 
oxidised cytochrome P450 (Baron et al_., 1973; Sasame et a1_., 1973).
The role of cytochrome P450 in drug metabolism has recently been 
reviewed (G ille tte  et a}_., 1972).
1.4 Induction of Foreign Compound Metabolism
Many compounds, when administered to experimental animals or man, 
e l ic i t  an increase in the a c tiv ity  o f the drug metabolising enzymes 
(Conney, 1967; Conney et al_., 1971; Ernster and Orrenius, 1965). Thss 
phenomenon, in addition to its  in trin s ic  in terest from a mechanistic 
point of view and as a model for the study of substrate-in itiated  
enzyme induction,rhas important practical implications since rate of 
metabolism is a prime determinant o f duration and intensity of 
pharmacological action. In view of the multi-step process involved, 
the increase in metabolic ac tiv ity  may result from one or more of a 
number of possible changes. Thus, administration of the widely studied 
compound phenobarbitone increases the amounts of both cytochrome P450
and NADPH-cytochrome c reductase (Orrenius et al_., 1965) and the rate
of reduction of cytochrome P450 (Gram et al_., 1968). In addition the
magnitude of both type I and type I I  substrate interaction spectra is
increased (Remmer et a K , 1969). The Vmax fo r type I substrate metabolism
is increased without change in the Km (Rubin et al_., 1964) w hilst in the
case of the type I I  substrate an ilin e , the is increased butmax
a ff in ity  for the substrate is decreased (Guarino et a ^ ., 1969). In 
contrast, administration of 3-methylcholanthrene increases the amount of 
cytochrome P450 (Hildebrandt et al_., 1968) but not the rate of its  
reduction (Gram et al_., 1968) or the a c tiv ity  of NADPH-cytochrome c
reductase (Hernandez et al_., 1967). The magnitude of the type I I  spectral
change is increased whereas the type I spectrum is e ither unaffected or 
decreased (Remmer et a l . ,  1969). Moreover, w hilst phenobarbitone 
induction does not change the pH at which the two maxima of the cytochrome 
P450-ethylisocyanide spectrum are of equal magnitude, 3-methylcholanthrene
treatment produces a decrease in the pH at which this equilibrium point
occurs (Sladek and Mannering, 1966). This change is paralleled by a 
s h ift in the absorption maximum of the cytochrome P450-carbon monoxide 
complex from 450 to 448nm (Kuntzman e t al_., 1969) or 446 nm (Hildebrandt 
et al_., 1968) and is considered to re fle c t the synthesis of a modified 
haemoprotein (Mannering, 1971).
These differences in the action of phenobarbitone and
3-methylcholanthrene on various component functions of the drug 
metabolising enzyme system are reflected in th e ir  respective effects on 
substrate metabolism. Thus, phenobarbitone, the effects of which are 
typical of the majority of inducing agents (Sher, 1971), stimulates most 
pathways of drug metabolism whereas polycyclic aromatic hydrocarbons, 
typ ified  by 3-methylcholanthrene, stimulate a more lim ited group pf
reactions (Conney, 1967). The induction of drug metabolism e lic ite d  by 
steroids - both naturally occurring and synthetic (Hamrick et a]_., 1973; 
Parke, 1972) -  and by polychlorinated bi phenyl s(Al vares et al_., 1973; 
Bickers et al_., 1974) has certain features in common with the effects  
both of phenobarbitone and 3-methylcholanthrene. Many other factors, 
genetic, hormonal, dietary and environmental are known to influence the 
ac tiv ity  of the drug metabolising enzymes (e .g . Anders, 1971; Flynn et 
a l . ,  1972; G ille tte , 1971; Gi 11 ette et al_., 1972; Kuntzman, 1969;
Vessel! et cfL, 1973) and the stimulatory effect of some inducers on 
hepatic blood flow (Ohnhaus et aj_., 1971) and b ile  flow (Klaassen, 1969) 
may also be important in determining the overall rate of drug 
elimination in the in tact animal. In this context, factors affecting  
the rate of drug metabolism in extrahepatic tissues may also be 
important: this topic has been reviewed by Lake et a]_. (1973) and, with 
particular reference to the gut, by Hartiala (1973). F in a lly , i t  may 
be noted that compounds such as phenobarbitone, w hilst stimulating a 
broad spectrum of drug metabolising enzyme a c tiv ity , may not stim ulate, 
or may even depress the a c tiv ity  of other microsomal enzymes such as 
glucose-6-phosphatase and ATP-ase (Ernster and Orrenius, 1965;
P la tt and C ockrill, 1967).
1.5 Pro liferation of Smooth Endoplasmic Reticulum
Induction of the drug metabolising enzymes is usually accompanied 
by pro liferation  of the smooth endoplasmic reticulum within the 
hepatocytes (Burger and Herdson, 1966; Jones and Fawcett, 1966;
Meldolesi, 1967), a response which appears to result both from 
enhanced membrane synthesis and decreased membrane degradation 
(Holtzman and G ille tte , 1968; Jick and Shuster, 1966; Shuster and 
Jick, 1966). The new membranes are believed to arise from a
'budding-off' of smooth-surfaced elements from the cisternal ends of 
the rough endoplasmic reticulum (Staubli e t al_., 1969).
Frequently the increase in smooth endoplasmic reticulum is dose- 
related and correlates with the degree of enzyme induction (Botham et 
a l . ,  1970; Conney, 1967). In fac t, Staubli et al_. (1969) have 
reported that in rats treated with phenobarbitone, the increase in 
the specific surface of the smooth endoplasmic reticulum is linearly  
related to the increase in drug metabolising enzyme a c tiv ity .
However, preparation of isolated smooth and rough endoplasmic 
reticulum has shown that drug metabolising enzyme ac tiv ity  is not 
confined to the smooth fraction (Holtzman et a K , 1968). Moreover, in  
the case of polycyclic hydrocarbons, enzyme induction is accompanied 
only by marginal increases in the amount of smooth endoplasmic 
reticulum (Fouts and Rogers, 1965)-. Equally, stimulation of smooth 
endoplasmic reticulum pro liferation  is not the sole perogative of 
enzyme inducers since several compounds are known to produce marked 
proliferation without increasing enzymic a c tiv ity  (Kunz et al_., 1966b) 
Many hepatotoxins and carcinogens can also e l ic i t  an increase in  
smooth endoplasmic reticulum (Meldolesi, 1967; Ortega, 1966;
Svoboda and Higginson, 1968) although the effects of such compounds 
are not restricted to this fraction of the liv e r  cell (Du Boistesselin 
1966; Rouiller, 1964). There is disagreement as to whether the smooth 
membranes so induced are identical with (Stenger, 1970), or d iffe ren t 
from (Arcasoy et al_., 1968), those induced by compounds regarded as 
non-hepatotoxic, e.g. phenobarbitone.
1.6 Liver Enlargement with Enzyme Induction
Enlargement of the liv e r  with p ro life ra tion  of the smooth 
endoplasmic reticulum may be brought about by a variety of chemicals
in the absence of any other histological or u ltrastructural changes 
(Barka and Popper, 1967; Fouts and Rogers, 1965; Wilson et al_., 1970). 
Where i t  is accompanied by induction of the drug metabolising enzymes, 
this response has been viewed as a physiological adaptation to 
increased metabolic demand - a so-called 'hyperfunctional' 
liv e r  enlargement (G ilbert and Golberg, 1965). The significance of 
this change in relation  to the concept of the no-effect level in 
toxicological assessment has been discussed by a number of authors 
(Hutterer et al_., 1969; P la tt and C ockrill, 1967, 1969; Popper, 1966; 
Wilson et al_., 1970; Wright et al_., 1972). I t  may be argued that the 
response is per se a beneficial one since i t  results in  accelerated 
metabolism, and hence excretion, of the administered compound. In 
this context G ilbert and Golberg (1967) showed that a fte r  
administration of butylated hydroxytoluene (BHT) fo r 5 days the total 
capacity of the ra t fo r the metabolism of BHT increased from 42 to 
330 mg/kg body weight/day. This induction of metabolism was 
paralleled by a sharp fa ll  in the body fa t concentration of BHT 
(G ilbert and Golberg, 1965). After pretreatment with low doses of 
d ie ld rin , Hutterer et a h (1969) showed that rats could survive 
previously lethal doses without i l l  e ffe c t. DDT, likewise, is known 
to stimulate its  own metabolism (Morello, 1965) and to e l ic i t  a dose- 
related increase in liv e r  weight (Hoffman et a l . ,  1970). These effects 
appear to be readily reversible a fte r  short-term administration of the 
inducing compound and this finding has strengthened the concept of an 
adaptive, hyperfunctional liv e r  response (Golberg, 1966). However, 
w hilst there other examples of arguably beneficial effects of enzyme 
induction, a number of situations are known in which a hyperfunctional 
l iv e r  response may have adverse consequences fo r the animal. This is 
mentioned in Chapter 8.
1.7 Liver Enlargement without Enzyme Induction
Enlargement of the liv e r  may not always be associated with increased 
drug metabolising enzyme a c tiv ity . Thus, administration of carbon 
disulphide to rats results in an increase in liv e r  weight with increased 
total liv e r  protein content but decreased drug metabolic a c tiv ity  (Bond 
and De Matteis, 1969). Chloroform, halothane and methoxyflurane cause 
marked proliferation of the smooth endoplasmic reticulum without enhancing 
enzyme a c tiv ity  (Kunz et a l.., 1966b). A sim ilar dissociation of liv e r  
enlargement from increased drug metabolising enzyme a c tiv ity  is seen with 
coumarin aid 2j4-xylidine: both of these compounds give rise to early  
histochemical, but not h isto logical, changes indicative of hepatotoxicity 
(Grasso et al_., 1974) and, on prolonged administration, to the 
development of gross pathological changes in the liv e r  (Hazleton et a l . ,  
1956; Lindstrom et al_., 1963). In the case of d ie ld rin , in i t ia l  
hyperfunctional liv e r  enlargement gives way, on continued administration 
of the compound, to a situation in which increased liv e r  weight and 
proliferation of the smooth endoplasmic reticulum are associated with a 
return of drug metabolising enzyme a c tiv ity  to control levels 
(Hutterer et al_., 1969). These changes occur while the liv e r  remains 
histologically normal but prolonged administration of d ie ld rin  is known 
to produce histopathological changes in the ra t liv e r  (Deichmann et a l . ,  
1970). This type of liv e r  response where increased liv e r  size and 
protein content precede the ultimate development of liv e r  in jury has 
been referred to as 'anabolic hepatotoxicity' (Madhaven et al_., 1970; 
Popper, 1966). Madhaven et al_. emphasise the d istinction between 
'anabolic' and 'catabolic' hepatotoxicity, the la t te r  produced by such 
compounds as dimethylnitrosamine and a fla to x in , being characterised by 
an early inhibition of protein synthesis, a rapid decline in drug 
metabolising enzyme a c tiv ity  and no increase in liv e r  weight.
1.8’ Nature of the Proposed Project
The depressive effects of potent hepatotoxins and carcinogens on 
drug metabolising enzyme ac tiv ity  are well known (Baldwin and Barker, 
1965; Barker and Smuckler, 1972; M ille r et al_., 1958; Trams et aj_., 1961) 
Less attention has been directed to compounds possessing a lower order of 
hepatotoxicity, whose effects may be manifest only a fte r  prolonged 
administration of high doses. The findings mentioned above, showing 
that liv e r  enlargement produced by such compounds is unaccompanied by any 
sustained induction of drug metabolising enzyme a c tiv ity , raise the 
possib ility  that the inadequacy or fa ilu re  of this enzyme response may 
be important in the subsequent development of pathological changes in 
the liv e r . Such a hypothesis is a corollary of the view that liv e r  
enlargement accompanied by drug metabolising enzyme induction is an 
adaptive response of benefit to the liv e r .
For the present study, therefore, four model compounds were selected 
a ll of which were known to produce liv e r  enlargement, and, at least 
in i t ia l ly ,  induction of the drug metabolising enzymes, but which 
ultimately give rise to widely d ifferin g  pathological changes in the 
liv e r . Sequential observations have been made during the prolonged 
administration of these compounds to rats with the aim of attempting to 
correlate biochemical and:histochemical changes with morphological 
alterations in the liv e r . The compounds selected are described below, 
lite ra tu re  relevant to each being b r ie fly  reviewed in the appropriate 
experimental chapters.
Butylated hydroxytoluene - a synthetic, hindered phenolic antioxidant 
which produces a typical hyperfunctional liv e r  enlargement without 
apparently giving rise to any pathological changes in the l iv e r , even 
a fte r life-span administration.
Safrole and Ponceau MX - a  naturally occurring food flavour and a 
synthetic azo food colour respectively, prolonged administration of 
which in high doses leads to the development of hepatic lesions 
variously described as nodular hyperplasia and benign and malignant 
neoplasia.
2-Acetyl ami nofluorene - a model carcinogen known to produce a high 
incidence of hepatocellular carcinoma, the development of which is  
preceded by the early appearance of hyperplastic liv e r  nodules.
Such a study, in addition to its  academic in teres t, was considered 
important in view of the widespread occurrence of enzyme inducers in 
the human environment, the paucity of data concerning the long term 
effects on drug metabolising enzyme a c tiv ity  of compounds not acutely 
toxic to the liv e r , and the current debate as to the toxicological 
significance of liv e r  nodules. Resolution of the nature of the la t te r  
is an important practical problem since several compounds which give 
rise to this lesion have extensive u t i l i t y ,  e.g. DDT (Fitzhugh and 
Nelson, 1947), safrole (Long et al_., 1963), carbon tetrachloride  
(Confer and Stenger, 1966; Reuber and Glover, 1967) and Ponceau MX
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2.1 Materials
a) Chemicals Administered to Rats
Butylated hydroxytoluene (Topanol OC), pharmaceutical grade, was a g if t  
from I .C . I .  L td ., Heavy Organic Chemicals Division, Billingham, Teeside. 
Safrole was purchased from Hopkin and Williams L td ., Chadwell Heath, Essex 
and the stated purity was > 98%. Ponceau MX was a g i f t  from Williams 
(Hounslow) L td ., Hounslow, Middlesex. A ll o f the dye used was from the same 
batch and conformed to British Standard N°* 3671:1963 for Ponceau MX for use 
in foodstuffs. 2-Acetyl aminofluorene (M.pt. 192 - 196°C) was obtained from
Ralph Emmanuel L td ., Wembley, Middlesex. 2 ,4 - , 2 ,5 - and 2,6-Xylidine  
(4-ami no-1,3-dimethyl, 2-ami no-1,4-dimethyl, and 2-ami no-1,3-dimethyl benzene
"'a
respectively) were purchased from Koch Light Laboratories L td ., Colnbrook, 
Bucks. Hexobarbitone, B.P. grade, was obtained from May and Baker L td ., 
Dagenham, Essex; sodium phenobarbitone, reagent grade, from BDH L td ., Poole, 
Dorset and 3-methylcholanthrene from Sigma (London).
2 ,4 -, 2 ,5- and 2,6-Xylidine were re d is tille d  under reduced pressure to gi 
colourless products. All other compounds were used without further 
purification .
b) Substrates
Aniline hydrochloride, biphenyl and sodium succinate were obtained from 
BDH L td ., cytochrome c (Type IIA ) , g lucose-6-phosphate dipotassium s a lt and 
sodium 3-glycerophosphate (Grade 1) from Sigma and ethylmorphine 
hydrochloride from May and Baker Ltd. Biphenyl was recrystallised from 
absolute ethanol, and sodium succinate from water. Other substrates were 
used as purchased.
For the studies in Chapter 7, substrates were obtained as follows: 
benzene, toluene, ethylbenzene, butylbenzene, he*ylbenzene, isopropylbenzene,
hexane, cyclohexane, carbon tetrachloride, 4-methoxyphenol, 4 ,4 '-b ipyrid y l 
and nicotinamide from B.D.H. Ltd.; napthalene and allylbenzene from Koch 
Light Laboratories Ltd.; butylated hydroxyanisole from May and Baker Ltd.;
N,N'-dimethylaniline and eugenol from Hopkins and Williams Ltd.;
4-phenylanisole, piperonal, piperonyl butoxide and aminopyrine from Phase 
Separations Ltd ., Deeside Industrial Estate, Queensferry, F lin tsh ire;
4 ,4 '-dimethyl biphenyl from Ralph Emmanuel Ltd. The octyl carbamate and 
dodecylcarbamate were synthesized by Dr. B. Houston in these laboratories. 
Imipramine was kindly donated by Biorex Laboratories L td ., London and SKF 
525A kindly donated by Smith, Kline and French Ltd., Welwyn Garden C ity , Herts.
c) Enzymes and Cofactors
Nicotinamide adenine dinucleotide phosphate (NADP), its  reduced form 
NADPH, reduced nicotinamide adenine dinucleotide (NADH) and glucose-6- 
phosphate (disodium sa lt) were in i t ia l ly  obtained from Boehringer (London)
Ltd. and subsequently from P-L Biochemicals (International Enzymes L td ., 
London). Glucose-6-phosphate dehydrogenase (Type X II) and Protease V II were 
purchased from Sigma.
d) Other Chemicals
2- and 4-Hydroxybiphenyls, 4-anrTnophenol and formaldehyde were obtained 
from B.D.H. L td ., bovine serum albumin and 2-(p-iodophenyl )-3 -(p -n itrophenyl) 
-5-phenyl-tetrazoliurn chloride from Koch Light, and te tra n itro  blue 
tetrazolium and Fast Blue RR sa lt from Sigma. Most other chemicals were 
obtained from B.D.H. Ltd. and were usually of reagent grade.
Gases were supplied by B.O.C. L td ., Crawley and, with the exception of 
ethanol (99.9% and 96%) from James Burroughs Ltd ., London, solvents were 
obtained from B.D.H. Ltd. Water was g lass-d is tilled  and stored in poly­
propylene containers.
2.2. Animals
a) Protocol of Usage
Wistar albino rats (Porton s tra in , random bred in closed colony) were 
supplied by the University of Surrey Animal Breeding Unit. For one series 
of experiments with 2-acetyl aminofluorene male rats were used  ^ for a ll other 
experiments female rats were used.
For the chronic dietary administration of test compounds, five week old 
(80-1OOg) female rats were randomly assigned to control and treated groups 
and housed in polypropylene cages with aluminium lids (26" x 13.5" x 8" ), 5 
rats per cage, on "Stero lit" bedding (W.P. Usher and Company, L td ., London). 
Prior to administration of the test d ie t, a ll rats were maintained on SpiTiers 
Laboratory Animal Diet N0# 2 for 7 days to allow acclimatisation to the powder 
form of d ie t. At a ll times animals were allowed access to d iet and tap water 
i^d libitum  and bedding was changed at weekly in tervals . Measurements o f body
j .
weight (individual) and food intake (per cage) were made at regular in tervals. 
Food intake was monitored over periods o f 3 consecutive days and accurate 
measurement was fa c ilita te d  by the use of stainless steel food pots,specially  
designed to minimise diet sp illage, which were kindly loaned by the British  
Industrial Biological Research Association, Carshalton, Surrey,
Where compounds were administered other than in the d ie t, rats were 
treated as above but were maintained on SpiTiers Laboratory Animal Diet N°* 1 
(pelleted form of N°* 2) and food intake was not measured.
The temperature and re la tive  humidity of the animal room was regulated 
to 22° C and 50% respectively and lighting was time-switched on at 06.30 and 
o ff at 18.30 hours.
b) Preparation of Diets
For dietary administration, compounds were mixed into the stock powdered 
diet using a Hobart food mixer (model A 200). BHT, safrole and xylidine  
diets were prepared by adding the compounds dissolved in a quantity of 
groundnut o il ("Saladin", Van den Burghs & Jurgens L td ., London) such as to 
raise the fa t content of the d iet by 21 (w/w). The groundnut o il was free 
from known additives (A. Rahim, personal communication, 1971). Control d iet 
was prepared by adding 2% (w/w) ground nut o il to the stock powdered d ie t. 
Ponceau MX and 2-acetyl aminofluorene diets were .prepared by dry^mixing the 
compounds into control d iet. In the case of the carcinogen, 2-acetyl-  
aminofluorene, mixing was carried out by shaking in a tig h tly  sealed glass 
ja r .
Diets were normally prepared at weekly intervals in 4 or 8 kg amounts and 
were mixed for 15 minutes at the slowest speed of the Hobart mixer. Oil 
solutions were in i t ia l ly  mixed ( 2 - 3  minutes) into 25% of the to ta l
i
quantity of d iet and this premix subsequently dispersed into the remainder.
On account of th e ir  v o la t i l i ty ,  safrole and the xylidine isomers were added to 
the d iet at a level 10% higher than the desired concentration (see Borchert 
et al_., 1973b; Hagen et al_., 1967) and were mixed for 10 minutes. A ll diets 
were stored in tig h tly  sealed dark glass jars at room temperature.
The distribution of Ponceau MX in the diet was shown to be even by 
reading aqueous extracts of aliquots of the d iet at 505nm: even d istribution  
was also shown for the 2-acetyl aminofluorene d ie t, ethanol extracts being 
read at 288nm. The other diets were not checked for uniformity o f mixing.
c) Administration of Compounds Other than in the Diet 
Compounds were administered by intraperitoneal in jection as follows 
unless stated otherwise:-
St/dium Phenobarbitone - 80 mg/kg daily fo r 4 days as a 5% (w/v) aqueous
solution.
3-Methylcholanthrene - 30 mg/kg daily for 2 days as a 1% (w/v) solution in 
groundnut o i l .
Safrole - 150 mg/kg daily for 4 days as a 7.5% (w/v) solution in groundnut
o i l .
Control animals normally received an equal volume of solvent but in the case 
of comparative experiments where a ll three treatments were used, only 
groundnut o il controls were run. Animals were k ille d  16 hours a fte r the 
fina l in jection.
2.3. Methods
a) Preparation of Liver Fractions
Rats were fasted overnight and k ille d  by cervical dislocation between 
08.00 and 10.00 hours. Livers were rapidly excised and rinsed in ice-cold  
1.15% (w/v) KC1. After removal of any adhering fa t or connective tissue the 
liv e r  was blotted dry and weighed. A homogenate was prepared in 2 volumes 
of ice-cold 1.15% KC1 using four return strokes of a size C Potter-Elvejhem  
type, teflon-glass homogeniser (A.H. Thomas and Co., Philadelphia, U.S.A.) 
power driven at 2,950 r.p.m. The homogeniser was rinsed with a further 
v^olume of 1.15% KC1 and the resultant 25% homogenate centrifuged in 
polypropylene tubes at 10,000 £  av. for 20 minutes at 2° C (M.S.E. "High 
Speed 18", 8 x 50 ml angle rotor, 11,000 r.p .m .). The supernatant, referred  
to as the microsomal supernatant and comprising the microsomal and soluble 
cell fractions, was used for the determination of a number o f enzyme 
a c tiv itie s . Further centrifugation at 105,000£ av. fo r 60 minutes or 
J57,000£ av. for 40 minutes at 2° C (M.S.E. "Superspeed 50", 8 x 25 ml angle
rotor at 40,000 r.p.m. or 10 x 10 ml rotor at 50,000 r.p .m .) yielded a clear
supernatant, which was retained for assay of g lucose-6-phosphate dehydrogenase, 
and a microsomal p e lle t which, a fte r rinsing to remove residual supernatant, 
was resuspended with two return strokes in a size B homogeniser, in a medium 
and to a protein concentration as detailed under specific
procedures. To obtain a "washed" microsomal fraction , in which contamination
by haemoglobin and trapped soluble enzymes and cofactors is reduced to a 
minimum, the p e lle t was resuspended in 1.15% KC1 and recentrifuged at 105,000 
o r .157,000 £  av. for 60 or 40 minutes respectively. The supernatant was 
discarded and, a fte r rinsing, the pe lle t was resuspended as described above.
All of the above procedures were performed as rapidly as possible and at 
a temperature of 0 -  4° C. Prior to use, a ll fractions were kept at 0° C.
b) Measurement of Protein Concentration
The method of Lowry et al_. (1951) was used.
To 0.5 ml aliquots of tissue suitably diluted in 0.5N NaOH, was added 
5 ml of freshly prepared Lowry reagent (2% Na2C03, V%> CuS0if; 5H20, 2% Na K 
ta rtra te  100:1:1 by v o l.) .  A fter at least 10 minutes, 0.5 ml of Folin- 
Ciocalteu Phenol reagent (diluted 1:1 with water) was added and immediately 
vortex mixed. After allowing 30 minutes for development, the blue colour 
was measured at 720 nm in a Cecil model CE 272 u.v. spectrophotometer 
(Cecil Instruments L td ., Cambridge). All determinations were carried out in 
duplicate and blanks (0.5N NaOH) and standards (50 - 150 yg bovine serum 
albumin in 0.5N NaOH) were treated id en tica lly .
Where microsomes were suspended in the presence of glycerol, the 
procedure was modified since traces of glycerol were found to markedly 
enhance the intensity of the colour. A d ilu tion  of the glycerol buffer was 
prepared in exactly the same manner as the d ilu tion  of the microsomal 
suspension . 0.5 ml o f this solution was then added to the standards,
blanks and other samples not containing glycerol, and 0.5 ml 0.5N NaOH 
added to the glycerol-containing samples prior to addition of the Lowry 
reagent.
c) In Vitro Enzyme Assays: General Considerations
The following points apply to a ll the in v itro  enzyme assays performed.
1. All incubation systems were prepared in duplicate on ice. Where 
subsequent extraction of the reaction product was necessary, te flo n - 
stoppered test tubes were used.
2. Incubations were carried out in an atmosphere o f a ir  in a shaking 
incubator (Mickle Laboratory Engineering Co., Gomshall, Surrey) with a 
shaking rate of around 100 oscillations per minute.
3. An M.S.E. "Mistral 6L" centrifuge equipped with a 6X IL swing-out rotor 
was used for a ll centrifugations.
4. For a ll assays based on colourimetric measurement of the reaction 
product there was a linear relationship between optical density and amount 
of product formed over a concentration range greater than the extremes of 
v a ria b ility  encountered. Reaction rates were checked for lin e a rity  over the 
incubation time used.
5. Enzyme ac tiv itie s  and protein and cytochrome concentrations were 
normally expressed per gram wet weight liver*. In certain cases 
measurements were also expressed per milligram of microsomal protein and 
per total liv e r  per 100 grams body weight.
d) Succinate Dehydrogenase
This enzyme a c tiv ity  was measured as succinate - 2-(p-iodophenyl)-3- 
(p-nitrophenyl)-5-phenyl-tetrazolium chloride (INT) reductase, according to 
the'method of Pennington (1961). A d ilu tion of l iv e r  whole homogenate 
(1:100 in 1.15% KC1) was used in the following incubation system: -
Buffer ml.
Substrate ml.
Whole homogenate ml.
Test Blank
0.3 0.5
0.2
0.5 0.5
Incubation volume = 1.0 ml.
Buffer: Sodium phosphate 0.2M pH 7.4 containing 1.25 mg INT/ml 
Substrate: Sodium succinate 0.3M at pH 7.4
After incubation for 8 minutes at 37° C the reaction was terminated by 
addition of 1.5 ml of ice-cold 10% (w/v) trich loroacetic acid. At this  
stage tubes were routinely stored at -10° C for 48 hours. 5 ml of ethyl 
acetate was then added and the tubes shaken vigorously. A fter
centrifugation fo r 10 minutes at 2,000 r.p.m. to separate the phases, the 
reduced INT was measured in the ethyl acetate phase at 490 nm in the Cecil 
spectrophotometer. Enzyme ac tiv ity  was calculated using an extinction  
coefficient for reduced INT of 20.1 mM 1 cm"1 (Pennington, 1961).
e) G1ucose-6-Phosphate Dehydrogenase
The assay system of LGhr and Waller (1963) was u tilis e d , in which the 
reduction of NADP is followed at 340 nm. No correction fo r  
6-phosphogluconate dehydrogenase a c tiv ity  was made.
Into each of two 1 cm quartz cuvettes, the following additions were 
made:-
The cuvettes were placed in the forward cell compartment of a Pye-Unicam 
SP 1800 dual beam u.v. spectrophotometer at ambient temperature. After 
recording the basal absorption, 0.5 ml of buffer was added to the reference 
cuvette and the reaction started by addition of 0.5 ml 20mM glucose-6- 
phosphate to the test cuvette from an Oxford Sampler (Boehringer L td ., 
London). Liquid is expelled from this instrument su ffic ie n tly  fo rcefu lly  
to provide adequate mixing without removing the cuvette from the 
spectrophotometer. The increase in absorption at 340 nm was followed and 
from the in i t i a l ,  lin ear phase of the reaction, g lucose-6-phosphate 
dehydrogenase a c tiv ity  was calculated using an extinction coeffic ien t for 
reduced NADP of 6.22 mM 1 cm 1 (Dawes, 1967).
Tris-HCl 50 mM pH 8.1 ml. 
NADP solution 4 mM ml^ 0.5
1.9
105,000 £  liv e r  supernatant ml.. 0.1
f )  Ethylmorphine N-Demethylase
N-demethylation is a typical reaction of the microsomal mixed function 
oxidase system9 the formaldehyde produced being conveniently measured by the 
method of Nash (1953). The following incubation system, based on that of 
Holtzman £ t al_. (1968), was used:-
Buffer ml.
Semicarbazide solution ml. 
Cofactor solution ml. 
Substrate ml..
Microsomal supernatant ml. 
Standard ml.
Test Blank Standard
0.7 0.7 0.6
0.2  0.2  0.2
0.2  0.2  0.2
0.2  0 . 2*  0 . 2*
0.5 0.5 0.5
0.1 *
*  denotes added a fte r  the incubation. Incubation volume = 1.8ml 
Buffer: Tris-HCl, 0.3M pH 7.4
Semicarbazide solution: 2% (w/v) aqueous solution adjusted to pH 7.0
with NaOH.
Cofactor solution: each 0.2 ml contained NADP 2 ymol, glucose-6-
phosphate 20 ymol and magnesium, as MgCl29 10 ymol. 
Substrate: Ethyl morphine hydrochloride, 75 mM aqueous solution 
Standard: aqueous formaldehyde approximately 5 ymol/ml, standardised 
using an extinction coeffic ient of 8 mM”1 cm 1 fo r the 
HCHO-Nash reagent complex.
Incubation was for 10 minutes at 37° C and the reaction was terminated by 
addition of 1 ml 15% (w/v) zinc sulphate a fte r  placing the tubes into ice .
After addition of substrate and standard to the appropriate tubes, 1 ml of 
saturated barium hydroxide was added to each tube and the contents mixed.
All tubes were then centrifuged at 2,000 r.p.m. for 15 minutes at 4° C. 2 ml
of clear supernatant was pipetted into clean tubes and 2 ml of freshly 
prepared Nash reagent (0.4% (v/v) acetyl acetone in 4 M ammonium acetate) 
added. A fter heating at 37° C for 40 minutes with shaking, the resultant 
yellow colours were measured at 412 nm in the Cecil spectrophotometer.
g) Ani1i ne 4-Hydroxylase
Aniline is hydroxylated at the nitrogen atom and at the ring 2 -, 3- 
and 4- positions. The major metabolite is 4-ami nophenol and this can be 
measured by the indophenol reaction. The following incubation system, based 
on that of Guarino et a l . (1969), was used:-
Buffer ml.
Cofactor solution ml. 
Substrate ml.
Microsomal supernatant ml. 
Standard ml.
Test Blank Standard
0.7 0.7 0.6
0.2  0 . 2  0.2
0.5 0 .5* 0.5*
0.5 0.5 0.5
0.1 *
*  denotes added a fte r the incubation. Incubation volume = 1.9 ml 
Buffer and Cofactor solutions: as fo r f )  above
Substrate: Aniline hydrochloride, 40 mM aqueous solution adjusted to 
approx. pH 7 with NaOH.
Standard: 4-ami nophenol, 5 ymol/ml in 0.01N HC1.
Incubation was fo r 15 minutes at 37° C and the reaction was terminated by 
placing the tubes into ice and adding to each, approximately Ig solid NaCl. 
After addition of substrate and standard as appropriate, 12 ml of diethyl 
ether containing 1.5% (v /v) isoamyl alcohol was added to each tube and a ll 
tubes extracted for 20 minutes on a rotary shaker. Any emulsion formed was 
broken by centrifugation at 2,000 r.p.m. for 5 minutes. 10 ml of the ether 
phase was then pipetted into clean tubes, 4 ml o f 1% (w/v) phenol in 0.5M
tripotassium orthophosphate added and the tubes extracted for 10 minutes on 
the rotary shaker. A fter standing for at least 30 minutes, the aqueous 
phase was read at 620 nm in the Cecil spectrophotometer. I t  is preferable 
not to aspirate o f f  the ether phase: i f  this is done, fa ir ly  rapid fading 
of the blue colour in the aqueous phase ensues.
h) Biphenyl 4- and 2- Hydroxylase
Biphenyl undergoes hydroxylation at a number of positions, but in the 
rat the major metabolite is 4-hydroxybiphenyl. Smaller amounts of 
2-hydroxybiphenyl are produced and both isomers can be measured 
simultaneously since at pH 5 .5 , they exhibit d ifferen t fluorescence spectra. 
An assay based on that of Creaven £ t  al_. (1965) was used, comprising the 
following incubation system:-
2-OH 4-OH
Buffer ml.
Test
0.5
Blank
0.5
Standard
0.5
Standard
0.5
1.15% KC1 ml. 0.5 0.5 - -
Cofactor solution ml. 0.25 0.25 0.25 0.25
Substrate ml. 0.25 0.25* 0.25* 0.25*
Microsomal supernatant ml. 0.5 0.5 0.5 0.5
2-hydroxybiphenyl standard ml. - - 0.5* -
4-hydroxybiphenyl standard ml. - - 0.5*
*  denotes added a fter incubation. Incubation volume: 2.0 ml.
Buffer: Tris-HCl, 0.05 M pH 8.1
Cofactor solution: each 0.25 ml contained NADP 2 ymol, g lucose-6-phosphate
10 ymol, MgCl2 10 ymol.
Substrate: Biphenyl 12 mM in 1.15% KC1 containing 2.5% (w/v)
Tween 80 (polyo^yethylene sorbitan monooleate)
Standards: 2-hydroxybiphenyl 12 yg/ml in 10% (v /v ) aqueous ethanol 
4-hydroxybi phenyl 60 yg/ml " " " 1 "
After incubation at 37° for 15 minutes the reaction was terminated by
addition of 0.5 ml 2N HC1. Substrate and standard were added to the 
appropriate tubes. After addition of 8 ml n-heptane, a ll tubes were 
extracted for 15 minutes on the rotary shaker: any emulsion formed was 
broken by centrifugation at 2,000 r.p.m. for 15 minutes. 2 ml of the 
heptane was then transferred to clean tubes, 5 ml of 0.1 N NaOH added and 
the tubes extracted for a further 15 minutes on the rotary shaker. After 
centrifugation at 2,000 r.p.m. for 15 minutes, the heptane layer was 
aspirated o ff at the water pump. Hydroxybiphenyls in the NaOH phase were
stable in the dark at 4° C for at least 48 hours.
2 ml of the NaOH phase was pipetted into a fluorimeter cuvette and the
pH brought to 5.5 by addition of 0.5 ml 0.5N succinic acid. 2- and
4-Hydroxybiphenyls were determined using a Perkin Elmer MPF 3 
spectrophotofluorimeter at 290 nm (excitation) and 420 nm (emission) and
282 nm (excitation) and 340 nm (emission) respectively (Instrumental
readings).
I t  is necessary to read the 4-hydroxybiphenyl standard and a ll test 
samples and blanks at the wavelength maxima of both 2- and 4-hydroxybiphenyl, 
since 4-hydroxybiphenyl, under the conditions employed, fluoresces s ligh tly  
at the wavelength maxima of 2-hydroxybiphenyl. A correction factor for
subtraction from the 2-hydroxy readings of a ll test samples and blanks is
derived as follows:-
4-OH biphenyl reading x concn. 4-OH biphenyl standard 
4-OH biphenyl standard reading
Xmax 40H b iPheny'1
y /4-OH biphenyl standard reading
concn. 4-OH biphenyl standard
Amax 2-OH biphenyl
i )  NADPH-Cytochrome c Reductase
An assay system based on that of Gigon et a ] . (1969) was used, in  
which the absorption of reduced cytochrome c is followed at 550 nm.
Into each of the two 1 cm glass cuvettes, the following additions were 
made:-
Tris-HCl 0.02M in 1.15% KC1, pH 7.4 ml.
Potassium cyanide 3 mM ml.
Cytochrome c 0.15 mM ml.
Microsomal suspension, 25% in Tris/KCl as above ml.
0.5
1.0
1.0
0.1
The cuvettes were placed in the forward cell compartment of the SP 1800 
spectrophotometer at ambient temperature. After zeroing the recorder, 0.2 ml 
Tris/KCl was added to the reference cuvette and the reaction started by the
addition of 0.2 ml of NADPH regenerating system* to the test cuvette from an
Oxford Sampler (see 2 .3e). The increase in absorption at 550 nm was 
followed and from the in i t i a l ,  linear phase of the reaction, cytochrome c 
reductase a c tiv ity  was calculated using an extinction co effic ien t fo r
reduced cytochrome c of 27.7 mM"1 cm”1 (Mahler and Cordes, 1966).
*  The NADPH regenerating system was prepared in Tris-HCl 0 .02M/1.15% KC1, 
pH 7.4 and its  composition was as fo llow s:-
NADP 7.5 mM 
Glucose-6-phosphate 50 mM 
MgCl2 25 mM
Glucose-6-phosphate dehydrogenase 5 units/ml
j )  Formation In Vitro of the 455 nm Absorbing Species from Safrole
The metabolic transformation of safrole to a species which 
absorbs maximally at 455 nm is discussed in Chapters 4 and 7. The reactions 
involved are not clearly understood but the process can be followed by 
measuring the rate of increase in absorption at 455 nm on addition of 
safrole to an NADPH-reduced microsomal suspension. However, the species 
formed has a maximum at 427 nm in addition to that at 455 nm and the two 
^re in pH-dependent equilibrium. With increasing pH the magnitude o f the 
455 nm maximum is re la tive ly  increased. Since the relationship between the 
apparent amount of species formed and the rate of its  formation was not 
necessarily d irect, the "optimum pH" of 8.0 as determined, may therefore 
have l i t t l e  absolute significance. Rate measurements were made as described 
below.
Microsomal isuspension, 20 -  25 mg protein/ml in 0.1M sodium phosphate 
buffer pH 8 .0 , was diluted to a concentration of 0.5 -  1.0 mg protein/ml
i .
with the same buffer but which had previously been saturated with oxygen.
To 2.5 ml of this diluted suspension in a 1 cm glass cuvette was added 
10 yl lOOmM NADPH solution (fin a l cuvette NADPH concentration 0.4 mM). The 
cuvette was closed with a Subaseal stopper (Gallenkamp L td ., London) and 
placed in the primary cell compartment (thermostatted at 30° C) of a Perkin- 
Elmer model 356~dual wavelength,“ cloUb'le'15eafn spectrophotometer~set~fn"the—  
dual wavelength mode with sample and reference beams at 455 and 490 nm 
respectively and the range selector at 0.03 A fu ll:s ca le  deflection. A fter  
establishment of a stable baseline absorption, the reaction was started by 
in jection through the stopper of 5 yl 250 mM safrole in absolute ethanol 
(fin a l cuvette safrole concentration 0.5 mM). The cuvette was rapidly 
shaken, replaced in the spectrophotometer within 5 seconds and the increase 
in absorption at 455 nm monitored until maximal ( 1 - 5  minutes). The rate
of change in absorption was calculated from the in i t i a l ,  linear phase of the 
reaction and both th is , and the to tal absorbance change were expressed per 
mg protein.
The rate of reaction was shown to be lin early  related to the microsomal 
protein concentration over a range 0.5 - 1.5 mg protein/ml. I t  is 
preferable to s ta rt the reaction by the addition o f safrole rather than 
NADPH so that the basal absorption is recorded in the presence of NADPH.
I f  this is not done, the increase in absorption at 455 nm immediately upon 
addition of NADPH to microsomes from safrole-treated rats (see 7.3.1a) makes 
measurement of the basal absorption impossible.
k) Cytochrome b5
The method of Omura and Sato (1964) was s lig h tly  modified. 2.5 ml 
microsomal suspension (1 -  3 mg protein/ml in 0.2M sodium phosphate buffer 
pH 7.4) was pipetted into each of two 1 cm glass cuvettes, a small amount 
(1 -  2 mg) of solid NADH added to the sample cuvette and the reduced minus 
oxidised difference spectrum recorded between 390 and 500 nm using the 
SP1800 spectrophotometer. Cytochrome b5 content was calculated using an 
extinction coefficient of 185 mM 1 cm 1 for the extinction difference  
between 409 and 427 nm. (Omura and Sato, 1964).
1) Cytochrome P450: Carbon Monoxide Ligand
In its  reduced form the cytochrome P450 -  CO complex absorbs strongly 
at 450 nm. Measurement of this spectral maximum permits quantitation of the 
cytochrome (Omura and Sato, 1964).
2.5 ml aliquots of microsomal suspension (as k) above) were pipetted 
into each of two 1 cm glass cuvettes and reduced with a few mg of sodium 
d ith io n ite . CO was bubbled through the contents o f the sample cuvette for
30 seconds and the difference spectrum then recorded between 390 and 500 nm 
using the SP1800 spectrophotometer. Cytochrome P450 content was calculated 
from the extinction difference between 450 and 490 nm. In the absence of an 
accepted extinction coeffic ient for ra t liv e r  cytochrome P450, the original 
value calculated for rabbit liv e r  cytochrome P450 of 91 rnM 1 cm 1 (Omura and 
Sato, 1964) was u tilised .
m) Cytochrome P450: Ethyl isocyanide Ligand
Ethyl isocyanide combines with reduced cytochrome P450 to produce a 
spectrum with maxima at 430 and 455 nm which are in pH dependent equilibrium. 
The spectrum was generated according to the method of Imai and Sato (1967).
2.5 ml aliquots of microsomal suspension (1-2 mg protein/ml in 0.2M 
sodium phosphate buffer pH 7.6) were pipetted into each of two 1 cm 
stoppered glass cuvettes and reduced with a few mg of sodium d ith io n ite .
After closing the cuvettes (with Subaseal stoppers, 50 yl ethyl isocyanide
(1 mM aqueous solution) was injected into the sample cuvette, an equal volume 
of water added to the reference cuvette and the difference spectrum recorded 
between 390 and 500 nm in the SP1800 spectrophotometer. The extinction  
difference between 430 and 490 nm and 455 and 490 nm was measured.
n) Cytochrome P450-Substrate Interaction Spectra
These spectra were generated essentially according to the method of 
Schenkman et al_. (1967).
2.5 ml washed microsomal suspension (1 -  2 mg protein/ml in 0.1M 
sodium phosphate buffer pH 7.6) was pipetted into each of two 1 cm stoppered 
glass cuvettes. The cuvettes were closed with the subaseal stoppers, placed 
in the forward cell compartment of the SP1800 spectrophotometer (a t ambient 
temperature) and a baseline of equal lig h t absorbance recorded between 350
and 500 nm with the recorder set to 0.2A fu ll scale deflection. Substrate 
solution was then injected into the sample cuvette and an equal volume of 
solvent injected into the reference cuvette using a 10 yl syringe. After 
adjusting the recorder pen to baseline at 500 nm the difference spectrum was 
recorded over the baseline between 350 and 500 nm. For investigation of the 
kinetics of substrate interaction the desired range of substrate 
concentrations was achieved by making sequential additions of substrate 
solution (and solvent) into the same 2.5 ml aliquots o f microsomal 
suspension. After each pair of additions the cuvette contents were mixed 
and the recorder pen adjusted to baseline at 500 nm - a baseline for each 
substrate concentration having been recorded prio r to the f i r s t  addition of 
substrate. Substrate concentrations u tilised  for each compound are detailed  
in the relevant chapters. Stock substrate solutions were prepared either  
in water or absolute ethanol at a concentration such that the maximum 
required cuvette substrate concentration could be achieved by the addition 
of no more than 20 yl (to ta l) o f stock solution. The assumption was made 
that ethanol, which i ts e lf  interacts with cytochrome P450 at high 
concentrations, did not, at the concentrations involved, exert any e ffec t on 
the interaction of the substrate under study.
For investigation of the e ffect of one compound on the interaction spectrum 
of another, equal m icrolitre amounts o f the modifier solution were injected  
into both sample and reference cuvettes before recording the baselines.
Spectral changes were quantitated as the sum of the absorption 
difference between the maximum and the baseline and the baseline and the 
minimum at each substrate concentration. The spectral dissociation constant 
(Ks) and the maximum absorption change (A0D max) - analogous to the Km and 
\nax resPec^lve^  Michaelis-Menton enzyme kinetics -  were calculated from 
double reciprocal plots according to Lineweaver and Burk (1934). Straight 
lines were f it te d  to the experimental points using an O liv e tti Programma
101 programmed for linear regression analysis. Where biphasic plots were 
obtained, straight lines were in i t ia l ly  f it te d  by eye to determine the 
"break-point" in the data.
o) Isooctane Extraction of Microsomes
The procedure of Leibman and Estabrook (1971) was s lig h tly  modified.
To a 3.5 ml aliquot of microsomal suspension (30 mg protein/ml in 0.1M 
sodium phosphate buffer pH 7.6) was added 3.5 ml isooctane (2 ,2 ,4 -trim eth y l- 
pentane, spectroscopic grade) and the mixture s tirred  for 30 minutes in a ir  
at 4° C. Replicates in which 3.5 ml phosphate buffer replaced the isooctane 
were used as controls. In i t ia l ly ,  centrifugation at 105,000 £  av. fo r 60 
minutes at 4° C was employed to re-sediment the extracted microsomal p e lle t. 
However, increasing the centrifugation conditions to 157,000 £  av. for 60 
minutes was found to improve substantially the recovery of microsomal 
protein.
i  . . .
p) Digestion of Microsomes with "Protease V I I1
The action of certain purified proteolytic enzymes is e ffec tive  in 
bringing cytochrome b5, but not cytochrome P450, into solution. Loss of 
cytochrome P450 as P420 can be minimised by the use of high concentrations 
of glycerol (Ichikawa and Yamano, 1967). In this study, "Protease V II"  
(derived from Bacillus subtil is ) was used in a method developed from those 
of Mitani £ t  £]_.( 1971); and Nishibayashi and Sato,(1968)-
Washed microsomes were suspended to a concentration of 4 -  6 mg 
protein/ml in 0.1M Tris-HCl buffer pH 7.4 containing 20% v/v glycerol. 
"Protease V II" (5 mg/ml in the Tris/glycerol buffer) was added to 5 ml 
aliquots of microsomal suspension in 25 ml conical flasks to give a 
concentration of 40 yg enzyme/mg of protein. The volume was made to 6 ml 
with buffer and the flasks flushed with nitrogen (02 fre e )fo r 30 seconds
prior to sealing with rubber bungs. The flasks were then incubated at 0° C 
for 10 hours a fte r which the digested microsomes were re-sedimented by 
centrifugation at 157,000 £  av. for 60 minutes at 2° C. Control incubates, 
to which no "Protease V II" was added, were also taken through the above 
procedure. A fter centrifugation the supernatants were carefully withdrawn 
using a Pasteur pipette and the pellets resuspended in Tris/glycerol buffer 
to a concentration of 2 -  3 mg protein/ml. Both fractions were assayed fo r  
cytochrome b5, 455 nm absorption maximum (where applicable) and cytochrome 
P450. Up to 90% of the cytochrome b5 (but no cytochrome P450) was usually 
recovered in the supernatant w hilst recoveries of 70 - 90% of the 
cytochrome P450 content in the p e lle t were normali Increasing the incubation 
time did not substantially increase the so lub ilisation of cytochrome b5 
and tended to decrease the recovery of cytochrome P450.
q) Hexobarbitone Sleeping Time
The duration of sleep a fte r  a single dose o f hexobarbitone is dependent 
primarily on the rate at which the drug is metabolised. Measurement of 
sleeping time therefore provides an assessment of drug metabolising enzyme 
a c tiv ity  in the in tact animal.
Diet was withdrawn from the rats at 16.00 hours. At 11.00 hours the 
following day control and treated rats were injected in traperitoneally  with 
a 5% (w/v) aqueous solution of sodium hexobarbitone at a dose level of 
100 mg/kg bodyweight. Sleeping time was measured as the time between loss 
and regaining of the righting re flex . The time from in jection to loss of 
righting reflex -  the induction time -  was also measured. Righting re flex  
was defined as the a b ility  of an animal to righ t i t s e l f  three times within  
30 seconds.
r) Enzyme Histochemistry: General Considerations
In addition to the in vitro  biochemical assays, a number of enzyme 
ac tiv itie s  were examined histochemically in cryostat sections of liv e r  from 
the same rats. Enzyme histochemistry is valuable in providing qualitative  
data on in tra lobular and in trace llu la r alterations in enzyme a c tiv ity  and 
distribution . This can be particularly useful in establishing correlations 
with histological changes.
Small pieces of liv e r  ('v 4 mm cube) from the centre of the le f t  lobe were 
frozen onto microtome chucks standing in a shallow dish of ethanol/solid  
carbon dioxide mixture. These tissue blocks could be stored at - 20° C for 
at least 48 hours without detectable loss o f enzyme a c tiv ity . Sections were 
cut at the required thickness in a Slee Type HR cryostat at -  20° C and 
transferred d irec tly  onto glass microscope slides. These were stored in the 
cryostat (fo r up to 2 hours) prior to incubation,taking care to avoid 
dehydration of the tissue. Some of this work was carried out in the 
Histochemistry Section of the British Industrial Biological Research 
Association at Carshalton, in which case tissue was in i t ia l ly  frozen onto 
chucks cooled in liquid  nitrogen. The incubation conditions described for 
each assay were adequate for 6 - 8  slides with 3 sections per s lide .
s) G1ucose-6-Phosphatase
The method of Wachstein and Meisal (1956) was used in which inorganic 
phosphate released from the substrate is "captured" by lead ions in the 
medium and precipitated as lead phosphate. Treatment with ammonium 
sulphide converts this to the readily vis ib le black lead sulphide.
Sections of liv e r  (10y) were incubated at 37° C fo r 30 minutes in 
50 ml of solution containing Tris-maleate buffer pH 6 .7 , 40 mM; 
g lucose-6-phosphate (dipotassium sa lt) 1.5 mM and lead n itra te  4.5 mM.
After incubation,slides were washed in d is tille d  water and then taken 
through the following sequence of reagents:-
1) Dilute ammonium sulphide solution (4 drops BDH stock solution in
50 ml water): leave until no further darkening takes place (approx.
1 minute)
2) Tap water below pH 6.5
3) Formaldehyde solution 6% (v /v ) for 2 minutes
4) Tap water.
Sections were mounted in glycerol je l ly  and examined in a lig h t microscope, 
sites of g lucose-6-phosphatase a c tiv ity  being stained dark brown. Control 
incubations from which the substrate was omitted were also run through the 
procedure.
t )  Succinate Dehydrogenase
Reduction o f .te tran itro  blue tetrazolium (TNBT) in this system (Nachlas 
et al_.,1957) results in the production o f insoluble blue formazan.
Sections (10y) were incubated at 37° C fo r 15 minutes in 50 ml of 
solution containing potassium phosphate buffer pH 7.8 , 100 mM, sodium 
succinate 85 mM and TNBT 0.1% (w /v). The TNBT was dissolved in the bu ffer/ 
substrate solution immediately prior to use by warming the solution to 
60° C, f i l te r in g  and cooling to 37° C. A fter incubation, sections were 
washed in three changes of d is tille d  water, mounted in glycerol je l ly  and 
examined in the lig h t microscope. Sites of succinate dehydrogenase a c tiv ity  
were evident as blue formazan deposits. Control incubations from which the 
substrate was omitted were also run through the procedure.
u) Aniline Hydroxylase
The simultaneous capture method of Gangolli and Wright (1971) was used
in which the primary reaction product, 4-ami nophenol, is coupled with Fast 
Blue RR sa lt to produce an insoluble dye complex.
Sections (20y) were incubated at 37° C for 2 hours, sections being 
transferred a fte r 1 hour to a freshly prepared substrate solution. This 
procedure is necessitated by the in s ta b ility  of Fast Blue RR s a lt under the 
conditions of the assay. The incubation medium contained the fo il owing:-
Sodium phosphate buffer pH 7.4 100 mM
MgCl2 3.0 mM
Nicotinamide' 3.6 mM
NADP 0.1 mM
Glucose-6-phosphate (disodium s a lt) 1.0 mM
Aniline hydrochloride 2.2 mM
G1ucose-6-phosphate dehydrogenase 0.1 units/ml.
I t  was prepared in 35 ml amounts in each o f which 20 mg Fast Blue RR s a lt 
was dissolved immediately prior to use. A fter incubation sections were 
washed in three changes of d is tille d  water, mounted in glycerol je l ly  and 
examined in the lig h t microscope. A brown deposit id en tified  sites of 
aniline hydroxylase a c tiv ity . Control incubations from which the substrate 
was omitted were also run but in this case the incubating solution was not 
changed a fte r 1 hour.
v) Acid Phosphatase
The method of Gomori (1952) was used. As in the case of s ) , inorganic, 
phosphate is captured by lead ions and converted to lead sulphide. For this  
assay however, formal in -fixed tissue is used, fresh frozen tissue giving 
poor results.
Small strips of liv e r (approx. 3 x 10 mm) were fixed at 4° C for
24 hours in formol sucrose (sodium phosphate buffer 60 mM pH 7.4 containing 
10% (v/v) formaldehyde and 7.5% (w/v) sucrose) -and then for a further 24 
hours in gum sucrose (1% (w/v) gum acacia in 30% (w/v) sucrose). The tissue 
was then frozen using an MSE "Pelcool" freezing stage unit and sections cut 
at 5 -  7y on a freezing microtome. Sections were collected into ice-cold 
gum sucrose prior to incubation, free-floating  at 37° C for 15 minutes. The
incubation medium was prepared by adding 10 ml 155 mM sodium
3-glycerophosphate to 100 ml of 100 mM sodium acetate buffer pH 5.0 containing 
4.8 mM lead n itra te . This mixture was pre-incubated at 37° C for 1 hour and 
f ilte re d  immediately before use. A fter incubation sections were washed in 
d is tille d  water, transferred to d ilu te  ammonium sulphide solution (see s) 
and f in a lly  washed again in d is tille d  water. They were then transferred to 
glass microscope slides and mounted in glycerol je l ly .  Sites of acid 
phosphatase a c tiv ity  were vis ib le  in the lig h t microscope as deposits of 
black lead sulphide. Control incubations were not routinely run.
w) Histology
Small strips of liv e r  from the le f t  and median lobes were fixed in
buffered formalin (10% (v/v) formaldehyde in 0.05 M sodium phosphate b u ffe r),
dehydrated in alcohol, cleared in xylene and embedded in paraffin  wax.
Sections approx. 5y in thickness were cut on a base-sledge microtome 
(M.S.E. Ltd.) and stained with haematoxylin and eosin ( Drury and Wallington, 
1967).
x) Electron Microscopy
1mm cubes of liv e r  were fixed for 1 hour at 4° C in 1% osmium 
tetroxide in sodium cacodylate buffer 0.1M, pH 7.4 . The tissue was 
rapidly dehydrated through graded alcohols and embedded in Epon 812.
Sections 1y thick were stained with toluidine blue and examined under 
the lig h t microscope. Selected, centrilobular areas were then 
sectioned on an LKB ultramicrotome and stained with uranyl acetate and 
lead c itra te . The sections were examined and photographed in an A .E .I. 
EM6B electron microscope. For these procedures reference was made to 
Glauert (1967).
y) S tatistics
For a ll parameters of which multiple determinations were made, 
results were expressed as the arithmetic mean ± the standard error of 
the mean (SEM). Significant differences between means (minimum of 3 
individual values) were established using Student's t - te s t .  An 
O livetti Programma 101, programmed fo r linear regression analysis, was 
utilised  for the determination of correlation coefficients.
CHAPTER THREE
BIOCHEMICAL AND MORPHOLOGICAL CHANGES IN THE 
LIVER DURING CHRONIC DIETARY ADMINISTRATION 
OF BUTYLATED HYDROXYTOLUENE TO RATS
Introduction
The phenolic antioxidant butylated hydroxytoluene (2 ,6 -d i-te rt-b u ty l-4 -  
methylphenol, BHT) is widely used in processed food products, cosmetics and 
pharmaceuticals as a preservative for unsaturated lip ids and other materials 
subject to spoilage by oxidation. Its  industrial applications include the 
stab ilisation  of aviation fuels , lubricating o ils , isoprene rubber and 
polyolefine packaging materials. From the la t te r ,  BHT may be transferred to 
food products and s im ila rly , its  use in animal feeds may result in residues in 
the edible tissues of farm animals. Currently the unconditional acceptable 
daily intake of BHT fo r humans is 0 -  0.5 mg/kg (F.A.O./W.H.O., 1967) although
in practice, intake is probably fa r less than th is: G ilbert and Martin (1967)
estimated the daily intake of BHT in the U.K. at 1 mg/head, 0.01 -  0.02 mg/kg.
The ubiquity of BHT in the human environment -  Collings and Sharratt (1970) 
found a mean BHT content of 0.23 ppm in 11 samples of human subcutaneous adipose
tissue - has led to extensive investigation of its  ac tiv ity  and disposition in
biological systems (see reviews by Hathway, 1966 and The Lancet, 1965). 
Administration of high doses (50 - 500 mg/kg) of BHT to experimental animals 
produces enlargement of the liv e r  and induction of the drug metabolising 
enzymes (Allen and Engblo/m, 1972; Botham et a /L , 1970; Creaven et aj_., 1966;
Deichmann et , 1955; Feuer et ctK, 1965; Gaunt et ^1_., 1965 a,b; G ilbert and 
Golberg, 1965, 1966, 1967; G ilbert e t j H . , 1969; Grantham e t j H . , 1973;
Johnson and Hewgill, 1961; Nievel, 1969). According to Gaunt e ta l_ . (1965 a,b) 
these changes were more marked in female than in male rats , although they were 
fu lly  reversible in both sexes during 14 days of "recovery" on control d ie t.
No change in e ither phenylbutazone plasma h a lf - l i fe  or amidopyrine excretion 
was detected a fte r administration of 140 mg BHT daily for 14 days to human 
males (Sharratt e t al_., 1970) . This dose level -  approximately 2 mg/kg - is 
some 25 times less than that required to produce enzyme induction in the ra t
(G ilbert and Golberg, 1965), but some 100 times greater than the practical 
human exposure.
The induction-sensitive step in the metabolism of BHT by the ra t appears 
to be oxidation o f the 4-methyl group to the hydroxymethyl derivative (G ilbert 
and Golberg, 1966) which is then rapidly oxidised to the carboxylic acid by a 
soluble enzyme (Wright e t a l . , 1965). This metabolite appears in the urine 
and the b ile , principally as an ester glucuronide, but its  faecal excretion and 
that of the other major metabolite in the ra t - S -(3 ,5 -d i-te rt-b u ty l-4 -  
hydroxybenzyl)-N-acetylcysteine - is delayed since both undergo enterohepatic 
circulation (Daniel et a]_., 1968). This delay probably accounts fo r the long 
h a lf - l i fe  (7 -  10 days) found by Daniel and Gage (1965) a fte r repeated 
administration of BHT to the ra t. Shaw and Chen (1972) have isolated a 
hydroperoxide (4-hydroperoxy-4-methyl- 2 ,6 -d i- te r t  butyl cyclohexa-2,5-dienone) 
a fte r incubation of BHT with ra t liv e r  microsomes. Formation of s ign ificant 
quantities of this material in vivo would be potentially hazardous in view of 
the high reac tiv ity  of most hydroperoxides. According to Daniel e t al_. (1968) 
man excretes an oxidation product of BHT in which a ll three alkyl substituents 
have been attacked, namely, 4-carboxy-2-p-carboxy-1-m ethylethyl]-6-[1-forrnyl- 
1-methylethy 1 Jphenol. This metabolite was not detected by Holder e t a/L (1970 
and its  existence therefore remains questionable.
The enzyme induction and liv e r  enlargement produced by BHT is accompanied 
by a pro liferation  of hepatocyte smooth endoplasmic reticulum (Lane and Leiber, 
1967), the extent of which is dose dependent (Botham et al_., 1970). Liver 
enlargement prim arily due to hypertrophy is suggested since BHT e lic ite d  e ither  
no change (Botham et a l . ,  1970) or only a s ligh t increase (Lane and Leiber,
1967) in m itotic a c tiv ity . D ifferent results were obtained by Schulte. -  
Hermann et al_. (1971) who contended that hyperplasia played a s ig n ifican t role 
in BHT-induced liv e r  enlargement. This hyperplastic, but not the hypertrophic,
response to BHT was blocked by coadministration of the drug metabolising 
enzyme inhibitors SKF 525A and CFT 1201 (Schulte-Hermann et al_., 1972).
Chronic administration o f BHT to rats at dose levels su ffic ien t to 
produce liv e r  enlargement has not been associated with any histopathological 
change e ither in the liv e r  or any other organ (Brown et al_., 1959;
Deichmann et al_., 1955; Feuer et a}_., 1965; Gaunt, et al_., 1965a). In young 
monkeys, hepatic nucleolar fragmentation - apparently unaccompanied by 
inh ib ition  of RNA synthesis -  was observed a fte r administration o f 500, but not 
50 mg/kg BHT fo r 28 days (Allen and Engblorm, 1972). Of 18 mice, 6 developed 
b ile  duct hyperplasia a fte r  administration for 12 months o f a d ie t containing 
0.75% BHT (Clapp et al_., 1973) -  an effective dose level some 5Q!,000 times the 
lik e ly  human exposure. Marino and Mitchell (1972) found that mice injected  
in traperitoneally  with BHT at dose levels between 250 and 2500 mg/kg developed 
lung damage. This was apparently reversible and no other organs were effected. 
A systematic study of the effects of BHT in mice is in progress (see Thorpe and 
Walker, 1973).
In this chapter, some aspects of the liv e r  response to BHT -  which 
produces liv e r  enlargement unaccompanied by histopathological change -  have 
been studied to provide a "positive control" with which the l iv e r  response to 
the other compounds studied (see 1.8) could be compared.
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2 Materials and Methods
a) Chronic Administration of BHT to Rats 
Female rats were maintained on a d iet containing 0.4% (w/w) BHT as
described in 2.2 . This dietary level was selected with reference to published 
work (see 3.1) as being equivalent to a dose level known to produce marked 
induction of the drug metabolising enzymes.
At weeks 1, 8, 16, 32 and 75, 4 treated and 4 control rats were k ille d  
and the livers used for the assays described in 2.3. Enzyme histochemistry 
(2 .3 ) was carried out on liv e r  samples from rats k illed  at weeks 1, 8 , 16 and 
80. Liver samples from the rats treated for 1 and 80 weeks were subjected to 
histological examination and the 80 week samples were additionally examined in  
the electron microscope.
b) Reversibility  of BHT-Induced Hepatic Changes 
A fter 80 weeks, 8 treated rats were given control d iet in place of the
BHT d ie t. A fter 14 days, 4 of these rats were injected in traperitoneally  
once daily fo r 3 days with sodium phenobarbitone at a dose level of 100 mg/kg. 
On day 18, a ll of these rats were k ille d , together with 8 control rats 4 of 
which had been sim ilarly treated with phenobarbitone. . Rats not receiving 
phenobarbitone were injected with an equivalent volume of saline.
c) Spectrally Apparent Interaction of BHT with Cytochrome P450
The kinetic constants K and A0Dm^ „ were determined as described ins max
2.3. BHT was added as a solution lOOmM in absolute ethanol to provide the 
following fina l cuvette concentrations (mM):- 0.04, 0.06, 0 .08, 0 .10, 0.12, 
0.16, 0.24, 0.32, 0.40, 0.80.
Results
a) Animal Body Weights and Food Intake
Growth curves for the. control and BHT-fed rats are shown in Fig. 3.1. 
The mean body weight of the treated rats was s lig h tly , but s ig n ifican tly  (a fte r  
4 weeks) less than that of the control rats throughout the experiment. There 
was no in i t ia l  rejection of the BHT d iet but the food intake o f the treated  
rats remained s lig h tly  depressed (Table 3 .2 ). The effects of BHT on body 
weight and food intake are summarised in Table 3.1 and the approximate daily  
intake of BHT in mg/kg, calculated from the food intake data, is shown in  
Table 3.2.
b) Biochemical Changes During Chronic Administration of BHT 7
These data, expressed in the form treated as % of control values, are
shown in Fig. 3.2 and Table 3.3 . The complete data with s ta tis tic a l treatment 
are included in the Appendix (Table AT).
Administration of BHT for 1 week produced increases -  per gram of 
l iv e r  -  o f 50 - 100% in the ac tiv itie s  of ethylmorphine N-demethylase, 
biphenyl 4- and biphenyl-2-hydroxylase and in the contents o f cytochrome P450, 
cytochrome b5 and microsomal protein. There was a 30% increase in the 
a c tiv ity  of NADPH-cytochrome c reductase but the ac tiv ity  o f an iline
4-hydroxylase was not s ign ifican tly  increased. The a c tiv ity  of glucose-6- 
phosphate dehydrogenase was s lig h tly  decreased whilst succinate dehydrogenase 
a c tiv ity  and to ta l liv e r  protein content were s ign ifican tly  depressed. Liver 
weight -  and re la tive  liv e r  weight -  was increased by 30%.
There was l i t t l e  change from this pattern of response a t subsequent 
sampling in tervals. Relative liv e r  weight increased s lig h tly  and the a c tiv ity  
of biphenyl 2-hydroxylase re la tive  to that of the 4-hydroxylase appeared to
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FIG. 3.2
Measurements o f Some Drug Metabolising Enzymes and Related Parameters
at Intervals During Chronic Dietary Administration of BHT to Female Rats
Mean values fo r the treated rats are expressed as % of control values 
(4 rats per group). Significant differences are shown (Units per g liv e r  
' only): a = p<0.05, b = p<0.01, c = p<0.001.
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TABLE 3.3
Some Parameters Additional to those Shown in Fig. 3.2*
WEEKS
1 8 16 32 75
Biphenyl 2-hydroxylase 21 lc 516c 214C 400b 194b
Succinate dehydrogenase 78a 70 77b 69b 75
Glucose-6-phosphate dehydrogenase 90 64a 77b 64a -
“Total liv e r  protein 93G 87C 102 100 92
*  Results expressed as % of control in units per g liv e r
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increase markedly. This increase in the % induction of biphenyl 2-hydroxylase 
is ,  however, misleading since the actual a c tiv ity  decreased in both treated 
and control rats but this decrease was greater in the control than in the 
treated group. The a c tiv ity  o f aniline 4-hydroxylase showed a significant 
increase at weeks 8 and 16 but this was no longer evident at weeks 32 and 75.
When expressed per to ta l liv e r  per lOOg body weight, increases in drug 
metabolising enzyme ac tiv ity  were greater than when expressed per gram of liv e r  
weight and the depression of succinate dehydrogenase was no longer evident. 
S im ilarly , the increased microsomal protein content resulted in specific  
a c tiv ity  of the drug metabolising enzymes considerably less than the increases
per gram liv e r .
/
c) Reversibility of BHT-Induced Hepatic Changes
Since induction o f the drug metabolising enzymes persisted during 
administration of BHT for 75 weeks, the remaining treated rats were u tilised  to 
determine whether these changes were readily reversible on withdrawal of the 
BHT, and whether the response of the drug metabolising enzymes to subsequent 
"re-induction" with phenobarbitone was in any way diminished as a result of 
chronic BHT-treatment.
The results of this experiment, expressed as % of respective control 
values, are shown in Table 3.4. After administration of BHT fo r 80 weeks, 18 
days of "recovery" on control d iet resulted in -a  decrease from the induced 
levels of drug metabolising enzyme a c tiv ity  observed at 75 weeks, but not a ll 
parameters returned to control levels. Thus, the a c tiv ity  of ethylmorphine 
N-demethylase and cytochrome c reductase and the content of cytochrome b5 
remained sign ificantly  increased and smaller increases persisted in a number 
of other parameters. The depression of succinate dehydrogenase observed at a ll 
previous intervals (Table 3 .3 ) .was no longer evident on withdrawal of the BHT 
d ie t.
Table 3.4
R eversib ility of BHT-Induced Hepatic Changes and Subsequent Effect
of Phenobarbitone 
(fo r details of animal treatments see 3.2b)
BHT 
75 Weeks
BHT
'Recovered'
BHT 'recovered'
+ phenobarbitone
Control + 
phenobarbitone
Body Weight 86a*t 891 82t 92 § 941
Liver Weight . 121 101 102 102 104
Relative Liver Weight 142 b 112 127 113 111
Succinate dehydrogenase 72 b .110 a 103 ns 94 ns 97 ns
Ethylmorphine N- 
demethylase
- 209 c 139a 348 g 250 c 325c
Ani1ine 4 -hydroxylase 90 113 176c 157b 166 c
Biphenyl 4-hydroxylase 130 a 115 251c 213C 240c
Biphenyl 2-hydroxylase 194 b 75 546c 748c 505C
NADPH-Cytochrome c 
reductase
o cr 129a 163b 127a 148b
Cytochrome P450 204 c 107 266C 249 c 236c
Cytochrome b5 00 00 o 131a 162b 124a 140a
Microsomal protein 131 a 105 120b 114b 113
Total protein 92 101 108 107 103
t) Mean values (4 rats per group) in units per gram liv e r , expressed as % o f, 
and compared s ta t is t ic a lly  to , untreated controls.
§) As 1) but expressed as % o f, and compared s ta tis tic a lly  to , BHT 
'recovered' values.
*) a = p<0.05 b = p<0. OJJ c = p<0.001
Phenobarbitone, administered to treated rats 14 days a fte r withdrawal 
of the BHT d ie t, e lic ite d  a degree of drug metabolising enzyme induction 
very sim ilar to that produced in untreated control rats (Table 3 .4 ).
d) Interactions of BHT with Cytochrome P450
BHT produced a typical type 1 interaction spectrum when added to liv e r  
microsomes from female rats. Mean values (3 determinations) for the 
kinetic constants were:-
K 3.3 ± 0.2 x lO^M s
A0Dm -0.050 ± 0.004 max
f •
e) Enzyme Histochemical Changes in the Liver During Chronic 
Administration of BHT
At each sampling interval the a c tiv ity  of glucose-6-phosphatase was 
s lig h tly  depressed and that o f aniline hydroxylase s lig h tly  stimulated 
in the centrilobular areas. The depression of succinate dehydrogenase 
observed biochemically, could not be clearly  discerned histochemically.
The very large centrilobular cells observed a t 80 weeks (see 3.3g) 
contained enlarged lysosomes, but no autophagic vacuoles Were present 
and the normal, pericanalicular distribution of the lysosomes was 
preserved (Fig. 3 .3 ).
f ) Macroscopic Changes in the Liver
Apart from enlargement, no other gross changes were observed.
FIG. 3,3 Acid phosphatase (x 450)
A «  ktwsrel liv e r * rwoml perieaneHeytfar distribufcien of
lyipga*naa,
I*  BHT week 80 -  normal lysosomal distribution 1n enlarged centrllobular 
ce lls .
g) Histological Changes in the Liver
The only histological change noted was centrilobular cell 
enlargement. This was evident at week 1 and by week 80 was pronounced. 
However, liv e r  from rats k ille d  18 days a fte r  withdrawal of the BHT 
diet at week 80 was indistinguishable from that of untreated control 
ra ts .
h) UltrastructuraT Changes in the Liver
The effects of short-term administration of BHT on the 
ultrastructure of ra t hepatocytes have been reported in detail (Botham 
et al_, 1970; Lane and Leiber, 1967). For the present study therefore, 
observations were confined to tissue taken at week 80. This differed  
from control tissue only in a moderate pro liferation  of the smooth 
endoplasmic reticulum.
Discussion
Enlargement of the liv e r  and induction of the drug metabolising 
enzymes following the administration of BHT to rats is a well documented 
response (e .g . G ilbert and Golberg,1965; Grantham et al_., 1973). The 
results obtained in this study are consistent with these findings but 
demonstrate, in addition, that the response is maintained during the 
continued dietary administration of BHT for up to 75 weeks. During 
this time there was no histochemical, histological or u ltrastructural 
evidence of l iv e r  in jury. This situation contrasts with the re la tiv e ly  
transient stimulatory effects on drug metabolising enzyme a c tiv ity  of 
safro le, Ponceau MX, 2-acetyl aminofluorene and a number o f other 
compounds which produce pathological changes in the liv e r . The 
significance of this difference in response is discussed in Chapter 8.
Changes in drug metabolising enzyme ac tiv ity  during the prolonged 
administration of enzyme-inducing chemicals do not appear to have been 
extensively investigated. In an early study,' G ilbert and Golberg (1965) 
found that l iv e r  weight add enzyme a c tiv ity  were very s ig n ifican tly  
increased a fte r  administration of BHT to female rats by oral intubation 
a t a dose-rlevel of 500 mg/kg/day for 12 weeks. At a lower dose level 
(0.1% in the d ie t, equivalent to approximately 50-80 mg/kg), these 
effects were no longer evident a fter 16 weeks (Gaunt et al_., 1965a). 
In -th is  case i t  seems 1 i kely th a t, with-the—i ncreasi ng body. wen ght of 
the ra ts , the effective intake of BHT in mg/kg body weight fe l l  to below 
the threshold level required to produce drug metabolising enzyme 
induction (G ilbert and Golberg, 1965). This eventuality did not occur 
at the dose level of BHT u tilised  in the present study.
A number of studies have shown that phenobarbitone also causes 
persistent enzyme induction and liv e r  enlargement when administered to 
rats and dogs fo r continuous periods of up to 12 weeks (Burns et a l . ,  
1963; Remmer, 1962), whilst an experiment recently completed at 
B.I.B .R.A. indicates that these effects may be maintained in defin ite ly  
with continued administration of the compound. Under these conditions 
phenobarbitone, lik e  BHT, produced no pathological changes in the liv e r .
In contrast to the depression of glucose-6-phosphate dehydrogenase 
observed in the present study, Feuer et a l.  (1965) reported that this 
a c tiv ity  was unchanged or s lig h tly  increased at comparable dose levels 
of BHT, w hilst higher doses (500 mg/kg) e lic ite d  a two-fold increase. 
Other enzyme inducers such as phenobarbitone or DDT may also enhance the 
a c tiv ity  of glucose-6-phosphate dehydrogenase (P la tt and C o c krill, 1969). 
An explanation fo r the present resu lt is not readily apparent. Decreased 
hepatic a c tiv ity  of succinate dehydrogenase in BHT-treated rats has been 
previously reported (Nikol'skaya, 1964; Placer et al_., 1965). Placer et 
a l . attributed th is effect to an interference with mitochondrial electron 
transport by BHT acting as an electron acceptor. The presently observed 
return of succinate dehydrogenase a c tiv ity  to control level on withdrawal 
of the BHT d ie t is consistent with such a view. However, a s ign ifican t 
effec t of this type in vivo seems improbable in view of the a b ility  of 
experimental animals to to lerate very high doses of BHT.
Gaunt et a l. (1965b) reported that the increases in ra t liv e r  weight 
and drug metabolising enzyme ac tiv ity  e lic ite d  by 14 daily doses of 
500 mg BHT/kg were fu lly  reversible w ithin a 14 day recovery period. 
Evidence is presented here that these changes are reversible even a fte r  
80 weeks although at this stage the process appears to proceed re la tiv e ly
slowly. According to G ilbert and Golberg (1965), an equilibrium between 
intake and excretion of BHT is established as soon as the response of 
enzyme induction is complete and thereafter, tissue levels of BHT remain 
re la tiv e ly  constant. Consequently, in view of the maintenance of enzyme 
induction, i t  is unlikely that the slower re ve rs ib ility  a fte r  80 weeks 
is the result o f increased tissue concentrations of BHT. Nor can i t  be 
explained in terms of a prolongation of the enterohepatic circu lation  
of metabolites since the major oxidation products of BHT in the ra t are 
poor enzyme inducers (G ilbert and Golberg, 1966). More probably the 
slower re v e rs ib ility  results from changes in enzyme regulatory function, 
possibly involving the s tab ilisation  of messenger or ribosomal RNA. There
is some evidence fo r th is  in the case of phenobarbitone, a fte r  the
( - .
prolonged administration of which a return to normal of the increased 
l iv e r  weight and drug metabolising enzyme a c tiv ity  may take several 
weeks or even months (Burns e t al_., 1963; Remmer, 1962). Thus, 
phenobarbitone is known to in h ib it ra t liv e r  ribonucleases I ,  I I  and I I I  
(S e ife rt and Vacha, 1970) and recent evidence indicates that i t  may also 
in h ib it the intranucleolar degradation of newly synthesised ribosomal 
precursor RNA (Smith et al_., 1974). I t  is not known whether BHT exerts 
sim ilar effects. However i t  seems clear that the prolonged administration 
(80 weeks) of BHT does not produce irreversib le changes in enzyme 
regulatory function since, on cessation of treatment, the drug metabolising 
enzyme response to subsequent administration of phenobarbitone was in no 
way impaired.
The fa ilu re  of any histopathological changes to develop in the liv e r  
is in keeping with the results of previous studies with BHT (see 3 .1 ) , as 
were the observed histological and ultrastructural changes. Even in the 
greatly enlarged centrilobular hepatocytes a fte r 80 weeks no 
histochemical evidence of liv e r  in jury (Grasso et al_., 1974) was apparent
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and the cells returned to normal size on withdrawal of the BHT d ie t.
This indicates that the BHT-induced cell enlargement possesses a 
significance quite d iffe ren t from that of the largely irreversib le  
hepatic megalocytosis as produced, for example, by pyrro lizid ine  
alkaloids (Schoental and Magee, 1959) or N-nitrosopyrrolidine (Hendy and 
Grasso, 1975).
In conclusion, the absence of any evidence of liv e r  damage and 
the findings of maintained enzyme induction during prolonged 
administration of BHT, strengthen the view (Golberg, 1966) that the 
changes evoked by this compound are more lik e ly  to represent an 
adaptive, physiological response than a degenerative one.
CHAPTER FOUR
BIOCHEMICAL AND MORPHOLOGICAL CHANGES IN THE 
LIVER DURING CHRONIC DIETARY ADMINISTRATION 
OF SAFROLE TO RATS
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Introduction
Safrole ( 4 - a l ly l - l , 2-methylenedioxybenzene) is a constituent of a number of 
naturally occurring flavours. I t  is the principal component (80 - 90%) of o il 
of sassafras from the roots of Sassafras albidum, of Brazilian sassafras o il 
from Octea pretiosa and of the o il o f Illic iu m  parviflorum (Foote, 1938;
Hickey, 1948). I t  is  also a major component of certain o ils from plants o f the 
Asiarum, Asarum and Heterotropa genera and a minor component of the o ils  of 
nutmeg, cinnamon le a f, star anise, mace, camphor, California laurel and American 
wormseed (Jacobs, 1958; Saiki e t al_., 1967 a, b, c, d). Safrole is thus a 
natural ingredient of Sassafras tea and i t  was quite extensively used as a 
flavouring agent in soft drinks - particu larly  root beer -  and in certain  
pharmaceutical preparations, until its  use as such was prohibited by the United 
States Food and Drug Administration in 1960 (Long al_., 1961). Because of its  
occurrence in essential o ils  however, safrole is s t i l l  ingested in smail 
amounts by many humans. Currently, almost the entire annual production of 
safrole -  about 1.4 m illion pounds -  is u tilised  in the manufacture of the 
insecticide synergist piperonyl butoxide, and piperonal, an intermediate in the 
synthesis of other methylenedioxyphenyl synergists (Hennessey, 1970).
A case of severe human intoxication resulting from ingestion of o il of 
sassafras was reported as early as 1888 (Albright 1888, cited by Jacobs, 1958), 
whilst Heffter (1895) noted that in animals, large doses of safrole produced 
rapid respiratory paralysis and lower doses caused.death from widespread fa tty  . 
degeneration of heart, l iv e r , kidneys and other organs. Other reports of 
human and animal to x ic ity  have been b rie fly  reviewed by Jacobs (1958).
More recent studies, with non-lethal dose levels, have shown that the
toxic effects of safrole are manifest principally in the liv e r . Administration 
of 0.04 -  1.0% of safrole in the d iet of male and female rats for 150 -  730 days
produced hepatic adenomas and carcinomas (Abbott et al_., 1961; Hagen et a l . ,
1965, 1967; Homburger e_t a K , 1961 , 1962; Long e t , 196;]). According to 
Long et al_. (1963), 19 out of 37 rats fed 0.5% safrole for 470 days had liv e r  
tumours, 74% of which were malignant on the basis of histological c r ite r ia  and 
the finding, in two rats (14%), of metastases to the lungs. Of these malignant 
tumours, 66% were diagnosed as hepatocellular carcinoma and the remainder as 
hepatocholangiocarcinoma. Other histological features of these livers included 
diffuse or nodular cell enlargement, fa tty  change, b ile  duct pro liferation  and 
focal, cystic necrosis. A fter repeated oral administration, or a fte r in jection  
into in fant animals, safrole is also hepatocarcinogenic in the mouse (Epstein 
.e t  al_., 1970; Innes et al_., 1969). The histological changes produced by safrole 
are sim ilar in both ra t and mouse liv e r  (Hagen et aJL , 1965).
The carcinogenicity of safrole in a tissue distant from the sites of 
administration suggests a requirement for metabolic activation. The number of 
potential metabolites of safrole is very large. Oxidative cleavage of the 
methylenedioxy ring appears to be a quantitatively important route of metabolism 
(Casida et al_., 1966; Fishbein and Falk, 1969), such that the numerous oxidation 
products of the a lly ! side chain may occur either as derivatives o f 
methylenedioxybenzene or catechol. The number of such derivatives is increased 
by the poss ib ility  of migration of the double bond from the 1,2- to the 2,3- 
position of the side chain (Solheim and Scheline, 1973; Williams, 1959). 
Reactions involving the a lly l group of safrole have been described by Borchert 
et al_. :(1973a) ,  Fishbein et al  ^ (1967), ! Kamienski and Casida (1970),
McKinney et ciK (1972), Oswald et aK (1971) and Williams (1959), whilst 
Solheim and Scheline (1973) have discussed the metabolism of 
4-metho*yallylbenzene in d e ta il. The roJe of these metabolites in the 
carcinogenicity of safrole is unknown, although Borchert et al_. (1973 a,b) 
have shown that 11-hydroxysafrole -  present to the extent of 1-3% in the urine 
of safrole-treated rats - is very much more carcinogenic to rats arid mice than 
safrole i ts e lf .  The proposed further metabolism of 1 'hydroxysafrole to form
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a reactive ester metabolite accords with the currently favoured view that the 
ultimate carcinogenic forms of most, i f  not a l l , chemical carcinogens are 
strong e lectroph ilic  reactants, able to bind covalently to tissue 
macromolecules (M ille r , 1970). Safrole i ts e l f  has no such a b ility  (Borchert 
et a l . ,  1973a).
The apparent requirement for metabolic activation suggests an important 
role for cytochrome P450, since this is known to be involved in the metabolism 
of safrole (Casida_et_al., 1966; Kuwatsuka, 1969) and since safrole is known 
to be a powerful inducer of cytochrome P450-dependent drug metabolism (Parke 
and Rahman, 1970; Wagstaff and Short, 1971). However, the interaction of 
safrole with cytochrome P450 appears to d iffe r  from that of a typical enzyme- 
substrate relationship. Thus, Parke and Rahman (1971) noted that the redox 
difference spectrum of liv e r  microsomes from safrole-treated rats contained an 
additional absorption maximum at 455nm. A sim ilar absorption maximum was 
produced in v itro  by incubation of piperonyl butoxide with mouse liv e r  
microsomes and NADPH (Philpot and Hodgson, 1971). Franklin (1971) showed that 
the formation of this maximum, on incubation of microsomes from phenobarbitone- 
treated rats with safro le , isosafro!e, piperonyl butoxide or 
methylenedioxybenzene, required oxygen and NADPH. This suggested the 
involvement of cytochrome P450-dependent metabolism and i t  is currently 
considered that the 455nm absorption maximum represents the formation of a 
re la tive ly  stable complex between cytochrome P450 and a methylenedio^yphenyl 
metabolite (Franklin, 1972a,b; U llrich and Schnabel, 1973). The formation of 
this complex is discussed in more detail in Chapter 7.
In the present study, sequential measurements of drug metabolising 
enzyme a c tiv ity  have been made during the chronic administration o f safrole to 
ra ts , to determine whether any relationship exists between the diverse effects  
of safrole on this enzyme system and the development of pathological changes in 
the liv e r .
4.2  Materials and Methods
a) Chronic Administration of Safrole to Rats
Female rats were maintained on a d ie t containing 0.25% (w/w) safrole  
as described in 2 .2 . This dose level was chosen because i t  was high enough to 
produce induction of the drug metabolising enzymes and, according to Hagen 
et a l . (1965), to give rise to gross pathological changes in the l iv e r , but
not high enough to resu lt in extensive early m ortality.
At weeks 1, 8 , 16, 25, 42 and 75, 4 treated and 4 control rats were 
k ille d  and the livers used for the assays described in 2.3. At week 85 a ll 
the remaining treated animals (8) were k ille d  and from the livers  o f 5 of these 
ra ts , samples of nodular tissue were obtained. The tissue taken was of a 
sim ilar texture and colour to the adjacent parenchyma and care was taken to 
discard any associated necrotic or cystic tissue. Where multiple nodules were 
present in any one liv e r  the tissue was pooled: in each case a sample of the 
nodular tissue was taken for histological examination. Subcellular fractions 
were prepared and assays carried out as for normal liv e r  tissue (2 .3 ).
Enzyme histochemistry (2 .3) was carried out on liv e r  samples from rats 
k illed  at weeks 1, 8, 16 and 25 and on nodular, and adjacent, non-nodular 
liv e r  from rats k ille d  at 80 weeks. Liver samples from the same rats were 
also examined by lig h t and electron microscopy (2 .3 ).
b) Co-administration of Safrole and Phenobarbitone
Female rats -  in i t ia l  body weight 100-120g - were given 0.1% (w/v) 
sodium phenobarbitone in th e ir  drinking water for 1 week prior to , and during 
administration of the 0.25% safrole d ie t for e ither 1 or 8 weeks. Control 
rats received e ither safrole d iet alone, phenobarbitone and control d ie t, or 
control d ie t alone. The phenobarbitone solution was freshly prepared on 
alternate days.
Results
a) Animal Body Weights and Food Intake
Growth curves for the control and safrole-fed rats are shown in Fig. 
4.1. Administration of safrole markedly depressed the rate o f body weight 
gain, the mean difference in body weight between treated and control groups 
being highly s ign ifican t a fter 1 week, and the proportionate difference between 
the groups increased gradually throughout the experiment (Table 4 .1 ). The 
early decreased growth rate could be correlated with the decreased food intake 
of the treated rats (Table 4 .2 ) , although the re la tive  decrease in body weight 
of these rats a fte r about week 50 was not associated with any further 
depression of food intake. On the f i r s t  day of safrole feeding there was 
almost to ta l d ie t re jection , but food intake stabilised by day 7. The effects  
of safrole on body weight and food intake are summarised in Table 4.1 and the 
approximate daily  intake of safrole, in mg/kg body weight, calculated from the 
food intake data, is shown in Table 4.2.
Under the conditions of this experiment, administration of safrole did 
not result in increased mortality and there was a much lower incidence of 
respiratory disease amongst the treated rats than amongst the control rats.
b) Biochemical Changes During Chronic Administration o f Safrole
These data are presented in the form treated as % of control values, in 
Fig. 4.2 and Table 4 .3 . The fu ll data, with s ta tis tic a l treatment are included 
in the Appendix (Table A2).
Administration of safrole for 1 week resulted in increases - per gram 
l iv e r  -  of 80 - 210% in the ac tiv ities  of ethylmorphine M-demethylase, aniline  
and biphenyl 4-hydroxylases and NADPH - cytochrome c reductase and in the 
contents of cytochrome P450 and b5« The 2-hydroxylation of biphenyl was
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stimulated to a greater extent than the 4-hydroxylation. Microsomal protein 
content was increased by 25%, w hilst there was no change in the total liv e r  
protein content or in the a c tiv ity  o f succinate dehydrogenase. Glucose-6- 
phosphate dehydrogenase was s ign ifican tly  depressed. The re la tiv e , but not 
the absolute, liv e r  weight was s ig n ifican tly  increased.
The in i t ia l  potent induction o f drug metabolising enzyme a c tiv ity  was 
greatly reduced a fte r administration of safrole for 8 weeks, although in terms 
o f to ta l liv e r  a c tiv ity , this decrease was partly offset by a 66% increase in 
re la tive  liv e r  weight. By 16 weeks induction was no longer apparent: in fact 
there was a significant depreission o f biphenyl 4-hydroxylase a c tiv ity , even 
when expressed per total liv e r  per lOOg body weight. However, despite this 
decreased a c tiv ity  towards drug substrates, the levels of NADPH-cytochrome c 
reductase, cytochrome b5 and microsomal protein remained greatly elevated. 
Throughout this period of change in drug metabolising enzyme a c tiv ity  there, 
was l i t t l e  change in the apparent content of the 455nm absorption maximum.
At week 42 there was some indication of a recovery of drug metabolic 
a c tiv ity  in the treated rats and by week 75, this was manifest in a s ign ifican t 
increase in the ac tiv ities  of ethylmorphine N-demethylase and biphenyl 
4-hydroxylase. Associated with these increases was some decrease in the 
content of the 455nm absorption maximum and in the very high levels of cytochrome 
b5 and NADPH-cytochrome creductase. However, by week 85, there was a reversal 
of this recovery. The very marked increase in re la tive  liv e r  weight evident at 
both 75 and 85 weeks was associated with the presence of gross pathological 
change in the liv e r . Consequently, the calculation of ac tiv ities  per to ta l 
l iv e r  per TOOg body weight was not considered to be meaningful, due to the 
presence of considerable amounts of cystic and necrotic tissue in the livers  of 
the treated rats k illed  at these in tervals.
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Measurements o f Some Drug Metabolising Enzymes and Related Parameters 
at Intervals During Chronic Dietary Administration of Safrole to 
Female Rats.
Mean values fo r the treated rats are expressed as % of control values 
(4 rats per group). S ignificant differences are shown (units per g 
liv e r  only): a = p<0.05, b = p<0.01, c = p<0.001
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TABLE 4.3
Some Parameters Additional to those Shown in Fig. 4.2.
WEEKS
1 8 16 25 42 /b 8b
biphenyl 2-hydroxylase b40c b/b c oo 225 c. 3211 oO 84bc
Succinate dehydrogenase 102 83 78 t 82 y 90 89 91
Glucose 6-phosphate dehydrogenase 73o 104 83 L 111 - - -
Total l iv e r  protein 102 86c 98 97 97 99 96
455 nm Absorption Maximum 1.04t 0.83 1.09 0.74 0.89 0.64 0.68
2.51S. 1.69 2.30 1.58 2.06 1.54 1.59
*  Results expressed as % of control in units per g .liv e r
t  Values are ftOD^go-^ss=;per g liv e rnm
§ Values are AODi*go if5 5 nmper g microsomal protein
c) Biochemical Investigations of Safrole-Induced Liver Nodules
Safrole did not induce the development of non-necrotic, solid liv e r  
nodules as readily as Ponceau MX (see 5.3) and, owing to d iff ic u ltie s  in 
maintaining an adequate number of ra ts , nodular tissue suitable for biochemical 
analysis could only be obtained from 5 rats . Table 4.4 shows the results 
obtained, in  the form nodular and non-nodular treated liv e r  as % of control, 
and nodular as % of non-nodular treated liv e r . Full data are given in the 
Appendix (Table A6)..
Results obtained from the nodular tissue tended to be very variable.
In general, the nodules were characterised by levels of drug metabolising 
enzymes lower than those of the surrounding, non-nodular liv e r  and 
considerably lower than those of the control l iv e r . These decreases were less 
evident when results were expressed per mg microsomal protein. The total 
protein content and succinate dehydrogenase a c tiv ity  of the nodular liv e r  was 
quite comparable with that of the control l iv e r . Although lower, the re la tive  
ac tiv ities  of the various parameters in the nodule were in general sim ilar to 
those in the non-nodular tissue. Exceptions in this respect were the 
re la tiv e ly  high a c tiv ity  of biphenyl 4-hydroxylase and the very low level of 
the 455 nm absorption maximum in the nodule.
d) Co-administration of Safrole and Phenobarbitone
These experiments were aimed to determine whether the fa l l  in drug 
metabolising enzyme a c tiv ity  produced by safrole (4.3b) was prevented by 
co-administration of phenobarbitone, whether additional stimulation of the 
synthesis of cytochrome P450 resulted in the formation of re la tive ly  greater 
amounts of the 455nm absorption maximum, and whether this treatment influenced 
the development of early histopathological change in the liv e r  (4 .3k ).
The results of these experiments are shown in Figs.4.3 and 4 .4 .
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E ffect of Coadministration of Phenobarbitone with Safrole fo r 1 Week
on Some Drug Metabolising Enzymes and Related Parameters
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Mean values for the treated rats are expressed as % of control values 
(4 rats per group) in units per g liv e r .
Treatments are shown as: P = Phenobarbitone, S = Safrole 
PS = Phenobarbitone + Safrole (see 4.2b)
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Co-administration of safrole and phenobarbitone for 1 week e lic ite d  
greater increases in drug metabolising enzyme ac tiv ity  than did either compound 
alone. Increases in the ac tiv ity  of ethylmorphine N-demethylase and aniline  
4-hydroxylase were v ir tu a lly  additive. However, the a c tiv ity  of biphenyl 
2-hydroxylase a fte r  co-administration was only some 50%, and the content of the 
455nm absorption maximum only 25%, of the respective values from rats given 
safrole alone.
A fter 8 weeks the drug metabolising enzyme ac tiv ity  of rats 
co-administered with safrole and phenobarbitone remained greatly elevated 
whilst in the rats given safrole alone there was a marked fa l l  in a c tiv ity  as 
previously observed. Values for the co-administered group were comparable with 
those of the group given phenobarbitone alone with the exception o f the content 
of cytochrome P450, which was s ign ifican tly  lower, and of cytochrome b5, which 
was s ign ifican tly  higher in the former-group. Surprisingly, the a c tiv ity  of 
biphenyl 4-hydroxylase in the co-administered group was higher than in the 
group given phenobarbitone alone, despite the apparent inh ib ition  of th is  
a c tiv ity  in the group given safrole alone. In comparison with the results a fte r  
1 week, the content of the 455nm absorption maximum was increased in the 
co-administered group, the value being 46 as opposed to 25% of the value for the 
group given safrole alone.
e) Hexobarbitone Sleeping Times
These experiments were performed to determine whether the results of an 
in vivo measurement of drug metabolic ac tiv ity  correlated with the observations 
in v itro  of an in it ia l  induction followed by an inhibition of drug metabolism, 
during chronic administration of safrole.
A fter administration of safrole for 1 week there was a highly s ign ifican t 
decrease in sleeping time, whilst a fte r  25 weeks, sleeping time was
oo
Table 4.5
Effect of Safrole Pretreatment for 1 and 25 Weeks 
on Hexobarbitone Sleeping Time in Female Rats
1 WEEK 25 WEEKS
Group Induction Sleeping Induction Sleeping
time* time time t i  me
Control 2 . 4  ± 0 . 2 6 0 . 4  ± 2 .3 2 . 8  ± 0.1 9 8 .0  ± 7 .0
Safrole 2 .6  ± 0 .1 2 0 .7  ± 3 . 0 t c 1.1 ± o . i c 155.0  ± 1 5 . 0b
*  Times (minutes) are means of values from 6 animals ± SEM
■f Mean s ig n ifican tly  d iffe ren t from control: b = p<0.01 c = p<0.001
sign ifican tly  prolonged (Table 4 .5 ). Changes in the induction time correlated 
with these results.
f ) Correlation of the Maintained Induction of NADPH-Cytochrome c 
Reductase with Enhanced in v itro  Formation of the 455nm Absorption 
Maxi mum
Although the in i t ia l  induction of drug metabolising enzyme ac tiv ity  was 
not maintained during chronic administration of safrole (4 .3b ), the ac tiv ity  of 
NADPH-cytochrome c reductase did remain at a greatly elevated level. The 
possib ility  that th is , otherwise anomalous, result was associated with 
induction o f the metabolism of safrole was therefore investigated by comparing 
the rate of formation of the 455nm absorption maximum from safrole in v it ro , in  
microsomes from untreated rats and rats administered with safrole fo r 1, 8 and 
16 weeks.
Table 4.6 shows that the percentage induction o f formation of the 455nm 
absorption maximum and of the ac tiv ity  of cytochrome c reductase was very 
sim ilar at each in te rva l. However, although no extinction coeffic ient is 
available fo r the 455nm maximum, i t  appears that the rate of reaction leading 
to its  formation is extremely slow - probably much slower than the a c tiv ity  of 
cytochrome c reductase.
g) E ffect of 455nm Absorption Maximum on the Apparent Content of 
Cytochrome b5
I t  seemed possible that the unexpectedly high level of cytochrome b5
induced by safrole was in fact due to a contribution to the reduced b5
spectrum ( a 427nm) of the 427nm maximum.of the safrole metabolite-cytochrome max
P450 complex (see 7 .1 ). This was investigated by selective solubilisation of 
cytochrome b5 a fte r Protease V II digestion (see 2.3) o f liv e r  microsomes from 
rats fed the 0.25% safrole d iet fo r 8 weeks.
00
Table 4.6
Induction of Cytochrome c reductase and Enhanced Formation 
in v itro  of the 455nm Absorption Maximum During Chronic 
■ Administration of Safrole to Rats
Safrole
Pretreatment
NADPH-Cytochrome c reductase Production in v itro  of 
455nm Absorption Maximum
Weeks n.mol/mg* % Control AOD/hrt % Control
Control
1
Safrole
29.3 ± 1 .0  
51.8 ± 1.7 177c§
0.051 ±0.002  
0.094 ± 0.003 184c
Control
8
Safrole
27.0 ± 0.8  
53.6 ± 1.7 199c
0.045 ± 0.002 
0.093 ± 0.002 206c
Control
16
Safrole
25.2 ± 1.1 
54.0 ± 1 .9 ‘ 214c
0.045 ± 0.004 
0.105 ± 0.010 233b
*  n.mol cytochrome c reduced per minute per mg microsomal protein
t  AOD per hour per mg microsomal protein
t f55_tf90nm
§ Mean values ± SEM (3 rats per group) s ign ifican tly  d ifferen t from control 
b = p<0.01; c = pcO.OOl
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Table 4.7 shows that a fte r  digestion the 455nm absorption maximum was
quantita tive ly recovered in the 105,000g p e lle t , despite loss of up to 60% of
the cytochrome P450 content. However, the ra tio  cytochrome bs in supernatant
cytochrome bs in pe lle t
was v ir tu a lly  identical for microsomes both from control and safrole-treated
rats , indicating that the contribution of the metabolite complex to the bs
spectrum was negligible.
h) Enzyme Histochemical Changes in the Liver During Chronic 
Administration of Safrole .
A fter administration of safrole fo r 1 week the only histochemical 
change observed was a s light centrilobular depression of glucose-6- 
phosphatase. After 8 weeks, this depression was more marked (Fig. 4.5) 
and there was a s lig h t, generalised loss of an iline hydroxylase.
Succinate dehydrogenase appeared normal but there were strik ing lysosomal 
changes. These were an increase in size , a loss of the pericanalicular 
distribution  of the lysosomes and the presence of enlarged lysosomes and 
autophagic vacuoles randomly distributed within many centrilobular 
hepatocytes (Fig. 4 .6 ). Changes a fte r 25 weeks were s im ilar, but there 
was an increase in the number of autophagic vacuoles. Although there was 
a generalised.loss of aniline hydroxylase, some individual hepatocytes 
showed a strik ing stimulation of an iline hydroxylase a c tiv ity  (Fig. 4 .7 ).
The non-nodular tissue of rats k illed  a fte r 80 weeks did not d if fe r  
greatly from that seen at 25 weeks, although there was a decrease in 
succinate dehydrogenase and an irregular d istribution  of acid phosphatase, 
some cells showing almost no a c tiv ity  whilst in other areas enlarged 
lysosomes and autophagic vacuoles were randomly distributed within the 
ce lls . Nodular tissue was characterised by great v a r ia b ility  
histochemically -  as i t  was biochemically. Large areas of ce lls  did
FIS. 4.5 Glucose-6-phosphatase (x 72).
A. Untreated control U ver -  even distribution
B. Safrole week 8 -  centrilobular loss.
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FIG, 4.6 Acid phosphatase (x 450).
A .  Untreated control H ver (c f. Fig, 3.3A).
B. Safrole week 8 -  clumping* enlargement and scattering of lysosomes.
V •
FIG. 4.7 Aniline hydroxylase (x 180).
A. Untreated control liv e r  -  even d istribution.
B. Safrole week 25 -  generalised loss with individual cell stimulation.
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Safrole week 80. Acid phosphatase -  autophaolc vacuoles 
(arrowed) in nodule (x 600).
FIG. 4.10 Safrole week 80, acid phosphatase (x 450)
A. Increased a c t iv i t y  and scattering o f lysosomes in nodule
B. Reduced a c t iv i t y  in nodule
not stain for glucose-6-phosphatase whilst some cells appeared normal 
(Fig. 4 .8 ): succinate dehydrogenase was generally very low but again, 
some cells appeared normal. Aniline hydroxylase a c tiv ity  was low -  
quite comparable with the surrounding, non-nodular tissue. In some 
areas lysosomal d istribution was re la tiv e ly  normal, in other areas th e ir  
numbers were greatly reduced (Fig. 4.10) whereas in s t i l l  other areas, 
there were increased numbers of lysosomes and autophagic vacuoles were 
abundant (Fig. 4.9 ) -  in short, a grossly disturbed pattern.
j )  Macroscopic Changes in the Liver
Up to and including week 42, the livers of the treated rats were 
s lig h tly  enlarged but otherwise, grossly normal. Gross changes were 
evident in the livers  of treated rats k illed  a t weeks 75 and 85 (Fig. 4 .11). 
In some ra ts , there was no recognisable normal liv e r  tissue, the whole 
being replaced by irregu lar, single or multiple nodules of up to 3 cm in 
diameter, w hilst in other rats , nodules were present only in one or two 
lobes of the liv e r  and some of these might be only 1-2 mm in diameter.
Some nodules, up to 1.5 cm in diameter were sim ilar in colour and texture to 
the adjacent parenchyma whilst others were associated with large amounts 
of connective tissue and areas of necrosis. Some nodules were cystic and 
f i l le d  with blood or clear f lu id . No invasion of neighbouring organs 
was noted. In one ra t k illed  at 75 weeks, ascitic  flu id  was present 
although the liv e r  of this ra t was subsequently shown to contain levels  
of drug metabolising enzymes higher than those of the other treated rats .
No abnormalities were.observed in control rats.
FIG. 4.11 Safrole week 80 - gross appearance of 
nodule-bearing liv e rs .
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k) Histological Changes in the Liver
Centrilobular ce ll enlargement was evident at a ll  stages of safrole 
treatment, this enlargement being particularly  marked a t 80 weeks (Fig. 4 .12). 
Individual cell necrosis was observed in the livers’ of some treated rats 
k illed  at 8 weeks and a t 25 weeks several necrotic hepatocytes were 
present in almost every centrilobular area (Fig. 4 .13): careful examination 
revealed no such changes in liv e r  from control rats . No other changes were 
apparent up to and including week 42, although small cytoplasmic vacuoles 
frequently seen in control tissue, were not seen in tissue from treated 
ra ts .
I t  was not possible to determine whether coadministration of 
phenobarbitone exerted any protective effect against the necrogenic e ffect 
of safrole since in th is experiment, individual cell necrosis was observed 
in both the treated arid untreated ra ts . However, mild inflammatory ce l1 
in f i lt ra t io n  was also evident and electron microscopy revealed the 
presence of virus particles in hepatocytes of both treated and untreated 
rats. Although these findings were restricted to th is particu lar  
experiment, i t  is clear that the significance o f individual l iv e r  cell 
necrosis in the stra in  of rats used and under the conditions o f the 
present experiments must be assessed with caution.
The principal histological features o f the non-nodular l iv e r  tissue 
obtained from treated rats k ille d  at weeks 80 and 85 included varying 
degrees of fa tty  change, in tra ce llu la r oedema, hydropic degeneration,, 
b ile  duct p ro life ra tio n , vascular d ila ta tion  and liv e r  ce ll necrosis 
(Fig. 4 .14). Small areas of hyperplasia surrounded by a rim o f 
compressed hepatocytes were seen quite frequently in this tissue. The 
nodular lesions subjected to biochemical analysis (4.3c) were a l l
&FIS. 4*12 Centrilobular ce ll enlargement
A. Safrole week 1 (Haematoxylln end eosln (H & t )  x 450).
B. Safrole week 80 ( * • •  *  i  180).
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FIG. 4.13 Safrole week 25 -  Individual cell necrosis (arrowed) 
around central vein (H & E x 450)
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FIG. 4.14 Safrole week 80 -  histological features of non-modular liv e r
A. Cell enlargement and hydropic degeneration (H & E x 180)
B. Higher power of part o f A -  several pyknotlc nuclei are arrowed (H & E x 770)
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FIG. 4.14 (continued)
C. B1le duct hyperplasia (H & E x 180)
D. Fatty change (H Si E x 180)
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R 6 . 4.15 Safrole week 80 -  histological features of nodule
A* Nodule (on righ t) containing a portal trac t and compressing adjacent 
parenchyma (H ft £ x 72).
B. Arrangement o f liv e r  cords within the nodule (H ft E x 180).
diagnosed as hyperplastic nodules. Within these nodules, there was 
d ila ta tio n  of the sinusoids and no recognisable lobular arrangement. 
However, portal tracts were.present and the trabecular arrangement was 
preserved with liv e r  cell cords no more than two cells thick: the 
cells were fa ir ly  regular and not greatly enlarged. The nodules 
compressed the surrounding parenchyma but they were not associated 
with extensive fib ro s is , nor did they show any tendency to invade the 
surrounding parenchyma (Fig. 4 .15). No nuclear abnormalities were 
apparent in either the nodule or the adjacent non-nodular liv e r  tissue.
1) U ltrastructural Changes in the Liver
After administration of safrole f o r i  week, free ribosomes were 
abundant and there was a moderate increase in smooth endoplasmic 
reticulum (Fig. 4 .19). A fter 8 weeks, proliferation of the smooth 
endoplasmic reticulum was marked, the rough endoplasmic reticulum 
appeared dilated and occasional autophagic vacuoles were evident. An 
•increased number of free ribosomes was no longer apparent. By week 25 
most of the extra-nuclear space was occupied by smooth endoplasmic 
reticulum (Fig. 4.17): in some cells this appeared as dilated tubules 
while in others i t  was fin e r and more densely packed. Autophagic vacuoles 
were abundant and frequently they appeared to have enclosed areas of 
smooth endoplasmic reticulum. Some of these vacuoles contained 
tightly-packed whorls of smooth membrane (Fig. 4 .18). The rough 
endoplasmic reticulum was dilated and had completely lost its  normal, 
paralle l array formation. Similar changes were observed a fte r  80 weeks 
in the non-nodular liv e r , whilst in the nodular tissue there appeared 
to be less smooth, and s ligh tly  more -  grossly disorganised -  rough 
endoplasmic reticulum (Fig. 4 .20). Apart from th is , there was great 
v a ria b ility  in the number and size of mitochondria, in the number of
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FIG, 4.16 Ontreit&d control rat liv e r  -  typical appearance o f centrilobular
hepatocytes. ti-nucleus; SER-smooth endoplasmic reticulum; R£R~rou$h 
endoplasmic reticulum; m itochondria; L*ly$osome; P~peroxtsoa»; L0-lip id  
droplet; BObile canaliculus (X 7,900).
FIG* 4.17 Safrole week 25. The greater part o f the cytoplasm 1s occupied 
by smooth endoplasmic retlculun (x 7S9Q0)
FIG, 4.18 Safrole week 25 -  extensive proliferation and local
d ilata tion  of smooth endoplasmic reticulum and two autophagic vacuoles 
(arrowed) (x 27,500).
FIO, 4.19 Safrole week 1. Apart from some Increase 1n the content
of smooth endoplasmic reticulum and free ribosomes9 the tissue 
appears normal (x 20,500).
FIG. 4.2QA Safrole week 80 -  non-nodular liv e r . There 1s an
abundance of smooth endoplasmic reticulum *  some o f I t  grossly dilated -  
and several autophagic vacuoles (arrowed) are* present (x 13,700)
FIG. 4.208 Safrole week 80 -  nodule. Portions of two cells are shown
divided by a longitudinally sectioned b ile  canaliculus (8C). hote the 
variable appearance of the rough endoplasmic reticulum {arrowed) and the 
dilated tubules o f smooth endoplasmic reticulum (x 20.S00).
autophagic vacuoles and in the size and vesiculation of Golgi apparatus. 
At no stage were any nuclear or nucleolar changes evident.
Discussion
A response of l iv e r  enlargement and drug metabolising enzyme
induction was seen (Chapter 3) to be sustained during prolonged
administration of BHT. Similar results have been obtained with
phenobarbitone (see 3 .4 ). These findings contrast with the effects of
compounds carcinogenic or acutely toxic to the l iv e r , many of which
produce a progressive depression of drug metabolising enzyme a c tiv ity
(Meyer and Barber, 1973; Vorne and Arvela, 1971). The hepatic effects
of safrole were biphasic and cannot easily be ascribed to e ither of
these categories of response. In it ia l  enzyme induction was associated
with an enlarged, but morphologically normal liv e r  -  indicative  
* ' * 
according to Golberg (1966) of a physiological liv e r  response -  whereas
subsequent reversal o f this induction correlated with the appearance o f
histochemical and, u ltim ately, histological changes indicative of
hepatotoxicity (Feuer et al_., 1965; Grasso et al_., 1974). Reversal of
drug metabolising enzyme induction during chronic administration of
safrole must be distinguished from the depressive effects of
hepatotoxins and carcinogens referred to above. The former comprised a
return o f some, but not a l l ,  ac tiv ities  of the enzyme system to control
le v e l, the la t te r  comprised a non-specific fa l l  from control leve l.
Effects of Safrole on Drug Metabolising Enzyme A ctiv ity
Despite its  known hepatocarcinogenicity, short term administration 
of safrole e lic ite d  a marked induction of drug metabolising enzyme 
ac tiv ity  resembling that produced by BHT or phenobarbitone. However, 
safrole cannot be simply classified as a phenobarbitone-type inducer 
(see 1.4) in view of its  action in preferentia lly  stimulating the
2-hydroxylation of biphenyl - an effect typical of carcinogenic polycyclic 
hydrocarbons (Creaven and Parke,. 1966) -  and in inducing the appearance 
of the absorption maximum at 455nm. In further contrast to the action of 
phenobarbitone, the present results have shown that the high levels of 
enzyme a c tiv ity  in i t ia l ly  induced are not maintained on prolonged 
administration of safrole.
This decline in hydroxylating enzyme a c tiv ity  cannot readily be 
attributed to non-specific effects such as decreased b io a v a ila b ility , 
increased metabolism via an alternative pathway or a d irect toxic action 
of safrole on the l iv e r , since certain components of the drug hydroxylase 
system remained greatly elevated even a fte r the appearance of gross 
pathological changes in the liv e r . Rather, the persistence of elevated 
levels of microsomal protein and cytochrome c reductase suggests that a 
state of induction is maintained, but that the expression of th is as 
increased enzyme a c tiv ity  is in some way impaired. The rate of reduction of 
cytochrome P450, rather than its  actual concentration, is  regarded as the 
ra te -lim itin g  step in drug metabolism (Gigon et al_., 1969). Whilst the 
ac tiv ity  of NADPH-cytochrome P450 reductase may not be d ire c tly  
reflected in the a c tiv ity  measured as NADPH-cytochrome c reductase 
(Davies et al_., 1969), i t  seems probable, in view o f the maintained 
induction of the la t te r ,  that the decrease in enzyme a c tiv ity  derives . 
from changes in the terminal oxygenase, cytochrome P450, such that its  
concentration does become ra te -lim itin g . In support of th is  view, i t  is  
known that the interaction of safrole, or a metabolite thereof, with 
liv e r  microsomes in v itro  results in a non-competitive in h ib ition  of 
ethylmorphine metabolism (Franklin, 1972a) and an inh ib ition  of up to 
50% in the binding of CO to cytochrome P450 (Philpot and Hodgson, 1971), 
these effects paralleling the appearance of the absorption maximum at 
455nm. I f  safrole interacts in a sim ilar manner in vivo, i t  follows
that the true level of cytochrome P450 in microsomes from safrole-treated  
rats is some 40-50% greater than the apparent leve l, i .e .  the induction 
of cytochrome P45G is e ffec tive ly  'masked'. Experimental evidence to 
support this contention is presented in. Chapter 7. However, since 
the extent of th is 'masking', as judged by the level of the 455nm 
absorption maximum, was sim ilar a t 1 week, when there was enzyme 
induction, and a t 16 and 25 weeks when enzyme ac tiv ity  was no more than 
control levels, i t  cannot d irec tly  account fo r the fa l l  in hydroxylating 
enzyme a c tiv ity . By the same argument, the apparent decrease in the 
level of cytochrome P450 between 1 and 16 weeks cannot be attributed to 
increased inhib ition of CO-binding, but must represent a genuine 
decrease. Thus, the decline in enzyme a c tiv ity  appears to result from a
- t
fa l l  in the true cytochrome P450 content to a level a t which 'masking'
by metabolite binding, reduces the amount of active cytochrome P450 to
around control leve l. For the substrates ethylmorphine and an iline ,
this conclusion is supported by calculation of the ratio
enzyme a c tiv ity _________ : there is l i t t l e  change in this ra tio
cytochrome P450 concentration
between 1 and 25 weeks. In the case of biphenyl, more complex changes 
appear to be involved since the decreased rate of its  4-hydroxylation 
was associated with a halving of this ra tio .
An explanation fo r this d iffe ren tia l e ffect on the rate of 
metabolism of the two type 1 substrates, ethylmorphine and biphenyl, 
may l ie  in the finding that under certain conditions, biphenyl, but not 
ethylmorphine, can displace the bound safrole metabolite from 
cytochrome P450. This is discussed in Chapter 7. In a sim ilar vein, 
i t  is notable that ethoxyquin induces the metabolism of ethylmorphine 
but not of biphenyl (Parke e t al_., 1972) and that piperonyl butoxide, a
methylenedioxyphenyl derivative related to safrole, when 
administered to rats 1 hr prior to k il lin g , inhibits the metabolism of 
aminopyrine competitively but inh ib its  the metabolism of biphenyl 
non-competitively (Friedman et a ! . ,  1972).
The view that the effects of safrole on drug metabolising enzyme 
a c tiv ity  are dependent on the balance between induction of cytochrome 
P450 and its  inactivation by metabolite binding, is supported by the 
finding that coadministration of phenobarbitone with safrole prevented 
the fa l l  in enzyme a c tiv ity  produced by safrole alone.
Phenobarbitone probably acts not only by increasing the to tal 
concentration of cytochrome P450, but also by accelerating the metabolism 
and excretion of safro le. This might involve induction of metabolism not 
leading to formation of the metabolite complex, or an increased rate of 
further metabolism of the bound metabolite -  possibly via induction of 
glucuronyl transferase (Halac and Sicignano, 1969). The la t te r  seems 
plausible since piperonyl butoxide is known to induce hepatic glucuronyl 
transferase a c tiv ity  (Goldstein e t 1973).
The decrease in cytochrome P450 content, unaccompanied by any fa l l  
in cytochrome c reductase a c tiv ity , suggests that safrole i t s e l f ,  or 
formation of the metabolite complex, may exert a specific influence on the 
balance between synthesis and degradation of cytochrome P450. An 
investigation of these rates (see Greim et al_., 1970), and the rate of 
turnover of the metabolite complex in vivo should be f r u i t fu l .  I t  seems 
improbable that the a lly ! group, which in certain other molecules causes 
destruction of microsomal haem and an impairment of haem biosynthesis 
(A b ritti and De Matteis, 1971/72; De Matteis, 1971, 1973), exerts any 
such effec t in the case.of safrole in view of the potent induction of 
cytochrome b5 e lic ite d  by safrole. This finding is perplexing, fo r
powerful inducers such as phenobarbitone or 3-methylcholanthrene 
produce only modest increases in cytochrome b5 concentration 
(Estabrook et al_., 1971). I t  has been proposed that electron transfer 
via cytochrome b5 is responsible for the stimulatory effects of NADH 
on drug metabolism (Hildebrandt and Estabrook, 1971). More recent work 
has shown that cytochrome b5 can donate the second of the two electrons 
required fo r mixed function oxidation (Baron et al_., 1973) but that 
NADPH, via NADPH-cytochrome c reductase, is the obligatory source of 
the f i r s t  electron (Sasame e t a K , 1973). Since, in the present study, 
the a c tiv ity  of NADPH-cytochrome c reductase remained induced, and 
since this flavoprotein cannot accept electrons from NADHrreduced- 
cytochrome b5 (Sasame et al_., 1973), i t  is d if f ic u lt  to envisage a
' • * i
function for the massive amounts of cytochrome b5 induced on prolonged 
administration of safrole. However, since piperonyl butoxide 
(Goldstein et al_., 1973) and isosafrole (Lake, 1974) also appear to 
induce the formation of large amounts of cytochrome b5, the possib ility  
that i t  functions in formation of the 455nm absorbing species produced 
by these methylenedioxyphenyl compounds cannot be excluded.
Although the extent of the induction, of-cytochrome c reductase and 
formation of the 455nm absorption maximum was very sim ilar, the very 
slow apparent rate of the la tte r  reaction argues against a d irec t, 
quantitative relationship between these two a c tiv it ie s . The results are 
more consistent with the view that the a c tiv ity  of cytochrome c reductase 
reflects  the effective maintenance of enzyme induction, as discussed 
above, and that the observed parallel increase in formation of the 455nm 
absorption maximum results from the slow rate of this reaction such that, 
in this case, the concentration of cytochrome P450 is not rate lim itin g . 
Thus, i t  seems improbable that these findings represent a specific
induction of safrole metabolism, although the unknown nature of the 
reaction -  particu larly  its  relationship to the further metabolism and 
excretion of safrole -  hinders further interpretation.
Interrelationships between the biochemical and the morphological changes 
produced by safrole
In considering the possible significance of the changes in drug 
metabolising enzyme a c tiv ity  observed in v it ro , account must be taken 
of the influence of increased liv e r  weight on the total drug metabolic 
capacity of the in tact treated rats . When expressed per total amount of 
l iv e r  per lOOg body weight ( i .e .  in relation to re la tive  liv e r  weight), 
only the a c tiv ity  of biphenyl 4-hydroxylase decreased to below control 
levels although metabolic a c tiv ity  toward a ll three substrates 
examined decreased markedly from the in i t ia l ly  induced levels. In fa c t, 
the measurements of hexobarbitone sleeping time indicate that the trends 
observed in v itro  may re fle c t quite closely the situation obtaining in 
vivo and that prolonged administration of safrole does lead to an 
impairment of drug metabolism.
I f  the in i t ia l  enzyme induction is viewed as a response to the 
metabolic load posed by ingestion of safrole, the demise of this 
response might be envisaged as being disadvantageous to the animal. A 
biphasic e ffe c t on drug metabolising enzyme a c tiv ity  rather sim ilar to 
that produced by safrole was observed by Hutterer et al .^ (1969) during 
the chronic administration of d ieldrin to rats . The decline in enzyme 
a c tiv ity  occurred while the liv e r  remained h isto log ically  and 
u ltras tru c tu ra lly  normal but was followed by the appearance of 
mitochondrial in jury . This sequence of events led the authors to 
conclude that loss of drug metabolising capacity resulted in the 
in tra ce llu la r accumulation of levels of d ie ldrin  toxic to the
mitochondria. No such precise chronology of biochemical and 
morphological events can be discerned from the present results with 
safrole. I t  can only be said that during the in it ia l  phase of enzyme 
induction the liv e r  showed no abnormalities whereas the phase of 
decline was associated with the appearance of histochemical and 
ultrastructural evidence of in jury . This situation lends i ts e lf  
equally well to the view that cell in jury was the cause of the decline 
as i t  does to the converse, that cell in jury was in some w a y ' a  
consequence of the fa ilu re  or breakdown of an adaptive response.
However, the finding discussed e a rlie r  that certain components of the 
drug metabolising enzyme system are maintained at high levels, would 
tend to favour the second of these two p o ss ib ilities .
Changes in hepatotoxic effects following alterations in drug 
metabolising enzyme a c tiv ity  depend largely on the re la tive  to x ic ities  
of the parent compound and its  metabolites. L it t le  information of 
this type is available in the case of safrole. Borchert e t al_. (1973a, b) 
have shown that I'-hydroxysafrole is a much more potent 
hepatocarcinogen than safrole i ts e lf  and that production of this  
metabolite is increased some 10-fold in rats pretreated with 
phenobarbitone or 3-methylcholanthrene. However, the practical 
significance of these findings may not be great, since safrole did not 
induce this pathway of its  own metabolism nor was tumour incidence or 
m ortality altered a fte r 14 months in rats treated simultaneously with 
safrole and phenobarbitone (Borchert et al_., 1973b). A role for the 
in tact methylenedioxy ring in the hepatotoxicity of safrole is 
suggested by observations that on chronic administration, 
methylenddioxybenzene but not allylbenzene or eugenol (4 -a lly l-l-hyd ro xy  
2-methoxybenzene) produced liv e r  changes sim ilar to , although less 
marked than those produced by safrole (Hagen et a l . ,  1965; Taylor e t a l . ,
117
1964). These morphological findings correlate with biochemical 
observations that both safrole and methylenedioxybenzene can combine with 
and inactivate cytochrome P450 -  as complexes absorbing at 455nm -  
whereas allylbenzene and eugenol cannot (Franklin 1971; Chapter 7 ). The
present results do not permit interpretation of the biphasic e ffe c t of 
safrole on drug metabolising enzyme a c tiv ity  in terms of increased or 
decreased tissue levels of safrole or its  metabolites. Nevertheless 
i t  seems probable that an early resu lt of the demise of the in i t ia l
enzyme induction would be a disturbance of the equilibrium between
'
intake and excretion of safrole. I t  is possible therefore, that the cell
injury produced by safrole might be in itia te d  by an increase in its  
in tra ce llu la r concentration. Such a hypothesis was advanced by
• * • i
Hutterer et al_. (1969) to explain th e ir results with d ie ld rin . Whilst 
i t  is almost certa in ly  too sim plistic , pharmacokinetic studies to 
determine whether changes in enzyme a c tiv ity  could be correlated with 
changes in tissue levels of safrole would seem to be ju s tif ie d . The 
a v a ila b ility  o f suitably radio-labelled safrole would enable accurate 
collection of such data by pulse-labelling during the chronic 
administration of unlabelled safrole.
The degree of pro liferation  of the smooth endoplasmic reticulum
increased progressively up to week 25 of treatment but i t  was
unaccompanied by any sim ilar increase in drug metabolising enzyme
a c tiv ity  or microsomal protein content. Normally, increases in these
two parameters are closely related (Fouts, 1971). I t  is noteworthy
however, that a dissociation of smooth membrane proliferation from
enhanced drug metabolising enzyme a c tiv ity , as seen with safro le , was 
«
also a feature of early d ieldrin  intoxication (Hutterer et al_., 1968; 
1969). The abnormal nature of the excessive smooth membrane 
proliferation induced by safrole is also indicated by the u ltrastructural
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finding that the autophagy observed histochemically appeared to be 
associated with these membranes. The histological findings in the 
present study were quite consistent with those reported in previous 
studies with safrole (see 4 .1 ). Results obtained with safrole-induced 
liv e r  nodules are discussed in Chapter 8 in the context of the nodules 
induced by Ponceau MX and 2-acetyl aminofluorene.
CHAPTER FIVE
t
BIOCHEMICAL AND MORPHOLOGICAL CHANGES IN THE 
LIVER DURING CHRONIC DIETARY ADMINISTRATION 
OF PONCEAU MX TO RATS
5.1 Introduction
The water soluble, red food colour, Ponceau MX (Ponceau R; Ponceau 
2R; Colour Index (1956) N° 16150) was defined by the British Standards 
In s titu te  (1963) as the disodium sa lt of l - ( 2 ,4 -  or mixed xyly.lazo)-2- 
naphthol-3,6-disulphonic acid. I t  was removed from the l is t  o f colours 
permitted in foods in the U.K. in 1971 on the grounds of its  
hepatotoxicity and possible hepatocarcinogenicity.
Commercial Ponceau MX consisted of a mixture of closely related  
dyes with 2-naphthol-3,6-disulphonic acid as the common constituent. 
Variations derived from the amine component of the molecule which could 
be e ither monomethylated, polymethyl ated or ethylated.' According to 
PI a Delfina (1968), dyes formed from up to 11 d ifferen t amines might 
commonly be present, although in practice derivatives of the 
dimethyl an ilines, 2,4-(45-60%) 2,5-(15-25%) and 2,6-xylidine(12-20%) were 
the principal components. The composition of d iffe ren t samples of 
Ponceau MX varied according to the composition of the in it ia l  
coal-tar d is t i l la te  subjected to the n itra ting  and reducing process.
In the closely related Ponceau 3R (C .I. 16155), dyes formed from 
trimethyl anilines -  principally 2,4 ,5-trim ethylan iline -  accounted 
for up to 50% of the total dye (Lindstrom, 1961; Pla Delfina, 1968;
Ttenell, 1964).
Early studies fa iled  to demonstrate c learly any toxic or 
carcinogenic effects of Ponceau MX. Cook et aK (1940) found no 
tumours related to the administration to mice of 2-3 mg per day of 
Ponceau MX for up to 25 months. S im ilarly , Waterman and Lignac (1958) 
found no s ign ificant increase in tumour incidence in mice fed 1 mg per 
day of Ponceau MX fo r up to 24 months. Bonser et al_. (1958) treated
mice with 0.05% Ponceau MX in the drinking water and a fte r a further 
observation period o f 9 months found benign caecal polyps, but no 
other tumours, in 4 out of 6 surviving animals. No tumours were 
found by Willheim and Ivy (1953) in rats ingesting for 19 months a 
d ie t containing 4% Ponceau MX.
In considering th e ir  negative results, Cook et a]_. (1940) 
subscribed to a view that " . . .  rapid elimination of these 
water-soluble sodium sulphonates would tend to prevent th e ir  exerting 
a carcinogenic influence". Such a view overlooked the possible 
consequences of reductive cleavage of the azo-link. This process, 
f i r s t  demonstrated by Sisley and Porcher (1911) in dogs fed Orange 1, 
is effected principally  by the(gut microflora and is now a well 
recognised facet of the metabolism of azo compounds (Radomski and 
Mellinger, 1962; Walker, 1970). In the case of Ponceau MX, azo- 
reduction yields a water soluble ami nosulphonic acid (1-ami no-2- 
naphthol- 3 ,6-disulphonic acid) and a mixture of water-insoluble 
aromatic amines (Daniel, 1962). Since, by analogy with the results  
of Radornski . and Mellinger (1962), the absorption of "intact" Ponceau 
MX is unlikely to exceed 5% and since the aminosulphonic acid is 
rapidly excreted, unchanged, in the urine (Daniel, 1962), the amines 
are lik e ly  to be the prime determinants of the biological a c tiv ity  of 
Ponceau MX.
The potential to x ic ity  of these amines was indicated by Treon 
et a l - (1949, 1950), although th e ir studies were conducted with 
commercial 'xy lid ine ' which contained a mixture of isomeric 
^ylidines. More sp ec ifica lly , Lindstrom et a l. (1963) showed that
2,4-xylid ine was hepatotoxic, chronic dietary administration to rats 
producing chalangiofibrosis, b ile  duct p ro life ra tion , hepatic cell
necrosis and foci of hepatic cell hyperplasia: no such changes were 
produced by 2 ,6 -xy lid ine . Similar results were obtained by 
Pla Delfina (1968) who fed rats diets containing 3% of Ponceau MX 
synthesised from pure 2 ,4 - or 2 ,6-xylid ine. However, in dogs, not 
only were these xylidines more acutely toxic but 2,6-xylid ine  
produced more severe liv e r  damage than 2,4-xylid ine (Magnusson 
et al_., 1971). 3 ,4 -X ylid ine , present to the extent of 2-6% in  
Ponceau MX can give rise to p itu itary  tumours in rats (Boyland and 
Sims, 1959) and 2 ,4 ,6-trim ethylan iline present in small amounts 
(0.05-3%) in Ponceau 3R is weakly hepatocarcinogenic (Morris et a l . ,  
^964).
The chronic hepatotoxici ty of 2,4-xylidine (Lindstrom et a l . ,
1963) and the weak hepatocarcinogenicity of Ponceau 3R (Grice e t a l . ,  
1961; Hansen et al_., 1963), suggested that sim ilar effects might be 
exerted by Ponceau MX and more recent studies support this view.
Thus, liv e r  enlargement with fa tty  change and cloudy swelling was 
observed by Hall.^et ja l. (1966) in rats fed diets containing 0 .5 - 
2.0% of Ponceau MX for 90 days. Ikeda et al_. (1966) found that rats 
given dietary levels of 0.2-5.0% of Ponceau MX containing over 85% of 
the 2,4-xylylazo derivative for 15 months developed lesions diagnosed
as liv e r  ce ll adenomas. In a subsequent study with mice (Ikeda et a l . ,
1968) sim ilar findings were reported, although some lesions were
classified as hepatocellular carcinoma. Rats given dietary levels of
0.125-1.0% Ponceau MX(mixed xylylazo derivative) for 2 years developed 
liv e r  lesions which were interpreted by Grasso et al_. (1969) as 
nodular hyperplasia following hepatocellular necrosis. This 
in terpretation has been a matter of some controversy (see Bonser and 
Roe, 1970).
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The disposition in the ra t of 35S-labelled Ponceau MX was studied 
by Urakubo (1967) who reported that a fte r  oral administration i t  was 
excreted mainly in the faeces and a fte r intravenous administration, 
mainly in the urine -  unchanged. However, these observations are 
probably misleading since, a fte r cleavage of the azo-link, they are 
informative only of the naphthol portion of Ponceau MX, an entity  
known to be poorly absorbed from the gastrointestinal trac t (Radomski 
and M ellinger, 1962) and also to be rapidly excreted, unchanged, in  
the urine (Daniel, 1962). The metabolism of the xylidine components 
of Ponceau MX was investigated by Lindstrom (1961) and Lindstrom et a l. 
(1963). They found that the hepatotoxic 2,4-xylid ine was metabolised 
by oxidation of the 4-methyl group to give 3-methyl-4-aminobenzoic
r
acid, whereas the re la tive ly  non-toxic 2 ,5 - and 2,6- xylidines were 
metabolised almost exclusively to the corresponding 4-ami nophenols. The 
extent to which cytochrome P450 is involved in these reactions is 
uncertain. Tonkopii and Fateev (1967) reported that 2,4-xylid ine given 
in traperitoneally  one hour before hexobarbitone increased the duration 
of anaesthesia, suggesting an interaction of this xylidine with 
cytochrome P450. Grasso et .al. (1969) c ite  unpublished experiments 
showing stimulation of drug metabolising enzyme a c tiv ity  when weanling 
rats were given a d iet containing 2% Ponceau MX for 14 days.
In this chapter, experiments have been performed, as in Chapter 4, 
to determine whether any correlations exist between the effects of 
Ponceau MX on drug metabolising enzyme a c tiv ity  and the development of 
pathological changes in the liv e r . Liver nodules from the treated  
animals have been studied, as have some effects of the constituent, 
xylidines of Ponceau MX.
5.2 Materials and Methods
For one experiment liv e r  and liv e r  nodular tissue was obtained from 
Wistar albino rats maintained for 56 weeks on a d iet containing 2%
Ponceau MX in the animal unit of the British Industrial Biological 
Research Association, Carshalton, Surrey.
All other, materials were as described in 2.1.
Methods
V
a) Chronic Administration of Ponceau MX
Female rats were maintained on a d ie t containing 1.0% (w/w) Ponceau 
MX as described in 2 .2 . This dose level was selected with reference to 
the study of Grasso e t aK (1969) as being su ffic ien t to produce a high 
incidence of liv e r  nodules without s ign ificantly  increasing m ortality .
At weeks 1, -16* 25, 42 and 80, 4 treated and 4 control'rats  
were k illed  and the livers  used for the assays described in 2 .3 . In 
addition, these assays were carried out on tissue obtained from liv e r  
nodules at weeks 66, 70 and 80. The procedures and precautions 
applied in obtaining this tissue were described in 4.2a.
Enzyme histochemistry (2 .3) was carried out on liv e r  samples from 
rats k illed  a t weeks 1, 8, 16 and 25-and on nodular, and adjacent, 
non-nodular liv e r  from rats k ille d  at 56 and 80 weeks. Liver samples 
from the same rats'were examined by lig h t microscopy and, in some 
cases, by electron microscopy (2 .3 ).
b) Administration of 2 ,4 - , 2,5- and 2,6-Xylidine
Three experiments were performed. The f i r s t  involved the
125
administration of each isomer at a level of 0.25% (w/w) in the d iet for 
7 days to groups of 4 female ra ts , a fourth group receiving control 
d iet only. In the second experiment the isomers were administered by 
oral intubation of 5% (w/v) solutions in groundnut o il a t a dose level 
of 150 mg/kg/day for 7 days. Controls received groundnut o il alone. 
Finally rats were fed the 0.25% 2,4-xylidine d iet for 1 and 8 weeks.
c) Interaction of 2 ,4 -, 2 ,5- and 2,6-Xylidine with Cytochrome F45Q
The kinetic  constants of and A0Dm„„ were determined as describeds max
in 2.3. Xylidines were added as solutions 500 mM in 50% (v /v) ethanol 
to produce the following, fina l cuvette concentrations ( mM):- 
0 .2 , 0 .3 , 0 .4 , 0 .5 , 0 .6 , 0 .8 , 1.2, 2.0.
5.3 Results
a) Animal Body Weights and Food Intake
Growth curves for the control and Ponceau MX-fed rats are shown in 
Fig. 5.1. The growth rate o f the treated rats was s lig h tly , but 
sign ifican tly  (a fte r  4 weeks), depressed. In it ia l  d ie t rejection was 
followed by a rapid s tab ilisa tion  of food intake at a level s ligh tly  
below that of the control group (Table 5 .2 ). Over the f i r s t  12 weeks, 
the depression of body weight of the treated rats correlated well with 
the depression of food intake: subsequently the re la tive  decrease in 
body weight was not accompanied by any further reduction of food intake 
(Table 5 .1 ). However, measurements of body weight a fte r about week 40 
were influenced by the development of severe respiratory disease in 
many of the rats. Whilst this outbreak affected roughly equal numbers 
of control and treated rats , there were many more deaths amongst the 
treated rats , severely reducing the numbers available for experimentation.
The effects of Ponceau MX on body weight and food intake are 
summarised in Table 5.1 and the approximate daily intake of Ponceau MX, 
in mg/kg body weight, calculated from the food intake data, is shown in  
Table 5.2.
b) Biochemical Changes During Chronic Administration of Ponceau MX
These data are presented in the form treated as % of control 
values, in Fig. J>.2 and Table 5.3. The fu ll data, with s ta tis tic a l 
treatment, are included in the Appendix (Table A3).
The induction of drug metabolising enzyme a c tiv ity  e lic ite d  by 
Ponceau MX was much less marked than that produced by either BHT or 
safrole. After 1 week, the treated rats showed increases - per gram
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liv e r  -  of 25-75% in the a c tiv itie s  of ethylmorphine N-demethylase, 
biphenyl 4-hydroxylase and NADPH-cytochrome c reductase and in the 
contents of cytochrome P450 and b5. In contrast, the a c tiv ity  of 
aniline 4-hydroxylase was s ign ifican tly  depressed, being only 64% 
of the control value. There were small increases in the content of 
microsomal (17%) and to ta l l iv e r  (8%) protein and in the a c tiv ity  of 
glucose-6-phosphate dehydrogenase (12%), whilst the a c tiv ity  of 
succinate dehydrogenase showed a decrease of 20% which was not 
s ta tis t ic a lly  s ign ifican t. Liver weight was sign ificantly  increased(35%). 
In common with the e ffec t of safrole, Ponceau MX produced a preferential 
increase in the 2-hydroxylation of biphenyl.
A fter administration of Ponceau MX fo r 8 weeks there was no marked 
decrease in the induced levels of drug metabolising enzyme a c tiv ity  such 
as was seen with safrole. The a c tiv ity  of ethylmorphine N-demethylase 
decreased s lig h tly  but that of biphenyl 4-hydroxylase increased from 
its  1 week level and, following its  early in h ib ition , the a c tiv ity  of 
aniline 4-hydroxylase showed a significant increase. These increases 
were not paralleled by any further increase in the content of 
cytochrome P450 or the a c tiv ity  of NADPH-cytochrome c reductase. The 
large increase in l iv e r  weight resulted in greatly elevated levels of 
a ll parameters when expressed per to tal liv e r  per lOOg body weight and 
this was true fo r a ll subsequent sampling intervals.
Continued administration of Ponceau MX brought about a gradual 
decrease in drug metabolising enzyme a c tiv ity  such that a t.th e  time of 
appearance of grossly recognisable liv e r  nodules (about 60 weeks) the 
a c tiv ity  of a ll parameters -  expressed per gram liv e r  -  had returned 
to , or fa llen  below, control levels. For the reasons outlined in 4.3b, 
values expressed per to tal liv e r  per lOOg body weight when there was
CO
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FIG 5,2
Measurements of Some Drug Metabolising Enzymes and Related Parameters 
at Intervals During Chronic Dietary Administration of Ponceau MX to 
Female Rats.
Mean values fo r the treated rats are expressed as % of control values.
(4 rats per group). Significant differences are shown (Units per g. live  
only): a = p<0.05, b = p<0.01, c = p<0.001.
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TABLE 5.3
•flp
Measurements of Some Parameters Additional to those shown in Fig. 5.2
WEEKS
1 8 16 25 42 80
Biphenyl 2-hydroxylase 245 400c oo 340c 320b 171
Succinate dehydrogenase 80 90 94 81b 80a 85a
G1ucose-6-Phosphate dehydrogenase 112 100 126b 87 - -
Total liv e r  protein 108 97 101 90c 82c 88
*  Results expressed as % of control in units per g l iv e r .
gross pathological change in the l iv e r , are not considered 
meaningful.
c) Biochemical Investigations of Ponceau MX-Induced Liver Nodules
H istologically, an area of hyperplasia was observed in the liv e r  of 
one ra t as early as 25 weeks: however, su ffic ien t nodular tissue for 
biochemical analysis was not normally present before 60-70 weeks.
Tables 5.4 - 5.6 show the results obtained a fte r  66, 70 and 80 weeks in  
the form nodular and non-nodular treated liv e r  as % of control, and 
nodular as % of non-nodular treated liv e r . The basic data are given 
in the appendix (Tables A7 -  A9).
As in the case of the safrole-induced nodules, the results were 
characterised by considerable v a r ia b ility  such that large differences 
between mean values for the nodules and either the control or 
non-nodular treated liv e r were not always s ta tis tic a lly  s ign ifican t. 
However, a consistent feature of the nodules was a content of microsomal 
protein s ign ifican tly  lower than that of liv e r  from control rats or the 
non-nodular part of livers from treated rats. Consequently, when values 
were expressed per mg microsomal protein , increases.in the nodule were 
accentuated and decreases were less marked re lative  to the control and 
non-nodular treated liv e r . In general, most parameters of microsomal 
enzyme a c tiv ity  were lower in the nodule than in.the control or the 
non-nodular treated liv e r , although these decreases were much less 
marked, and in some instances no longer apparent, when values were 
expressed per mg microsomal protein. Fa irly  consistently the 
ac tiv itie s  of biphenyl and aniline 4-hydroxylase were higher in the 
nodular tissue, even when expressed per gram of tissue. In contrast, 
the a c tiv itie s  of ethylmorphine N-demethylase and NADPH-cytochrome c
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reductase and the content of cytochrome P450 were usually lower in the 
nodule expressed either per gram of tissue or per mg microsomal 
protein. The a c tiv ity  of the mitochondrial marker enzyme, succinate 
dehydrogenase, was s im ilarly  depressed in the nodule. Total protein 
content of the nodules was either the same or s lig h tly  less than that 
of the control and the non-nodular treated liv e r , in contrast to the 
findings fo r microsomal protein. A sim ilar pattern of results was 
observed in a ll three experiments and there was no obvious correlation  
between enzyme a c tiv ity  and size of the nodules. Similar results were 
also obtained in a preliminary experiment with tissue from rats fed 
2% Ponceau MX for 56 weeks. In this experiment there was a strik ing  inverse 
relationship between a c tiv itie s  in the nodule and the non-nodular
* i
treated liv e r  within any one animal.
d) Effects of 2 ,4 - , 2 ,5- and 2,6-Xylidine on Drug Metabolising 
Enzyme A ctiv ity
Results of the administration of xylidine isomers in the d ie t and 
by oral intubation are shown in Figs. 5.3 and 5.4 respectively, 
expressed as % of control values. Results of the dietary  
administration of 2,4-xylid ine for 1 and 8 weeks are shown in Fig. 5.5 
expressed in the same manner.
When xylidines were given in the d iet the 2,4- isomer produced 
marked increases in a ll the parameters studied whilst 2 ,6 -xy lid ine had 
l i t t l e  e ffe c t. The effec t of 2,5-xylidine was intermediate between 
these two. Only 2 ,4-xylid ine produced a sign ificant increase in liv e r  
weight, w hilst both 2,4- and 2,5- but not 2 ,6-xylid ine e lic ite d  very 
marked increases in biphenyl 2-hydroxylase -  approximately twice the 
respective increases in biphenyl 4-hydroxylase.
\
Effect of Dietary Administration for 1 Week of 2 ,4-, 2,5- and
2,6-xylid ine on Some Drug Metabolising Enzymes and Related Parameters
Mean values for the treated rats are expressed as % of control 
values (4 rats per group) in units per g liv e r.
Treatments are shown as: 24, 25 and 26 = 2 ,4 -, 2,5- and 2 ,6 -xy lid ine  
respectively (see 5.2b)
2 2 5 r
200
o
cn
oo
150
100 24 25 26 24 25 26 24
25 26
Ethylmorphine N- 
demethylase
Aniline 4- 
hydroxylase
Biphenyl 4- 
hydroxylase
200
150
100
75
24 25 26
Cytochrome P450
24 25 26
Cytochrome b5
24 H ZL 26
Microsomal Protein
200 -
150
100 24 25 26
Relative liver weight
400
300
200
100 24 25
Biphenyl 2-hydroxylase
Effect of Administration by Oral Intubation for 1 Week of 2 ,4 -, 2,5- and
2,6-xy lid ine on Some Drug Metabolising Enzymes and Related Parameters
Mean values for the treated rats are expressed as % of control values 
(4 rats per group) in units per g liv e r .
Treatments are shown as: 24, 25 and 26 = 2 ,4 -, 2,5- and 2,6-xylidine  
respectively (see 5.2b)
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Rather d iffe ren t results were obtained when the xylidines were 
given by oral intubation. The stimulatory effects of 2 ,4- and
2.5-xy lid ine were much less pronounced, with the exception of their 
effects on biphenyl 2-hydroxylase which was unchanged and the effect 
of 2 ,4 -xy lid ine on re la tive  liv e r  weight which was increased. 
Although remaining s lig h t, the stimulatory e ffec t of 2,6-xylidine  
appeared to be greater when given by oral intubation.
I t  should be noted that 2 ,4 -xy lid ine, when given in the d ie t, 
depressed food consumption to a much greater extent than 2,5- or
2 .6 -xy lid ine . Consequently, over the 7 days, the mean dose level 
for 2 ,4 -xy lid ine was approximately 150 mg/kg as opposed to 
approximately 250 mg/kg for the other two isomers. The dose level 
given by intubation was selected to be comparable with that for
2.4 -xy lid ine given in the d ie t: therefore the dose level of
2.5- and 2,6 -xy lid ine given by intubation was lower than that given 
d ie ta r ily . None of the isomers had any effect on food consumption or 
rate of body weight gain when given by intubation.
The increases in drug metabolising enzyme a c tiv ity  produced by 
dietary administration of 2,4-xylidine for 1 week were much less 
pronounced when administration was continued fo r 8 weeks. An 
exception was biphenyl 2-hydroxylase, the a c tiv ity  of which increased 
s lig h tly  re la tive  to the control value. The re la tive  liv e r  weight 
increased from 150 to 200% of the control value a fte r  8 weeks.
No histological changes in the liv e r  were seen in any of these 
experiments.
Drug Metabolising Enzymes and Related Parameters
Mean values for the treated rats are expressed as % of control values (4 rats 
per group). Significant differences are shown (units per g. liver only): 
a = p <0.05, b = p<0.01, c = p<0.001.
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e) Interaction of Xylidine Isomers with Cytochrome P450
2 ,4 - and 2 ,5 -xy lid ine produced typical type I I  interaction spectra 
with liv e r  microsomes from untreated female rats. 2 ,6 -xy lid ine , in 
concentrations up to 5mM, produced no spectral change at a l l .  The kinetic
constants determined were as follows:- ' ■
' K_ (M x 10”1*) AOD No. of determinationss . m a X ______________________ _ _
2.4-Xylid ine 10.0 ± 0.2 0.053 ± 0.005 3
p < 0.05
2.5-Xylid ine 9.2 ± 0 .3  0.037 ± 0.002- 3
f )  Enzyme Histochemical Changes in the Liver During Chronic
Administration of Ponceau MX
A fter administration of Ponceau MX for 1 week, histochemistry 
revealed a centrilobular depression of glucose-6-phosphatase (as Fig. 4.5) 
and a s lig h t, generalised loss of succinate dehydrogenase. Despite the 
depression observed biochemically, there was no histochemical change in  
aniline hydroxylase a c tiv ity . Liver sections' stained by the Gomori acid 
phosphatase technique showed a decreased number of lysosomes in the 
centrilobular cells  with some cells containing enlarged, randomly- 
distributed lysosomes (Fig. 5 .6 ). Marked centrilobular depression of 
glucose-6-phosphatase was consistently noted at subsequent in tervals .
Succinate dehydrogenase a c tiv ity  appeared variable but although no 
consistent pattern was evident the overall impression was of decreased 
ac tiv ity  -  in agreement with the biochemical findings. At week 8 and 
subsequently a s lig h t centrilobular depression of an iline  hydroxylase was 
observed although at la te r  intervals (week 25 onwards) some individual 
cells appeared to contain high levels of aniline hydroxylase (as Fig. 4 .7 ).
>. V "  < V- - ■
FIG. 5.6 Ponceau MX week 1. Acid phosphatase.
A. Reduced ac tiv ity  1n centrilobular areas (x 72).
B. High power of centrilobular area showing enlarged, randomly 
distributed lysosomes (x 720).
The lysosomal changes which were confined to centrilobular areas at 
week T progressed subsequently and by week 25, involved the greater 
part o f the liv e r  lobule. Autophagic vacuoles were seen in some 
areas a t week 8 and subsequently, but these were.never as frequent as 
with safrole (4 .3h). The nodules induced by Ponceau MX showed a 
v ir tu a lly  complete loss of histochemically demonstrable 
glucose-6-phosphatase (as Fig. 4 .8 ). In some nodules or in some areas 
within nodules the a c tiv ity  of succinate dehydrogenase appeared 
considerably reduced. Aniline hydroxylase a c tiv ity  in the nodules was 
fa ir ly  evenly distributed and appeared comparable to or greater than 
that in periportal areas of the non-nodular liv e r  (Fig. 5 .7 ).
Lysosomal d istribution was quite sim ilar to that observed in the
r '
safrole-induced nodules, i .e .  a wide variation in numbers, size and 
distribution o f the lysosomes. However, autophagic vacuoles were less 
frequently present.
g) Macroscopic Changes in the Liver
Apart from enlargement, no changes were observed before week 42 
when the liv e r  of 1/4 rats k illed  contained a single small nodule 
(approx. 0.2 cm diameter), the colour and consistency of which was 
sim ilar to that of the adjacent parenchyma. Between weeks 52 and 58, 13 
of the remaining 30 treated rats died -  apparently as a result of 
respiratory infection - and in 8 of these rats the liv e r  contained
i
sim ilar nodules ranging from 0.2 -  0.6 cm in diameter. Of the rats 
k ille d  at weeks 66, 70 and 80, the livers of 4 /5 , 6/6 and 4/6 
respectively contained nodules. These might be single, nonrnecrotic 
nodules as described above, but up to 1.5 cm in diameter, and there 
might be several such nodules in any one liv e r . In other cases 
multiple nodules up to 3 cm in diameter might be present, these
FIG,'5.7 Ponceau MX week 80 - nodule showing a n il in e  hydroxylase a c t iv i t y  
equal to or greater than in adjacent5 non-nodular l i v e r  (X 72).
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FIG. 5.8 Ponceau MX week 25 - isolated area o f l i v e r  ce l l  hyperplasia
(H & E x 180)
comprising areas of necrosis, blood or clear f lu id - f i l le d  cysts and 
other re la tiv e ly  "normal" areas. These multiple nodules usually 
accounted fo r more than 75% of the total "liver" weight and were 
often associated with large amounts of connective tissue. The 
macroscopic appearance of the nodules induced by Ponceau MX was 
essentially identical to that of the safrole-induced nodules shown in  
Fig. 4.11. Ascites flu id  was not observed, even in animals whose 
liv e r  was grossly abnormal and no invasion of neighbouring organs was 
noted.
h) Histological Changes in the Liver
Centrilobular ce ll enlargement was evident in the livers of 3/4
rats treated with Ponceau MX for 1 week but only occasionally at
\
subsequent sampling in tervals . Individual centrilobular cell necrosis
(as Fig. 4.13) was noted in 2/4 treated rats k illed  at week 1 and with
a s im ilar, or increased frequency at subsequent intervals up to week 
U
this lesion was not observed in control rats at any stage (c f. 4 .3k ). 
A small area of l iv e r  cell hyperplasia was noted in 1 ra t k ille d  at week 
25 (Fig. 5.8) and at week 42 the liv e r  of 3/4 rats contained several 
such areas.
Non-nodular l iv e r  tissue sampled at week 80 showed s lig h t fa tty  
change, small areas of hydropic degeneration and liv e r  cell necrosis 
and occasional areas o f hyperplasia (Fig. 5 .9 ). Nodular lesions 
compressed the surrounding hepatocytes but, as in the case of sa fro le , 
a ll the nodules examined biochemically were diagnosed as hyperplastic. 
Within these nodules the normal liv e r  architecture was absent and the
porhj-L
cells were irreg u larly  enlarged but occasionalj tracts were present
(Fig. 5 .10). The histological findings in the present study were 
thus in accord with those described by Grasso et al_. (1969).
j )  U ltrastructural Changes in the Liver
At week 1 clusters of normally arranged rough endoplasmic reticulum 
were prominent and there appeared to be an increased number of free 
ribosomes. There was no unequivocal pro liferation  of smooth 
endoplasmic reticulum and the other cell components appeared normal. An 
abundance o f rough endoplasmic reticulum was also observed at week 25.
In some areas this appeared somewhat dilated and the normal parallel 
array formation was absent. P ro liferation and local d ila ta tion  of the 
smooth endoplasmic reticulum was pronounced in some cells (Fig. 5.11) but
• i
in the majority there was only a marginal increase in this component. 
Extensive stacks of d ilated rough endoplasmic reticulum were prominent 
in the non-nodular liv e r  at week 80 (Fig. 5 .12). In some cells the 
smooth endoplasmic reticulum and Golgi apparatus were grossly dilated  
w hilst in Other cells these appeared re la tiv e ly  normal. This variable 
appearance was also a feature of the nodular tissue as is evident from 
Figs.5.13A and B. Some o f the swollen rough endoplasmic re tic u la r  
elements in  both nodule and non-nodular liv e r  appeared to be undergoing 
a loss of bound ribosomes. In many respects the appearance of both 
nodule and non-nodular liv e r  was sim ilar although areas of re la tive ly  
normal cells were more frequently encountered in the nodule. In neither 
tissue were mitochondrial, nuclear or nucleolar abnormalities observed.
V c ,
F I G .  5.9 P o n c e a u  MX w e e k  80 -  h i s t o l o g i c a l  features of non-nodular 
T T v S r .
A. Hydropic degeneration (H & E x 180).
B. Fatty c h a n g e  a n d  l i v e r  c e l l  n e c r o s i s  (H 8 E x 180).
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f f G- S.10 Ponceau MX week 80 -  histological features of nodule
A. Part o f a large nodule with compression of adjacent parenchyma: note the
uniform structure of the nodule (H 4 E x 72)
B. Higher power view of part of a nodule showing the arrangement o f the ce ll
cords: re la tive ly  normal liv e r  occupies the fa r  righ t of the fie ld
( H S E x  180)
F I G ,  5 . 1 1  P o n c e a u  N X  w e e k  2 5  -  a b u n d a n t  r o u g h  e n d o p l a s m i c  r e t i c u l u m  a n d
m i l d  p r o l i f e r a t i o n *  t o g e t h e r  w i t h  l o c a l  d i l a t a t i o n *  o f  t h e  s m o o t h  
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F I G .  5 . 1 2  P o n c e a u  M X  w e e k  8 0  -  o o f r - n o d u l a r  l i v e r ,  P r o l i f e r a t i o n  a n d
g r o s s  d i l a t a t i o n  o f  b o t h  r o u g h  a n d  s m o o t h  e n d o p l a s m i c  r e t i c u l u m  
( x  2 0 * 5 0 0 )
S S ^ L U A  P o n c e s - ,  M X  w e e k  8 0  -  n o d u l e .  N u m e r o u s  f r e e  r i b o s o m e ;  a n d  
c l u s t e r s  o f  d i l a t e d  r o u g h  e n d o p l a s m i c  r e t i c u l u m  a r e  p r e s e n t  ( *  2 0 , 5 0 0 )
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O J L I J I I  P o n c e a u  M X  w e e k  3 0  -  d i f f e r e n t  c e l l  f r o m  t h e  s a n e  n o d u l e
* h 0 * 1 ! ! 9  9 r o ? s  d 1 1 a t a « « » n  O f  t h e  s m o o t h  e n d o p l a s m i c  r e t i c u l u m  a n d  n u m e r o u s  f r e e  r i b o s o m e s  ( *  2 7 , 5 0 0 ) .
5.4 Discussion
Hepatic nodular hyperplasia following the chronic ingestion of 
Ponceau MX has been previously reported (Grasso et a /h , 1969), the 
lesions produced resembling both grossly and histo logically those seen in  
the present study. Such resu lts , however, contrast with those of e a rlie r  
studies (see 5.1) in which dietary levels higher than that used here were 
without long-term effec t in rats . An explanation for these discrepancies 
lies  most probably in the variable composition of d ifferen t dye samples 
and, since the systemic effects of Ponceau MX are probably dependent on 
its  in testinal azo-reduction, in differences in the composition of the 
in testinal microflora. Certainly i t  is known that this flo ra  can vary 
quite markedly between rats from d iffe ren t colonies as judged, fo r 
example, by. differences in rates of reduction of azo-compounds 
(Walker, 1970) and in the extent of conversion of cyclamate to . 
cyclohe>(y:lamine (H i l l ,  1970).
These same considerations, particu larly  the chemical heterogeneity 
of Ponceau MX, impose d iff ic u lt ie s  in interpretation of the biochemical 
changes observed. Thus, the early inhib ition of aniline 4-hydroxylase 
in rats fed the in tact dye contrasted with the stimulatory e ffec t of 
each of the three principal (PIa Delfina, 1968) constituent xylidines 
when these were fed ind iv idually . This suggests that the changes 
e lic ite d  by Ponceau MX may represent no more than the balance between 
the simultaneous action of stimulatory and inhibitory constituent 
compounds. Evaluation of this possib ility  is hindered by ignorance of 
the precise amine composition of the dye sample u tilise d . However, 
apart from the result with an iline 4-hydroxylase, the changes produced 
by Ponceau MX appeared compatible with those produced by 2 ,4 -, 2 ,5- 
and 2,6-xylid ine.
Although Ponceau MX e lic ite d  a re la tive ly  weak induction of drug 
metabolising enzymes i t  caused a marked increase in liv e r  weight. 
Accordingly, the calculated 'to ta l liv e r  a c tiv ity ' values for these 
enzymes were greatly in excess of control values and remained so in  
contrast to the changes produced by safrole. A some what sim ilar  
situation produced in mice was described by Beckett ert al_,(1972). They 
found that the hypo!ipidaemic drug Nafenopin evoked l i t t l e  increase in 
drug metabolising enzyme a c tiv ity , as measured in v itro  on a per g liv e r  
basis, but produced an approximate doubling in liv e r  weight. Despite 
th is , a corresponding doubling of 'to ta l l iv e r ' drug metabolising 
capacity was not observed in vivo, the hexobarbitone sleeping time of 
the treated mice being only s ligh tly  decreased. This would suggest 
that values fo r 'to ta l a c tiv ity ' predicted from measurements of liv e r  
weight and enzyme a c tiv ity  in v itro , may bear l i t t l e  re lation to the drug 
metabolising capacity o f the in tact animal. Certainly there is no 
evidence to suggest that liv e r  enlargement in i ts e l f  represents an 
adaptive response to foreign compound administration. Indeed, as pointed 
out in 1.7 , l iv e r  enlargement unaccompanied by increased drug 
metabolising enzyme a c tiv ity  may be indicative of incipient in jury .
The observation as early as 1 week of histochemical changes involving 
glucose-6-phosphatase and lysosomal acid phosphatase provides some support 
for this view. Such changes were never observed with BHT, and in the case 
of safrole, only a fte r  the demise of the in it ia l  enzyme inductive response. 
The situation a fte r  administration of Ponceau MX fo r 1 week might therefore 
be equated with that prevailing a fte r 8 weeks in the case of safro le. 
Accordingly, less significance can be attached to the biphasic nature of 
the drug metabolising enzyme response to Ponceau MX and the gradual, 
uniform (c . f .  safrole) downward progression of the graphs in Fig. 5.2 is 
probably a non-specific reflection of progressing hepatocellular in ju ry .
Such progression is also indicated by the gradual extension o f the 
lysosomal changes, which in i t ia l ly  were confined to centrilobular 
areas, to involve the greater part of the lobule. At week 25 and at 
subsequent in tervals , scattered, individual centrilobular cells showed 
marked stimulation of an iline hydroxylase a c tiv ity , indicating that the 
hepatocytes in this zone may be heterogeneous in th e ir  response to 
Ponceau MX (and/or its  metabolites). A sim ilar e ffect was noted a fte r  
administration of 2,4-xylid ine for only 7 days (Grasso et al_., 1974) .
This observation was correlated with electron microscopic observations 
that individual centrilobular cells showed:proliferation o f the smooth 
endoplasmic reticulum w hilst the majority did not. A simf1a r  e ffec t on 
the smooth endoplasmic reticulum was apparent in the present study with 
Ponceau MX. The relationship of these various hepatic changes produced 
by Ponceau MX to the'subsequent development of liv e r  nodules is  discussed 
in Chapter 8.
The divergence between effects on drug metabolising enzyme 
a c tiv ity  and liv e r  weight seen with Ponceau MX was also notable with
2.4-xylid ine - particularly  when given by oral intubation -  but not with
2.5- or 2,6-xylid ine. 2,4-xylid ine is known to be hepatotoxic, chronic
*
administration leading to changes sim ilar to those produced by Ponceau 
MX (Lindstrom et a lk , 1963). In the study o f Grasso et al_. (1974),
2 ,4-xylid ine given by oral intubation evoked l i t t l e  or no increase in  
aminopyrine demethyl ase a c tiv ity  or cytochrome P450 concentration and gave 
rise to lysosomal abnormalities within 7 days. Fairly  sim ilar biochemical 
results were obtained in the present study. In contrast, when given in  
the d ie t fo r 7 days, 2,4-xylid ine e lic ite d  a marked stimulation o f drug 
metabolising enzyme a c tiv ity . I t  would be of in terest, therefore, to 
determine whether lysosomal changes occur also in this case or whether 
th e ir  f i r s t  appearance can be correlated with the subsequent (8 weeks)
demise of the enzyme induction.
I t  is known that the isomeric dimethylanilines d iffe r  in th e ir  
biological a c tiv ity  (see 5.1) and the three isomers studied here 
differed in th e ir  respective effects on liv e r  weight and drug metabolising 
enzyme a c tiv ity . Whilst 2 ,4-xylid ine was 5-6 times more potent in  
producing liv e r  enlargement than 2,5 or 2 ,6 -xy lid ine, the re la tive  
efficacy of these isomers as enzyme inducers followed more evenly the 
sequence 2 ,4->2,5->2,6-xylid ine. This sequence appeared to correlate  
with the extent to which each compound was able to e l ic i t  a type I I  
cytochrome P450 interaction spectrum. These differences in a b il ity  to 
undergo spectrally apparent interaction with cytochrome P450 may be due 
to the increasing steric  hinderance (Gorrod et a l . ,  1972) and/or 
hydrophobicity around the nitrogen atom with the s h ift o f the 4-methyl 
group in 2,4 -xy lid ine through position 5- to position 6- as in
2 .6-xy lid ine. These factors would favour a s h ift towards the production 
of a type I spectrum (Gorrod et al_., 1972) and i t  might be that the 
apparent fa ilu re  of 2,6-xylid ine to give rise to any spectral change 
results from an equal generation of type I and type I I  spectral 
components. This seems improbable however, since injection of 
^,6-xylid ine into rats 60 minutes prior to k illin g  the animals was without 
effect on the metabolism of either type I or type I I  substrates. In  
contrast, 2 ,4 - and 2,5-xylid ine under the same conditions produced a 
marked inh ib ition  o f both reactions. I t  appears, therefore th a t
2.6-xylid ine does not in teract appreciably with cytochrome P450 and th is  
presumably accounts fo r its  minimal influence on drug metabolising 
enzyme a c tiv ity . The factors contributing to the greater stimulatory
e ffe c t.o f 2*,4- c^ompared with 2,5-xylid ine on both drug metabolising 
enzyme a c tiv ity  and liv e r  weight are not clear. The apparent a f f in i ty  
(Ks) of each compound for cytochrome P450 was sim ilar and the differences
* 156
in A0Dmav are unlikely to be important in this context since spectrally
i I l a A
apparent interaction appears to bear l i t t l e  re lation  to metabolism in 
the case of type I I  substrates (Jefcoate et a l . ,  1969; Mannering, 1971). 
The differences in metabolism between 2,4- and 2,5-xylid ine  
(Lindstrom, 1961; Lindstrom_et _al. ,  1963) are probably of more d irect 
relevance to th e ir d iffe rin g  effects on drug metabolising enzyme 
a c tiv ity .
From a metabolic viewpoint, i t  is perhaps not surprising that
2.4-xylid ine appears to be more hepatotoxic than 2,5- or 2,6-xylid ine  
Lindstrom et al_., 1963). The substituted ring 4- but unsubstituted 
ring 2- position would tend to favour 2-hydroxylation, a reaction 
frequently associated with increased biological a c tiv ity  (Clayson, 1962). 
S im ilarly , by analogy with the hepatocarcinogenic 2 ,4 ,6-trim ethy lan iline , 
i t  is possible, that N-hydroxylation is important in the to x ic ity  of
2.4-xylid ine (Weisburger and Weisburger, 1973). Either of these 
reactions might be favoured by the demise of the in it ia l  enzyme induction 
produced by 2,4 -xy lid ine.
Differences in the effects of 2 ,5- and 2,6-xylid ine on l iv e r  weight 
and enzyme a c tiv ity  according to the ir mode of administration were not 
so pronounced as with 2,4 -xy lid ine, particu larly  when consideration is 
given to the possible influence of the lower dose level of these two 
compounds when given by oral intubation. Similar differences in e ffec t 
between intubation \and dietary administration have been observed with 
the antioxidant, butylated hydroxyanisole (P. Grasso, personal 
communication). Since with both of these modes of administration access 
to the systemic circulation must be via the gastrointestinal tra c t, the 
d ifferen t effects produced must presumably relate to differences in the 
kinetics of absorption and distribution of the compound. Oral intubation
usually involves administration of the entire  daily dose a t a single time, 
moreover, a time at which the gastrointestinal trac t is lik e ly  to be 
re la tive ly  empty. Accordingly, the maximum plasma level achieved is 
l ik e ly  to be considerably higher than when the same dose is ingested in 
the d ie t over a period of 12 hours or more. In the case of 2 ,4 -xy lid ine, 
this raises the possib ility  of acute toxic damage as a cause both of the 
decreased enzyme response and of the re la tiv e ly  increased liv e r  weight in  
the intubation experiment. I t  would be of in terest to compare the course 
of development of pathological changes in the liv e r  produced by
2,4-xylid ine given in the d ie t or. by intubation. A further possib ility  
is that large differences in plasma level/tim e relationships may lead 
to qualita tive  alterations in routes of metabolism and excretion. This 
could account fo r the apparently-greater e ffec t of 2,6-xylid ine on drug 
metabolising enzyme a c tiv ity  when given by oral intubation despite the 
lower overall dose administered. Some of these factors have recently 
been discussed by Chasseaud and Taylor (1974). Such differences may not 
result with a ll enzyme inducers, however, since Hashimoto et aj_. (1972) 
found that the degree of induction of ethylmorphine N-demethylase, 
an iline 4-hydroxylase and cytochrome P450 was very sim ilar when cedrene 
was administered to rats either in traperitoneally , by oral intubation or 
by inhalation.
CHAPTER SIX
f
BIOCHEMICAL AND MORPHOLOGICAL CHANGES IN THE 
LIVER DURING CHRONIC DIETARY ADMINISTRATION 
OF 2-ACETYLAMIN0FLU0RENE TO RATS
6.1 Introduction
The carcinogenicity of 2-acetylaminofluorene (AAF; N-2-fluorenyl- 
acetamide) was discovered a fte r the compound had been patented by the 
United States Department of Agriculture as a potential insecticide. 
Toxicity studies revealed that 3 - 1 1  months a fte r commencement of AAF 
administration, rats developed tumours in a number of tissues 
including liv e r , kidney, lung, urinary bladder, pancreas, ear duct, 
mammary gland and gastrointestinal trac t (Wilson et al_., 1941; Cox et 
a l . ,  1947). Subsequent work showed AAF to be carcinogenic in most species 
of experimental animal -  with the exception of_the_guinea-pig_--although 
the s ite  and incidence of tumour development varied markedly 
according to the species, strain and sex of animal: these studies have 
been comprehensively reviewed by Weisburger and Weisburger (1958). Of the 
species examined, the ra t has proved to be the most susceptible to the 
carcinogenic action of AAF and in the male ra t, the principal target organ 
is the liv e r . The almost exclusively hepatocellular derivation of the 
l iv e r  tumours in this animal and th e ir precedence by the early development 
of hyperplastic nodules (Epstein _et aj_., 1967; Skoryna and Webster, 1951; 
Teebor and Seidman, 1970), has led to the extensive u tilis a tio n  o f AAF as 
a model hepatocarcinogen.
In practice, the development of hepatocellular carcinoma is 
considerably influenced by the dosing schedule employed, ch iefly  because 
of the chronic hepatotoxicity of AAF. At dose levels leading to a high 
tumour incidence, the continuous administration of AAF produces severe 
cirrhosis and consequent early m ortality may preclude the development of 
frank carcinoma (Reuber, 1965). Epstein et al_.(1967) avoided th is  
d iff ic u lty  by treating th e ir  rats with alternate cycles of AAF and control 
diet: under these conditions the hepatotoxic effects of AAF were minimised
and an incidence of hepatocellular carcinoma approaching 90% was 
obtained a fte r 8-10 months.
The hyperplastic liv e r  nodule has been implicated by a number of 
authors as a precursor to the development of hepatocellular carcinoma 
(Epstein et al_., 1967; Farber, 1968, 1973a,b, 1974; Merkow et a l . ,  1971; 
Stewart and Snell, 1959) and as such, nodules induced by AAF have 
received considerable attention. Areas of hyperplasia appear at an early  
stage in the livers of male rats given AAF, discrete, macroscopically 
vis ib le  nodules being evident a fte r  6-15 weeks (Kitigawa and Sugano,
1973; Teebor and Seidman, 1970). The morphology of these nodules, of the 
subsequently appearing carcinomas and of the liv e r  tissue adjacent to each 
of these lesions has been described in detail by Epstein et al_. (1967), Farber 
(1973b), Kitigawa (1971), Merkow et. a l. (1967, 1969) and Reuber (1965).
E arlier studies have been reviewed by Stewart and Snell (1959) w hilst 
Flaks (1970, 1971, 1972, 1973) has provided sequential u ltrastructural 
studies of the changes produced in ra t liv e r  by both AAF and its  non- 
carcinogenic isomer, 4-acetylaminofluorene. Histologically the nodules 
comprised fa ir ly  uniform, enlarged hepatocytes but the normal lobular 
hepatic architecture was lacking and portal tracts were scant or absent. 
Carcinoma tissue was characterised by a cell population much more variable  
in size , shape and staining a f f in ity . U ltrastructurally both nodule and 
carcinoma contained prominent clusters of smooth endoplasmic reticulum but 
the rough endoplasmic reticulum was reduced in quantity and had lost its  
normal paralle l array formation. Both tissues contained annulate lamellae 
but additionally , there were nuclear and mitochondrial abnormalities and 
more frequent autophagic vacuoles in the carcinoma. In comparison, l iv e r  
adjacent to the nodules and carcinomas resembled untreated, control l iv e r  
although h isto log ically , areas of cholangiofibrosis and diffuse 
hyperplasia were evident.
Results of the morphological studies referred to above 
are compatible with the view of the hyperplastic nodule as a forerunner 
of the hepatocellular carcinoma but unequivocal evidence to this effect 
is lacking. Perhaps the most d irect evidence for such a relationship  
comes from the studies of Epstein e t al_. (1968) and Teebor and Becker 
(1971). The former showed that a fte r administration to rats of 
llfC-AAF, DNA- and glycogen-bound label persisted for months in the cells  
of the nodules and subsequently in the carcinomas but not in the 
adjacent liv e r  ce lls . The la tte r  found that i f  hyperplastic nodules 
either did not develop, or were allowed, before a certain c r it ic a l stage, 
to regress, then the subsequent incidence of hepatocellular carcinoma was 
less than 5% (1 /25). However, Peraino ert al_. (1973) observed a tumour
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incidence of 21% (22/106) a fte r 9 months in male rats given AAF at a 
dietary level of 0.02% for 18 days, a treatment unlikely to give rise to 
early hyperplastic nodules. This would suggest that the early development 
of hyperplastic nodules may not be mandatory fo r the subsequent production 
o f tumours. A number o f reports on the biochemical characteristics of the 
nodules are available and these are discussed in Chapter 8.
The female ra t is much less susceptible than the male to the 
hepatocarcinogenicity of AAF (Sidransky et a K , 1961; Skoryna and Webster, 
>951 ; Teebor and Seidman, 1970) although females of d iffe ren t strains may 
d if fe r  considerably in sensitiv ity  (Weisburger arid Weisburger, 1958). 
Females are, however, more susceptible than males to the development of
ear duct and mammary gland carcinoma (M ille r et al_., 1958) and
prolongation of lifespan by surgical removal of mammary tumours increased 
the incidence of liv e r  tumours (Sidransky et al_., 1961). Hyperplastic 
nodules were found only infrequently in these animals and the liv e r
tumours produced were more highly d ifferen tia ted  than in male rats . I t
is noteworthy that the early liv e r  ce ll pro liferation  produced by AAF in
the male ra t does not occur in the female (Farber 1956; Jackson and 
Irving, 1972). Moreover, induction of cell division by partia l 
hepatectomy of AAF-fed female rats did not lead to the development of 
hepatocellular carcinoma despite the irregu lar, nodular liv e r  
regeneration observed (Jackson and Irving, 1973). However, 
gonadectomised female rats given testosterone did develop liv e r  tumours 
in response to AAF and, conversely, hypophysectomised or 
thyroidectomised male rats were markedly more resistant than th e ir  
controls (De Baun-et al_., 1970a). The e ffect of these procedures with 
regard to the early development o f hyperplastic nodules was not stated.
Most chemical carcinogens require metabolism to a reactive species 
for the exertion of th e ir  carcinogenic a c tiv ity  (M ille r , 1970) and 
AAF is no exception, in this respect. Essentially two major pathways 
for its  metabolism are known, namely ring- and N-hydroxylation, although 
the quantitative importance o f each d iffers  in d ifferen t animal species 
(Weisburger and Weisburger, 1958). In the ra t, the fluorene nucleus 
undergoes hydroxylation principally at the 3 -, 5- and 7- positions 
(Cramer' e t al_., 1960a) but trace amounts of the 1 -, 6- and 8-hydroxy 
derivatives have also been identified  (Weisburger and Weisburger, 1958). 
These ring hydroxylated metabolites are inactive and are excreted 
chiefly in the urine as glucuronides. N-hydroxylation of AAF was f i r s t  
demonstrated by Cramer et al^.. (1960b). The product, N-hydroxy-2- 
acetylaminofluorene (N-0HAAF)?was shown to be a more potent carcinogen 
than AAF?giving rise to higher levels of macromolecule bound fluorene 
derivatives in the liv e r  (De Baun et al_., 1970a; Irving and Veazy, 1969) 
and producing tumours at sites of its  administration (M ille r  et a l . ,
1961) as well as in species in which AAF is inactive, e.g. the, guinea 
pig (M ille r et a l . , 1964). Moreover, synthetic N-hydroxylation converted 
the inactive 7-hydroxyAAF into a potent carcinogen (Gutmann et al_., 1967).
However, the observation that N-OHAAF was formed in equal amounts 
from AAF by the susceptible male and the resistant female ra t 
(Weisburger et cfL, 1964) and its  low reac tiv ity  with ce llu la r  
macromolecules under physiological conditions in v itro  (M ille r  et a l . ,  
1968; M ille r , 1970) suggested a requirement for further metabolic 
activation. Recent evidence points to the sulphate ester of N-OHAAF 
as a key ultimate carcinogenic metabolite of AAF in ra t liv e r , the 
formation of this highly electrophilic reactant being mediated by a 
soluble sulphotransferase (De Baun et a K , 1970a; De Baun et a l . ,  1970b; 
King and P h illip s , 1968; Weisburger e t al_., 1972). In support of this  
view, Gutmann et al_. (1972) correlated AAF hepatocarcinogenicity with 
metabolic activation using two strains of ra t d ifferin g  in th e ir a b ility  
to N-hydroxylate AAF and to sulphate-esterify N-OHAAF: other species, 
strain and sex differences in susceptibility to AAF hepatocarcinogenesis 
also correlated well with differences in hepatic sulphotransferase 
a c tiv ity  (De Baun et al_., 1968; De Baun et a K , 1970a; Jackson and 
Irv ing , 1972). However, the existence of other activation mechanisms 
seems probable since other target tissues of AAF, e.g. ear duct and 
mammary gland, do not possess detectable N-OHAAF-sulphotransferase 
a c tiv ity  (see Bartsch et a K , 1973). The metabolic activation of AAF 
and other carcinogenic aromatic amines and amides has been the subject 
of a number of recent reviews (Irv ing , 1972; M ille r , 1970; M ille r  and 
M ille r , 1969; Weisburger and Weisburger, 1973).
The ring hydroxylation of AAF appears to be a typ ica l, cytochrome 
P450-mediated mixed function oxidation (Cramer et a l . ,  1960a) but the 
nature of the N-hydroxylation reaction has been a matter of some 
controversy. In apparent confirmation of the studies of Kampffmeyer 
and Kiese (1965) on nitrogen oxidation, Matsushima et aj_- (1972) and 
Matsushima and Weisburger (1972) reported that the N-hydroxylation of
AAF was not necessarily cytochrome P450-dependent. In a rather more 
thorough approach, however, Thorgiersson e t al_. (1973) produced 
seemingly unequivocal evidence for the involvement of P450 in this 
reaction. These considerations are important with regard to the 
influence of effectors of cytochrome P450 on AAF carcinogenesis.
Thus,'coadministration of 3-methylcholanthrene with AAF markedly 
reduced tumour incidence at a ll sites in the ra t (Marugami et al_., 1967; 
M ille r et a K , 1958), a resu lt, according to Lotlikar et a l. (1967), 
of marked induction of the ring hydroxylation (detoxication) of AAF. 
Coadministration of butyl ated hydroxytoluene (BHT) (Grantham et al_., 1973) 
or phenobarbitone (Peraino et aJL, 1971, 1973) also reduces the 
hepatocarcinogenicity of AAF in the ra t although apparently via a 
d ifferen t mechanism to 3-methylcholanthrene. Thus, BHT stimulates the 
N-hydroxylation of AAF to a considerably greater extent than the 
ring-hydroxylation (Grantham et al_., 1973) and the key effec t here appears 
to l ie  in acceleration of the excretion of N-OHAAF as a result of 
induction of glucuronyl transferase (Weisburger and Weisburger, 1973).
Despite these considerations, l i t t l e  is known of the effects that 
AAF i ts e l f  exerts on the a c tiv ity  o f the drug metabolising enzymes. In 
male rats there is evidence that AAF causes a depression of drug 
metabolic ac tiv ity  which may or may not be preceded by a transitory  
enzyme induction (Trams et al_., 1961). No comparable measurements 
appear to have been made in the female ra t.
In the experiments described in this chapter, AAF has been 
administered to both female and male rats in order that the results 
obtained in the previous chapters could be compared with measurements 
of the same parameters in rats treated with a known hepatocarcinogen.
Male rats were u tilised  since i t  was not possible to obtain adequate
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nodular liv e r  tissue from the female rats to permit biochemical 
analysis. Whilst the higher basal levels of drug metabolising enzyme 
a c tiv ity  in male rats (Gigon and Bickel, 1971) precluded direct 
comparisons with the liv e r  nodules induced in female rats by safrole  
and Ponceau MX, i t  was considered that comparisons on a 'percent of 
control1 basis were va lid .
6.2 Materials and Methods
a) Chronic Administration of AAF to Male and Female Rats
Male and female rats were maintained on a d ie t containing 0.06%
(w/w) AAF. This dietary level has been shown to produce a high 
incidence of hepatic nodular hyperplasia, and, subsequently, 
hepatocellular carcinoma (Teebor and Becker, 1971; Teebor and Seidman, 
1970). Female rats received the AAF d ie t continuously. For 
comparability with the experiments using female ra ts , both in this and in  
previous chapters, i t  was clearly desirable that the male rats should 
also receive the AAF d ie t continuously. The d iff ic u lt ie s  associated with 
this were mentioned in 6.1 and were reinforced by the death of 8/12 male 
rats a fte r ingestion of the AAF d ie t fo r 3 - 4  weeks in a preliminary 
experiment. As a compromise therefore, control d iet was substituted fo r  
the AAF d ie t during weeks 3 and 4, week 9 and weeks 13 and 14 and 18 and 
19.
At weeks 1, 8 , 16 and 24 (females) and 1 and 8 (males), 4 treated  
and 4 control rats were k illed  and the livers used for the assays 
described in 2.3. At week 16, 6 treated male rats were k ille d  on the 
assumption that these would have developed liv e r  nodules(cf. Teebor and 
Seidman, 1970); a ll had but there was insu ffic ien t nodular tissue to 
permit biochemical analysis. The remaining 8 male rats were k ille d  at 
week 22 and from the livers of 6 of these, nodular tissue was obtained.
In each case, m ultiple, small (2-5 mm diameter)smooth surfaced nodules 
were present and these were carefully freed from the surrounding 
parenchyma and pooled to give one sample of nodular tissue for each 
treated ra t.
Enzyme histochemistry, histology and electron microscopy (2 .3 )
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were carried out on liv e r  samples from a number of both male and 
female rats.
b) Interaction of AAF with cytochrome P450
For these investigations, AAF was prepared as a solution 100 mM 
in a mixture of absolute ethanol and acetone (75: 25 v /v ).
6.3 Results
a) Animal Body Weights and Food Intake
Growth curves for female and male rats are shown in Figs. 6.1 
and 6.2 respectively. In both sexes, but particu larly  in the males, 
ingestion of the AAF d ie t resulted in severe depression of growth rate^f
such that from week 1 onwards, the mean body weight of the treated rats 
was very s ig n ifican tly  (p < 0.001) less than that of the controls. 
'Catch-up' growth during the periods when male rats received control 
in place of AAF d ie t was only minimal. The mean body weight of the 
male rats reached a maximum at week 14 and thereafter was decreased 
gradually in para lle l with the deteriorating condition of the animals.
Mean body weight fo r the female rats continued to increase up to week 
24. Although the food intake of both treated and control rats was 
sim ilar on day 1, the intake of the treated rats of each sex 
subsequently decreased and remained markedly depressed throughout the 
experiment. The extent of this depression correlated with the 
depression of growth rate in the male rats , but less closely in the 
females, whose growth rate was less severely affected. The effects of 
AAF on body weight and food intake are summarised, in Table 6.1 and 
the approximate da ily  intake of AAF, in mg/kg body weight, calculated 
from the food intake data is shown in Table 6.2.
b) Condition of Rats During AAF Feeding
Apart from the decreased rate of body weight gain, the female rats  
showed no obvious signs of i l l  health prior to week 21. At this stage, 
several of the remaining 16 rats developed outgrowths from the side of 
the head which appeared to originate from the ear duct. Since this is a 
known target organ of AAF (Miller_ert a l . ,  1958; Weisburger and
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Weisburger,1958), no further investigations were made. I t  was noted, 
however, that in 9/10 rats that developed these lesions, only the 
right ear was involved: the 10th ra t had tumours in both ears. From 
week 23 onwards the condition of the remaining rats deteriorated  
rapidly with severe loss of weight in some animals. In 2 rats , k illed
in extremis, there was evidence of jaundice. At week 30 the remaining
3 rats were given control d ie t in place of AAF d ie t. The size of the 
ear tumours necessitated k illin g  these rats a fte r a further 16 weeks 
and although in each case the liv e r  was grossly abnormal, no
tumours were observed in this organ.
The male rats appeared to be much more susceptible to the toxic 
effects of AAF. Of the 8 ,rats dying within 4 .weeks of commencement of 
AAF feeding, a ll  showed ascitic  flu id  on opening the abdomen and in 4 
animals there was evidence of pronounced jaundice. Ear tumours were 
not observed in rats surviving up to week 24.
c) Biochemical Changes During Chronic Administration of AAF
Data for female and male rats , in the form treated as % of control 
values, are presented in  Figs. 6.3 and 6.4 respectively and in Table 
6.3 . The fu ll data with s ta tis tic a l treatment are included in the 
Appendix (Tables A4 and A5). Since the changes produced in each sex 
were quite d issim ilar, i t  is convenient to consider the experiments 
with male and female rats separately.
Female: When administered to female rats AAF proved to be a
moderately powerful inducer of drug metabolising enzyme a c tiv ity . A fter 
1 week there were increases - per gram of liv e r  -  of 60-140% in the
ac tiv ities  of ethylmorphine Nrdemethylase, aniline 4-hydroxylase and
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biphenyl 4-hydroxylase. The activ ity  of NADPH-cytochrome c reductase
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was raised by .35% and the content of cytochromes P450 and b5 by 53 
and 76% respectively. In contrast there was only a marginal increase 
in microsomal protein content (12%) and there was no change in the 
to tal liv e r  protein content. The increase in biphenyl 2-hydroxylase 
was less than that fo r the 4-hydroxylase and, a t this early stage, 
there was no depression of succinate dehydrogenase. Despite the 
enzyme induction there was no increase in re la tive  liv e r  weight and 
the absolute liv e r  weight was s ign ifican tly  decreased -  in parallel 
with the body weight.
Continued administration of AAF brought about a sharp fa l l  in the 
levels o f NADPH-cytochrome c reductase and cytochromes P450 and b5 
back to control values or below. Although lower than th e ir  1 week 
levels , the rates of metabolism of ethylmorphine, an iline and biphenyl 
remained s ig n ifican tly  elevated a t week 8 and that of biphenyl remained 
so even at week 24 when liv e r  damage was grossly apparent. Succinate 
dehydrogenase a c tiv ity  decreased steadily to reach 69% of control at 
week 24 w hilst the a c tiv ity  of biphenyl 2-hydroxylase increased to 3 
times the control Tevfcl a t 16 weeks. Microsomal protein content 
decreased gradually but progressively whereas no clear trend could be 
discerned in the values for to tal protein content. The re la tive  l iv e r  
weight increased steadily being more than double that of the. controls 
at week 24. One o f the rats k illed  at 24 weeks appeared jaundiced: 
levels o f drug metabolising enzymes in the liv e r  of this animal were 
v ir tu a lly  undetectable and the a c tiv ity  of succinate dehydrogenase was 
less than 20% of control. Subsequent histological examination revealed 
that much of the hepatic parenchyma had been replaced by an extensive 
lymphosarcoma.
Male: The administration of AAF to male rats resulted in a fa ir ly
uniform depression of drug metabolising enzyme a c tiv ity  which, with 
the exception of the small increases in biphenyl 4- and 2-hydroxylases 
and cytochrome b , was evident at week 1 and became progressively 
more marked on continued administration. Thus, at week 22 the 
a c tiv itie s  of ethylmorphine N-demethylase, aniline 4-hydroxylase, 
biphenyl 4-hydroxylase and NADPH-cytochrome c reductase and the levels 
of cytochromes P450 and b5 were only 24-58% of control levels. The 
depression of microsomal protein content from week 1 onwards, but 
particu larly  a t week 22, resulted in somewhat higher values when these 
parameters were expressed on a specific a c tiv ity  basis. Succinate 
dehydrogenase a c tiv ity  and to tal protein content fe l l  to 63 and 80% of
f
control respectively a t week 22. Relative liv e r  weight was maximal a fte r  
16 weeks at 270% of control.
d) Biochemical Investigations of AAF-Induced Liver Nodules
These investigations were confined to tissue obtained from the 
male rats . Results are presented in Table 6.4 in the form nodular and 
non-nodular liv e r  as % of control, and nodular as % of non-nodular 
l iv e r . The basic data are given in the Appendix (Table A10).
I t  was evident th a t, with respect to the parameters measured, the 
nodular tissue resembled closely the surrounding parenchyma: in both 
tissues drug metabolising enzyme a c tiv ity  was very s ign ifican tly  lower 
than control levels.
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e) Interaction of AAF with Cytochrome P450
No recognisable substrate interaction spectrum was obtained when 
AAF was added to liv e r  microsomes from untreated male or female rats 
at concentrations up to ImM.
f )  Enzyme Histochemical Changes in the Liver During Chronic 
Administration of AAF
Female ra ts : After 1 week there was a s light but defin ite
centrilobular depression of glucose-6-phosphatase and stimulation of 
aniline hydroxylase. There were no clear cut changes in acid phosphatase 
distribution although in some centrilobular and mid-zonal cells "clumping"
i
of lysosomes with loss of the normal pericanalicular distribution was 
evident. At week 8,' the centrilobular depression of 
glucose-6-phosphatase was pronounced and stimulation of aniline  
hydroxylase was no longer apparent. There was a s lig h t, overall loss 
of succinate dehydrogenase. Lysosomal changes comprised a s ligh tly  
decreased centrilobular ac tiv ity  of acid-phosphatase with aggregation of 
lysosomes in the centre of some ce lls , as at week 1. Enlarged 
individual lysosomes were present in some scattered groups of cells but 
there were very few autophagic vacuoles. At week 16, changes were 
sim ilar to those seen at week 8. In the livers of 2 rats , however, 
microscopic nodules were present and th e ir constituent cells showed 
levels of enzyme a c tiv ity  lower than in the surrounding parenchyma.
This loss of enzyme a c tiv ity  was most marked in the case of 
glucose-6-phosphatase, a c tiv ity  of which was v irtu a lly  undetectable 
in the hyperplastic nodules (as Fig. 6 .5 ).
Male rats: Administration of the AAF diet for 1 week
resulted in decreased a c tiv ity  of glucose-6-phosphatase throughout the 
l iv e r  lobule but particu larly  in the centrilobular areas. No changes 
were detected in e ither the a c tiv ity  or distribution of succinate 
dehydrogenase or aniline hydroxylase. Lysosomal changes were sim ilar  
to those seen in the female rats at week 1. After 8 weeks the normal 
lobular architecture of the liv e r  was disrupted by the presence of 
numerous areas of hyperplasia. These micronodules were v irtu a lly  
devoid of glucose-6-phosphatase a c tiv ity  although the surrounding 
parenchyma stained quite heavily (Fig. 6 .5 ). The a c tiv ity  of succinate 
dehydrogenase was variable throughout the "normal" liv e r  but in the 
nodules i t  was markedly reduced (Fig. 6 .5 ). There was an overall 
decrease in aniline hydroxylase a c tiv ity  with the nodules staining  
only s lig h tly  more weakly than the remainder of the liv e r . Sections 
stained for acid phosphatase presented a very damaged picture: in  the 
nodules there was an overall loss of a c tiv ity  w hilst in the surrounding 
liv e r  enlarged lysosomes and autophagic vacuoles were abundant.
Enzyme histochemistry was not carried out on liv e r  from male rats  
k illed  at weeks 16 and 24 or from female rats k illed  a t week 26.
g) Macroscopic Changes in the Liver
Female Rats: No changes in the gross appearance of the
liv e r  at autopsy were noted until week 16 when in 2 out of 4 rats k ille d
the liv e r  had a fa ir ly  granular surface and a mottled appearance. At
week 26 the liv e r  in a ll  4 rats was markedly enlarged and gross pathological 
changes were evident. The surface of the liv e r  was irregular with a rather 
pale, mottled appearance and in 2 rats several small (1-3 mm diameter),
FIG. 6.5 AAF (male) week 8 (x 72)
A. Loss of succinate dehydrogenase In hyperplastic nodule
B. Loss of glucose-6-phosphatase In hyperplastic nodule
smooth surfaced, tan-coloured nodules were present.
Male Rats: Abnormalities were f i r s t  seen at week 8, when in
a ll 4 rats k ille d  the surface of the liv e r  was fin e ly  granular and 
rather pale, almost yellowish in colour. By week 16, livers were greatly  
increased in size and numerous smooth-surfaced, pale tan-coloured 
nodules (1-3 mm diameter) protruded from the surface of the major lobes. 
Similar changes were evident a t week 24. At this stage, larger smooth- 
surfaced nodules were present (2-6 mm diameter) and these were sharply 
demarcated from the rough, irregu lar surface of the intervening liv e r  
tissue. Ascitic flu id  or evidence of jaundice was not seen. The gross 
appearance o f the liv e r  nodules induced by AAF has been illu s tra ted  in
f
several publications (Epstein .et a K , 1967; Farber, 1973b; Reuber, 1965) 
Fig. 6.6 shows the liv e r  of a male ra t treated for 16 weeks with AAF.
h) Histological Changes in the Liver
Female Rats: No changes were observed prior to week 16. In
2 rats k illed  a t this stage there were several small areas of l iv e r  ce ll 
hyperplasia and occasional small foci of hepatocytes in the early stages 
of hydropic degeneration. The liv e r  of 2 other rats showed no 
abnormalities. Histopathological changes were present in the l iv e r  of a ll  
4 rats k ille d  at week 26. In one, the hepatic parenchyma had been 
extensively replaced by a lymphosarcoma. Patchy hydropic degeneration, 
which did not appear to follow a lobular d istribution , was a feature of 
each of the other 3 livers and in 2 of these, there was also s lig h t fa tty  
change. Numerous areas of hyperplasia were present. These were usually 
composed of fa ir ly  uniform enlarged cells and the larger hyperplastic 
nodules compressed the surrounding parenchyma. Occasional portal tracts
FIG. 6.6
FIG. 6.6 AAF (male) week 16 - gross appearance of  l i v e r .
Numerous, small (1-3 mm diameter) pale nodules are present 
in a l l  lobes of  the l i v e r .  (This l iv e r  was preserved in 
buffered formalin prior to photography).
were present w ithin the nodules but in 1 ra t an area of adenoid and papilliform  
architecture and dilated sinusoids within a large, structureless nodule 
indicated the presence of an early hepatocellular carcinoma. There was 
l i t t l e  fibrosis and no evidence of nuclear changes or ce ll necrosis in 
the livers examined.
Male Rats: Histological changes were f i r s t  observed at
week 8» when in  each of the 4 rats k illed  the presence o f numerous small 
areas of hyperplasia imparted a micronodular appearance to the liv e r .
The cells in these hyperplastic nodules were generally larger than those of 
the adjacent parenchyma and th e ir  nuclei were frequently enlarged and 
vesicular with prominent nucleoli (Fig. 6 .7 ). M itotic figures were seen
f ’ ■ '
quite frequently in the nodules but not in the adjacent l iv e r  (F ig . 6 .9 ).
The la t te r  contained areas of fa tty  change and early hydropic degeneration.
Bile duct hyperplasia and early fibrosis were also noted (F ig. 6 .8 ) . A 
sim ilar picture was seen at 16 weeks although the nodules were larger and 
associated with more extensive fib rosis . There was no evidence of liv e r  
cell necrosis a t this stage. By week 24 there was l i t t l e  recognisable 
liv e r  tissue and the overall picture was one of micronodular cirrhosis  
(Fig. 6.10A). Within some of the larger nodules there was fa tty  change, 
hydropic degeneration and, occasionally, individual cell necrosis. A 
majority of cells contained enlarged, vesicular nuclei (Fig. 6.1 OB).
Occasional portal tracts were present within most of the larger nodules.
No histological abnormalities were observed in the livers  o f any of 
the male or female control rats .
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FIG. 6.7 AAF (male) week 8
A. Nuclear enlargement and veslculatlon 1n hyperplastic nodule 
(on righ t) (H & E x 180).
B. Higher power of hyperplastic nauule 1n A (H & E x 450).
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FIG. 6.10 AAF (raale) week 24 
A. Micronodular cirrhosis (H & £ x 72).
3. Enlarged nuclei within a nodule (H & E x 450).
j )  U ltrastructural Changes in the Liver
Electron microscopy was carried out only on liv e r  tissue from male 
and female rats given the AAF d iet for 1 week. In the females, the 
hepatocytes appeared to contain an increased amount of smooth, but a 
s lig h tly  reduced amount of rough endoplasmic reticulum (Fig. 6 .11). The 
smooth endoplasmic reticulum in the male ra t ,  w hilst somewhat increased 
in amount, was quite markedly d ilated . There was a d is tin c tly  reduced 
amount of rough endoplasmic reticulum. This too appeared somewhat dilated  
and assumed an unusual configuration encircling the mitochondria (Fig. 6 .12). 
There were frequent areais of apparently "unoccupied" in tra ce llu la r space. 
Although the rats were starved prior to k il l in g , i t  is possible (c f.
Epstein e t al_., 1967) that some of this space represents glycogen.
Although apparently normal in structure, the mitochondria in the male ra t 
appeared to be swollen as is evident from a comparison of Figs. 6.11 and 
6.12, both of which were taken a t the same magnification. Measurements of 
succinate dehydrogenase both biochemically and histochemically revealed 
no differences between the males and females at this stage or subsequently.
FIG. 6011 AAF week 1 (female). Apart from an Increased amount and some
d ila ta tion  of the smooth endoplasmic reticulum, the tissue appears 
re la tive ly  normal (x 20,500).
FIG. 6.12 AAF week 1 (male). Note swollen appearance o f the
mitochondria (c f F1g, 6 .11), reduced amount and unusual arrangement o f the rough 
endoplasmic reticulum, dilated smooth endoplasmic reticulum and areas o f "empty15 
Intracytoplasmic space, (x 20,500).
6.4 Discussion
The biological a c tiv ity  of AAF has been extensively investigated 
at both the morphological and biochemical levels and forms the 
subject o f a very considerable lite ra tu re . In the present 
experiments the observed changes in body weight, liv e r  weight and in  
the gross and microscopic appearance of the liv e r were substantially  
in agreement with those reported for other studies using comparable 
dietary levels o f AAF (Albert et al_., 1972; Epstein et al_., 1967; 
Flaks, 1970; Jackson and Irv ing , 1972; Sidransky et a K , 1961;
Teebor and Seidman, 1970; Trams et al_., 1961). Although overall 
consumption of the AAF d ie t was markedly reduced in both sexes, intake
f  -  ■
was essentially normal on day 1 of feeding. This s ituation , the 
converse of that seen with safrole and Ponceau MX, suggests th a t taxic  
anorexia, rather than unpalatability , was a key factor in  the reduced 
consumption of AAF d ie t. In the female rats there was an apparent 
increase in food conversion ra tio . Numerous factors could give rise  
to such an e ffe c t, making interpretation d if f ic u lt  without additional 
information (Sharratt, 1972).
The uniform depression of drug/metabolising enzyme a c tiv ity  
caused by AAF in the male rats is consistent with the reported effects  
of a number of hepatotoxins on this enzyme system (Donelli et a l . ,  
1970; Smuckler e t al_., 1967). Trams et al_. (1961) found that hepatic 
N-demethylase and aromatic hydroxylase ac tiv ities  fe ll to 20-40% 
of control over a 24 week period of'administration of a d ie t 
containing 0.025% AAF to male rats . The effects of AAF on other 
microsomal enzymes appear to be variable since Trams, et a l„ (1961) 
reported a s ign ificant elevation of glucuronyl transferase a c tiv ity  
whilst in the present study, the a c tiv ity  of glucose-6-phosphatase
could be shown histochemically to be markedly depressed.
The action of AAF on drug, metabolising enzyme a c tiv ity  in the 
female ra t contrasted sharply with its  observed effects in the male. 
Although this sex difference might be considered to re fle c t the 
fact that AAF is more potently hepatocarcinogenic in the male ra t ,  
the available evidence suggests that i t  is more probably the result 
of a greater sen s itiv ity  of the male ra t to the hepatotoxic effects  
of AAF. Thus, in the present study, early fa ta lit ie s  occurred only 
in the males, an observation made also by Wilson et al_. (1941), and 
histopathological changes in the liv e r  were seen much e a rlie r  in this  
group than in the females. Furthermore, depression of drug 
metabolising enzyme a c tiv ity  in the male occurred at a very early 
stage and therefore well before the liv e r  cells are reported to show 
any features of neoplastic growth (S lifk in  e t al_., 1972; Teebor and 
Beckerjl971; Teebor and Seidman, 1,970). Many carcinogens and/or 
th e ir  metabolites cause inhib ition  of protein synthesis (e .g . ttultin  
and Arrhenius, 1965). A sex difference in the rate or extent of 
production of such a metabolite of AAF -  as has been shown for the 
production of AAF N-sulphate (Jackson and Irv ing , 1972) -  could 
therefore account for the early depression in the level o f microsomal 
protein observed in the male rats". On the other hand, Teebor and 
Seidman (1970) reported that the ac tiv ities  of glucose-6-phosphatase, 
tryptophan pyrrolase and tyrosine transaminase were depressed to a 
sim ilar extent in both male and female rats fed a d ie t containing 
0.06% AAF for up to 12 weeks. The present results confirmed this  
e ffec t on glucose-6-phosphatase and showed that the a c tiv ity  of 
succinate dehydrogenase was also depressed to a sim ilar extent in  
both sexes. Thus i t  appears that re la tiv e ly  specific effects on the 
synthesis o f particu lar microsomal enzyme proteins may be involved in
the observed sex difference in drug metabolising enzyme response to 
AAF. These effects might be related to the reported differences in  
the extent to which AAF becomes bound to t -  and r-RNA fractions in  
male and female ra t livers (Irv ing  and-Veazy, 1971).
The apparent fa ilu re  of AAF to give rise to a recognisable 
substrate interaction spectrum with cytochrome P450 in liv e r  
microsomes from either sex o f untreated ra t contrasts with results 
obtained with hamster and mouse liv e r microsomes. In these 
preparations, AAF e lic its  a typical type I interaction spectrum 
(F .J. McPherson, personal communication). Although metabolism may 
not always correlate closely with spectrally apparent binding to 
cytochrome P450, i t  is noteworthy that the basal levels of AAF-ring 
hydroxylases are much lower in the ra t than in the hamster (Cramer 
et a l . ,  1960a). Moreover, the observed decline in aromatic 
hydroxylase a c tiv ity  in the male rats may result in a s h ift in the 
re la tive  proportions of ring -  and N-hydroxylated metabolites formed 
from AAF. This might account for the observation of M ille r  et a l.  
(1960) that the proportion of N-OHAAF excreted in the urine 
increased from an in it ia l  1-2% to some 10-14% a fte r 14 weeks. 
Nevertheless, i t  seems unlikely that these factors are of primary 
importance in predisposing the ra t to the hepatocarcinogenicity of 
AAF since among species capable of N-hydroxylating AAF, differences in  
hepatocarcinogenicity correlate closely with differences in N-OHAAF 
sulphotransferase a c tiv ity  (De Baun et al_., 1970a).
The biochemical results obtained with AAF -  at least in the male 
ra t -  contrast sharply with those obtained with safrole and Ponceau MX 
although, as mentioned above, i t  is doubtful whether this contrast is
d irec tly  related to the hepatocarcinogenicity of AAF. Since the 
d ifferin g  response of male and female rats to AAF appears to correlate  
with th e ir d iffe rin g  levels of sulphotransferase a c tiv ity , i t  is 
d if f ic u lt  to argue that the induction of drug metabolising enzyme 
a c tiv ity  in the female ra t plays an important part in the re la tive  
resistance of this animal to the effects of AAF. The converse of this  
situation is more probably correct. Once established however, the 
enzyme induction may exert a protective effect in view o f the known 
ameliorating effects of drug metabolising enzyme inducers on the 
toxic and carcinogenic action of AAF in the ra t (Peraino et.al_*» 1971, 
1973; till and et al_., 1973). That AAF is a potential inducer even in 
the male ra t is suggested by its  p ro lifera tive  influence on hepatocyte 
smooth endoplasmic reticulum (Flaks, 1970). Meldolesi (1967) has 
pointed out that smooth membrane pro liferation  may s t i l l  occur in  
response to chemicals which are themselves, or whose metabolites are 
inhibitors of protein synthesis.
The sequence of morphological changes produced by AAF was quite  
d iffe ren t from that produced by either safrole or Ponceau MX. In  
particular the hyperplastic nodules which developed in the livers  of 
both male and female rats were not preceded by cell necrosis. This 
absence of early necrosis, which is in agreement with published 
findings (Farber, 1956; Flaks, 1970; Sidransky et al_., 1961; Teebor 
and Seidman, 1970), imparts on the AAF-induced nodules a significance 
rather d iffe ren t from that of the nodules induced by safrole and 
Ponceau MX. The la t te r  not only developed at a much la te r  stage but 
were invariably preceded by cell necrosis. The significance of this  
difference is discussed in Chapter 8. Despite the absence of necrosis, 
mild fibrosis was evident in the livers of male rats a t week 8. I t  is
possible that this early response, also noted by Flaks (1970), is  
related to the action of N-OHAAF. This substance, when 
administered in re la tive ly  large doses, is known to cause massive 
periportal necrosis (De Baun et al_., 1970b). The extensive fibrosis  
subsequently seen surrounding the nodules of hyperplasia in both 
male and female rats may re fle c t a pressure effect of the rapidly  
growing hyperplastic tissue on the surrounding parenchyma. The 
nuclear changes observed in the male, but not the female rats from 
week 8 onwards were very sim ilar to those described by T.eebor and 
Seidman (1970). These authors also noted the confinement of such changes 
to male rats . In contrast to these findings, Flaks (1970) observed no 
nuclear abnormalities in the livers of male rats fed 0.05% AAF for
f
8-12 weeks. This may re fle c t strain differences in susceptib ility  to 
the hepatotoxic or carcinogenic effects o f AAF since there was also 
l i t t l e  early nodule formation in these liv e rs .
Despite the evident hepatotoxicity of AAF, lysosomal changes of 
the type produced at an early stage by safrole and Ponceau MX were not 
prominent prior to the appearance of histological abnormalities in the 
livers of AAF-treated rats . The histochemical changes in acid 
phosphatase and glucose-6-phosphatase associated with the development of 
early nodules in the male rats were in agreement with the findings of 
Kitigawa and Sugano (1973).
The early m ortality of a ll the rats used in this series of 
experiments could most probably have been averted by avoiding 
continuous administration of the AAF d ie t and by withdrawing this  
completely a fte r  an appropriate period of time (see Farber, 1973b;
Teebor and Becker, 1971). However, for comparison of the biochemical
results with those obtained with safrole and Ponceau MX continuous 
administration was desirable. Since the compromise of withdrawing 
the AAF d ie t fo r b r ie f intervals was not successful,it would seem 
preferable for future studies to adopt the procedure of Teebor and 
Becker (1971). Those hyperplastic nodules that did not regress on 
withdrawal of the d ie t and the subsequently developing hepatocellular 
carcinomas could then be compared with nodules persisting in safro le-' 
and Ponceau MX-treated rats a fte r  cessation of treatment.
CHAPTER SEVEN
STUDIES ON THE INTERACTION OF SAFROLE WITH 
HEPATIC MICROSOMAL CYTOCHROME P450
Introduction
Evidence that a metabolite of safrole binds tenaciously to cytochrome 
P450, producing a spectral species absorbing maximally at 455nm, was outlined 
in section 4.1 . I t  was subsequently suggested that inactivation of cytochrome 
P450 in this manner was largely responsible for the reduced a b ility  to 
metabolise foreign compounds, shown both by in v itro  and in vivo techniques, to 
result during chronic administration o f safrole to rats. Experiments were 
therefore carried out to investigate more closely the nature o f this metabolite 
-  cytochrome P450 interaction and in p articu lar, to determine whether or not i t  
was reversible.
Studies in v itro  suggest that i t  is from the methylenedioxy moiety of 
safrole that the species absorbing at 455nm is derived. Thus, of the compounds 
methylenedioxybenzene, allylbenzene and eugenol (4 -a l ly l-1 -hydroxy-2- 
metho^ybenzene), only methylenedioxybenzene interacts with cytochrome P450 to 
produce an absorption maximum at 455nm (Franklin, 1971). In addition to an 
in tact methylenedioxy ring, a suitably lip o p h ilic  character appears to be 
necessary since related, but more polar compounds e.g. methylenedioxybenzoic 
acid (piperonylic acid) do not undergo this interaction (Lake and Parke, 1972). 
According to Casida et al^ . (1966), extensive cleavage o f the methylenedioxy 
ring occurs both in v itro  and in vivo a fte r oral administration of safrole to 
mice. This reaction requires NADPH and oxygen and is thought to involve 
hydroxyl ation of the methylene group followed by loss o f formaldehyde to 
produce catechol derivatives. None of these possible derivatives, when added 
to liv e r  microsomes either in the presence or absence of NADPH, produce any 
increase in absorption at 455nm (unpublished results of B.G. Lake, 1972). 
Therefore i t  appears that the species responsible for the 455nm absorption 
maximum is an intermediate produced during oxidative metabolism of the 
methylene group.
In considering th e ir  efficacy as pesticide synergists (see reviews by 
Casida, 1970, 1973), Hennessey (1965) proposed that methylenedioxyphenyl 
compounds could in teract irreversib ly  with the drug metabolising enzyme 
system.. He postulated that loss o f a hydride ion from the methylene ring gave 
rise to the e lectrop h ilic  benzodibxolium ion which could then bind covalently 
to , and inactivate , the enzyme protein. An alternative view (Hansch, 1968), 
held that an anionic free radical species was produced by homolytic cleavage of 
a proton from the methylene group. Based on more recent theory, U llrich and 
Schnabel (1973) have proposed the metabolic formation of a carbanion by 
abstraction of a methylene proton by the strongly nucleophilic active oxygen 
species formed on donation of the second electron to the reduced cytochrome 
P450-oxygen-substrate complex. Formation of the absorption maximum at 455nm is 
explained by the ligand binding of this carbanion to cytochrome P450. This 
mechanism is based on observations with the fluorene anion and with the 
compounds 2-nitropropane and carbon tetrachloride both o f which can give r is e , 
non-enzymically, to anionic species.
The 455nm absorbing species derived from safrole possesses considerable 
s ta b ility  as judged by its  presence in microsomes isolated from rats treated  
in vivo with safrole (Lake and Parke, 1972; Parke and Rahman, 1971). A 
carbanion formed as proposed by U llrich  and Schnabel (1973) could ppssess 
such s ta b ility  in the re la tiv e ly  aprotonic environment of the lip o p h ilic  
substrate binding s ite  of cytochrome P450. Factors influencing, and the 
mechanism of the decay of the 455nm absorbing species are unknown. Franklin 
(1972b) reported that addition of uridine diphosphate-glucuronic acid, 
s-adenosylmethionine, cysteamine, hexobarbital or metyrapone to microsomes 
containing excess NADPH but lim iting  amounts of piperonyl butoxide, did not 
influence the rate of decay of the 455nm absorption maximum.
Stable interaction of a metabolite e ither with the type I substrate
binding s ite  or involving ligand binding to cytochrome P450 haem would result 
in inh ib ition  of drug metabolism. Accordingly, Franklin (1972a) has observed 
a d irect relationship between the degree of inh ib ition  of ethylmorphine 
demethylation and the amount of 455nm absorbing species formed in v itro  from 
d iffe re n t, lim iting  amounts of piperonyl butoxide. In the same vein, an in tact 
methylenedioxy moiety, with both methylene hydrogens unsubstituted, was shown 
to be essential fo r high synergistic ac tiv ity  in the s tructu re -ac tiv ity  
correlations o f Metcalf et a l. (1966) and Wilkinson et (1966).
Results presented in this chapter show that under certain conditions the 
metabolite-cytochrome P450 complex can be dissociated and suggest that the 
novel interactions of safrole may provide a useful tool for studying substrate- 
cytochrome P450 interactions.
Methods
a) Animal pretreatment and preparation o f microsomes
Female ra ts , in i t ia l  body weight 120-150g, were given a d iet containing 
0.25%(w/w)safrole (see 2 .2 ) fo r 7-14 days, or were injected intraperitoneally  
with safro le, phenobarbitone or 3-methylcholanthrene as described in 2.2.
Washed liv e r  microsomes, prepared as described in 2 .3 , were suspended in 0.1M 
sodium phosphate buffer pH 7.6 to a concentration of 2 mg protein per ml, 
measured by the method of Lowry (2 .3 ). For experiments involving the use of 
glycerol, microsomes were suspended in 0.1M sodium phosphate buffer pH 7.6 
containing 20%(v/v)glycerol.
b) Determinations of Kc and A0Dmav
S UlaX
These were made as described in 2.3. Biphenyl was added as solutions' 
50 and 250 mM, safrole lOOmM and aniline 500mM, a ll in absolute ethanol. The 
following fina l cuvette concentrations (mM) were u tilis e d :-  
Biphenyl: 0.04. 0.05, 0 .06, 0.08, 0.10, 0.14, 0.20 (added as 50mM solution)
0.30, 0.40, 0.50, 0.60, 0.80, 1.00 (added as 250mM solution)
*
Safrole: 0.04, 0.06, 0 .08, 0.10, 0.12, 0.16, 0.20, 0.28, 0 .40, 0.80
Aniline: 0.20, 0.30, 0 .40, 0.60, 0.80, 1.20, 2.00.
c) Measurement of Enhanced Interaction Spectra Associated with Loss of
455nm Absorption in Microsomes from Safrole-Pretreated Rats
All measurements were carried out using a Pye-Unicam SP 1800 dual 
beam spectrophotometer at ambient temperature a fte r allowing at least 60 
minutes for instrument warm-up. Oxidised microsomal suspension was added into  
each of two glass cuvettes and substrate solution added to the sample cuvette. 
The resultant interaction spectrum was recorded at intervals - cuvettes being 
removed from the lig h t path between recordings - until no further increase
occurred (15-120 minutes). Any residual 455nm absorption was then recorded, 
f ir s t ly  a fte r addition of NADH and then a fter addition of sodium d ith io n ite  
to the sample cuvette. D ithionite was then added also to the reference 
cuvette, the cuvette positions in the spectrophotometer reversed, and the 
reduced difference spectrum recorded. The resultant type I I I  spectrum 
(Philpot and Hodgson, 1971) provided a measure of the 455nm absorption 
of the original reference suspension re la tive  to that of the substrate- 
treated suspension. The process of spectral enhancement could be halted 
a t any stage, and measurements of residual 455nm absorption made, by 
addition of NADH to the sample cuvette.
With the following exceptions, a ll substrate solutions were prepared 
in absolute ethanol:- SKF 525A, ethyl morphine hydrochloride, 
aminopyrine and nicotinamide were dissolved in d is tille d  water,
2,4-xylid ine in 50% (v /v) aqueous ethanol and 2-acetyl aminofluorene in 
ethanol/acetone (75:25 v /v ).
All substrate concentrations quoted in the text are fin a l cuvette 
concentrations in m.mol s / l i t r e .
7.3. Results
7 .3 .1 . Some Properties of the 455nm Absorbing Species
a) Spectral Characteristics
The NADH-reduced minus .oxidised difference spectrum of liv e r  microsomes 
prepared from rats pretreated with safrole (safrole microsomes*) showed an 
absorption maximum at 455nm in addition to the spectrum of reduced cytochrome 
b5. The magnitude of this 455nm maximum was not further increased by addition 
of NADPH and only s lig h tly  so (< 5%) by addition of Na2S20if .
Incubation of control microsomes* with safrole and NADPH, but not NADH, 
led to the progressive appearance of an absorption maximum at 455nm. This 
maximum disappeared when residual NADPH was oxidised by bubbling oxygen through 
the cuvette contents, but was fu lly  and immediately regenerated by addition of 
NADH. A 455nm absorption maximum generated by sim ilar incubation of control 
microsomes with piperonyl butoxide could only be re-reduced with NADPH or 
N a^O i*, and not NADH.
The difference spectrum between NADPH-reduced control microsomes in the 
presence and absence of safro le, had maxima at 427 and 455nm. This spectrum, 
generated under sim ilar conditions from piperonyl butoxide, was termed type I I I  
by Philpot and Hodgson (1971). A "type I I I "  spectrum was also resolved when 
NADH-reduced safrole microsomes were compared with NADH-reduced control 
microsomes although, in contrast to the spectrum described above, the 427nm 
maximum was greater than the 455nm maximum, probably due to the increased 
cytochrome b5 content of the safrole microsomes. These observations are 
summarised in Fig. 7.1.
*  Liver microsomes prepared from rats treated with safrole are referred to 
throughout as safrole microsomes and those from untreated ra ts , as control 
mi crosomes.
Spectral Characteristics of the 455nm Absorbing Species
Cuvette
Sample 
Safrole microsomes 
NADH (> 1 mM)
Control microsomes 
NADPH (1.5 mM) 
Safrole (0.5 mM)
Control microsomes
NADPH (0.15 mM)
Piperonyl butoxide 
(0 .5  mM)
Control microsomes 
NADPH (0.4 mM) 
Safrole (0.5 mM)
Safrole microsomes 
NADH (> 1 mM)
Contents
Reference 
Safrole microsomes
Control microsomes 
NADPH
Control microsomes 
NADPH
Control microsomes 
NADPH
Control microsomes ’ 
NADH
Spectral Change
E
in10
1o
CD*3-OO
<
LO
LO
Iocr>
□O
<3
400- ' 420 440 460 If80.
Wavelength (nm)
NADH0.04
0.03
0.02
0.01
0.00
Minutes
0.04
0.03
0.02
0.01
0.00
NADH NADPH
i  . 1  ■
JL
15- 
Minutes
Type I I I  
spectrum
0.1A
440  4 6 0 4 8 0  
Wavelength (nm) .
'tm
b) E ffect of Deoxycholate Treatment and Isooctane Extraction on the
455nin Absorption Maximum
Conversion of cytochrome P450 to P420 by solution of sodium deoxycholate 
(fin a l concentration approx. 1%) in safrole microsomes, resulted in a loss of 
455nm redox absorption. Sequential measurements, in the presence of 20% 
glycerol to retard the breakdown of cytochrome P450, showed that loss of 455nm 
redox absorption paralleled the conversion of cytochrome P450 to P420.
Conversion of cytochrome P450 to P420 did not appear to be slower in safrole  
than in control microsomes.
Extraction of safrole microsomes with isooctane (2 .3) resulted in 
complete loss of the a b ility  to generate an interaction spectrum on addition of 
a type I substrate. However, the 455nm absorption maximum was not diminished
a fte r extraction, recovery approaching 100% when expressed per unit of
microsomal protein recovered (Table 7 .1 ). In the safro le , but not the control
microsomes, 10-20% of the cytochrome P450 was recovered as P420.
c) S ta b ility  of the 455nm Absorbing Species During Storage o f Safrole
Microsomes
The re la tive  rates of decay of the 455nm absorption maximum and 
cytochromes P450 and b5 determined during storage of safrole microsomes at 
approximately 20°C are shown in Fig. 7.2 . Under these conditions, the 455nm 
absorbing species appeared to be rather less stable than e ither cytochrome 
P450 or b5.
TABLE 7.1
Effect of Isooctane Extraction on the Integrity of the 455nm Absorption Maximum
% Recovery a fte r Extraction*
Experiment
No. Microsomes
Cytochrome
P450
Cytochrome
b5
455nm Absorption 
Maximum
Microsomal
Protein
1
Control 76 § 69 - 70
Safrole 43 58 61 59
o
Control 119 116 - 105
C
Safrole 76 94 98 99
* Values expressed as % of those for phosphate buffer-extracted microsomes
(see 2.3 o)
§ Mean values. Expt. 1, 2/rats/group, Expt. 2, 3 rats/group.
Rats treated d ie ta r ily  with safrole (see 7.2a)
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FIG. 7.2
Decay of Cytochromes P450 and bg and the 455nm Absorption Maximum 
During Storage of Safrole Microsomes at 20°C.
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7.3 .2 . Substrate-Cytochrome P450 Interactions a fte r Pretreatment of Rats
with Safrole
a) Determination of Kinetic Constants at Intervals During Chronic
Administration of Safrole
A fter administration of safrole for 1 ,8 , 16 and 25 weeks, the kinetic  
constants Ks and A0Dmax were determined for the spectrally apparent 
interactions with cytochrome P450 o f biphenyl, safrole and an iline. For the 
determinations o f these values (Table 7.2) the cytochrome P450 content of the 
control and safrole microsomes was equalised a fte r measurement of th e ir  CO 
spectra. However, subsequent findings (see 7.3.3a) showed that as a result of 
inh ib ition  of CO binding, the actual cytochrome P450 content of the safrole  
microsomes was some 40% greater than that determined by the CO spectrum. 
Consequently, the k inetic  constants determined are of lim ited absolute value; 
they are included since they are of in terpretative value.
The spectral minimum of the aniline (type I I )  interaction with safrole 
microsomes was blue-shifted to around 395nm, producing a spectrum resembling 
that given by n-octylamine in microsomes from 3-methylcholanthrene pretreated 
rats (Jefcoate e t aK 1969).
b) Displacement of the 455nm Absorption Maximum
I f  the observed effects of safrole pretreatment on substrate metabolism 
and interaction were attributed to the purported safrole metabolite bound to 
cytochrome P450, i t  seemed possible that high concentrations of a lternative  
substrates of cytochrome P450 might displace the bound metabolite. Support 
for this contention was obtained.
Addition of up to 4mM of the type I substrates biphenyl or 
ethylbenzene to oxidised safrole microsomes, followed by reduction with NADH, 
did not a lte r  the intensity of the 455nm absorption maximum e ither
Table 7.2
Kinetic Constants for Substrate Interaction with Cytochrome P450
a fte r Pretreatment of Rats with Safrole
PRETREATMENT TIME (WEEKS)
1. 8 16 25
Ks1 0.54 ± 0.03 3.59 ± 0.07 0.53 ± 0.03 0.50 ± 0 . 0 5
Control
A0Dmax 0.047± 0.003 3.053± 0.003 0.063± 0.002 0.049+ 0.004
BIPHENYL a2
(High A ffin ity ) Ks 0.49 ± 0 . 0 4 3.81 ± 0.08 0.75 ± 0.05 0.60 ± 0.09
Treated
A0DmA max 0.058± 0.03 3.050± 0.002 0.062± 0.001 0.050+ 0.003
Ks 1.48 ± 0.25 1.67 ± 0.31 1.57 ± 0.29 1.34 ± 0.20
Control
A^ Dmax 0.060± 0.002 3.069± 0.001 0.083± 0.007 0.061± 0.004
BIPHENYL
(Low A ffin ity ) Ks 1.48 ± 0.007 2.53 ± 0 . 1 0 2.73 ± 0.46 2.15 ± 0.41
Treated
A0Dmax 0.075± 0.006 3.074± 0.004 0.094± 0.007 0.077± 0.005
Ks 4.67 ± 0.60 6.04 ± 0.19 5.63 ±0. 31 5.40 ± 0.42Control
A0Dmax 0.028± 0.001 0.029± 0.001 0.028± 0.003 0.025± 0.002
ANILINE u
K 4.30 ± 0.61 3.58 ±0 . 1 6 3.34 ± 0.40a 3.80 ± 0.19a
Treated L L u
AODmax 0 .04U  0.002° 3.043± 0.002° 0.047± 0.001 0.033± 0.001®
K 0.71 ± 0.05 3.77 ± 0.06 0.75 ± 0.06
.Control
AOD 0.072± 0.002 ).060± 0.001 0.70 ±0 . 002
SAFROLE max
K 1.01 ± 0.09 .13 ± 0.17 1.01 ± 0.03aTreated u u
AOD 0 .107± 0.008° ).088± 0.005° 0.097± 0.005max
 ^ Values are means (3 rats per group) ± SEM expressed in M x 10"^
2 Means s ign ifican tly  d iffe ren t from control, a = p < 0.05 b = p < 0.01
2uy
immediately, or on standing for up to 30 minutes. However, i f  NADH was not 
added until 30 minutes a fte r  addition of substrate (ImM ethylbenzene), a 
marked decrease in absorption at 455nm was seen. By increasing the time . 
interval between addition of substrate and reduction with NADH, complete loss 
of 455nm absorption could be achieved.
c) Enhancement of Substrate Interaction Spectra Accompanying Loss of
455nm Absorption
When the oxidised difference spectrum was recorded at intervals a fte r  
addition of ImM ethylbenzene to safrole microsomes, a progressive 
enhancement o f the type I spectrum was observed, resulting in a final 
spectral change 2 -3 .times the k in e tica lly  determined A0Dmax. No such effect 
could be reproduced in control microsomes. The time required for maximal 
enhancement o f the type I spectrum was very sim ilar to that required to 
produce complete loss of 455nm absorption (section.(a) above) and the close, 
inverse relationship between these two events is illu s tra ted  in Fig. 7.3.  
Further, in 12 d ifferen t preparations o f safrole microsomes the degree of 
spectral enhancement appeared to be d irectly  related to the in i t ia l  magnitude 
of the 455nm absorption maximum (Fig. 7.4) .  F ina lly , the d ith ion ite  reduced 
difference spectrum between safrole microsomes (sample cuvette) and the same 
microsomes plus ImM ethylbenzene (reference cuvette) showed the progressive 
appearance of a type I I I  spectrum, clearly indicating the decreased amount of 
455nm absorbing species in the ethylbenzene-treated microsomes.
The time taken to e ffect complete displacement of the 455nm 
absorption maximum varied between about 15 and 120 minutes dependent on a 
number of factors which are considered in section 7.3.2f .  The process of 
displacement could be halted at any stage by reduction of the microsomes with 
NADH.
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d) Characteristics of Enhanced Interaction Spectra
The enhanced substrate interaction spectrum associated with 
displacement of the 455nm absorption maximum did not d if fe r /o th e r  than in  
magnitude, from the type I spectrum produced on f i r s t  addition of the substrate. 
Wavelengths of the Soret maximum and minimum were not altered and the vis ib le  
minimum at around 575nm -  characteristic of type I interactions - in tensified  
in paralle l with enhancement of the Soret spectrum. When the in i t ia l  type I 
component o f an enhanced spectrum was cancelled out by addition of an equal 
amount of substrate to the reference cuvette, the residual "spectrum due to 
enhancement" again appeared identical to a type I spectrum.
Type I spectra produced by high (> ImM) concentrations of certain  
substrates, e.g. biphenyl, safro le , show an increase in absorption towards 
350nm which is not attributab le  to the absorption spectrum of the substrate. 
Enhancement o f such spectra was accompanied by a progressive return to baseline 
absorption at 350nm. The "spectrum due to enhancement" s im ilarly  showed 
baseline absorption at 350nm.
Some spectra, typical of those described in sections b) c) and d) 
above are shown in Fig. 7.5.
e) Correlation of.Physicochemical Properties with A ctiv ity  in Displacing
the 455nm Absorption Maximum
A range of substrates of cytochrome P450 was u tilised  to determine 
whether a b ility  to displace the 455nm absorption maximum was a property common 
to a ll such substrates and i f  i t  were not, what features were peculiar to 
those substrates possessing this a b ility .
The substrates examined are shown in Table 7.3 c lassified as active , 
p a rtia lly  active and inactive in displacing the 455nm absorption maximum.
Where available, Hansch values (log partition  coefficient between n-octanol
FIG. 7.5 Some Spectra of Safrole Microsomes
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TABLE 7.4
Structural Formulae of Some Substrates Active or Inactive in Displacing 
the 455nm Absorption Maximum
A C TIVE I
Safrole
Ethylbenzene
Allylbenzene
Cyclohexane
Naphthalene
Biphenyl
o - f H a
CH2CH = CHj 
CH2CH3
CH2CH=CH2
0
INAC TIVE \
ch3 
1
Hesobarbital ■
Ethylmorphine 
c ^ o
HO
JNCHs
SKF 525A Os
CH3“ CH2-CH2- -C -C -0 - ’CH2-C H 2 N \p.
A H 5
CaHs
2 -  AcetylaminofLuorene
^-✓NHCOCH3
Am inopyrine p
ch3„
ch3'
ch3
ch3
Bntylated Hydroxytoluene
ch3. OH ,c h3
CH3"c- r ^ V CCCH3 
CH3"  jj ^C H 3
CHn
Type H  Substrates
and water) are included as an index of lip o p h ilic ity . Substrates classified as 
active displaced a ll the NADH-reducible 455nm absorption and le f t  no more than 
10% reducible by Na2S20it . P a rtia lly  active substrates might displace up to 
50% of NADH-reducible 455nm absorption but might leave as much as 90% reducible 
by Na2S20tf (see section 7 .3 .2 f) .
C learly, many substrates were inactive and these remained so, 
irrespective o f the substrate concentration used. Such substrates tended to be 
less, although some were much more, lipoph ilic  than those that were active, a ll 
of which were highly lip o p h ilic  (Table 7 .3 ). A d istinction between active and 
inactive substrates emerged more clearly when structural formulae were 
compared (Table 7 .4 ). Thus, inactive substrates were e ither large or 
s te ric a lly  "bulky" molecules - or were type I I  substrates -  active substrates 
being comparatively "simple" molecules. In an attempt to assess further the 
re la tive  importance of lip o p h ilic ity  and steric  factors, experiments were 
performed with a series of alkylbenzenes in which lip o p h ilic ity  increased with 
increasing alkyl chain length. Results of these experiments are summarised in 
Fig. 7.6. Comparison of the highly lip oph ilic  but s te ric a lly  very "bulky"
2 ,6-di-tert-butyl-4-methylphenol (BHT) with the less lip o p h ilic  but less 
"bulky" 2-tert-butyl-4-methoxyphenol (BHA) showed the former to be inactive but 
the la t te r  to be active.
Atypical results were obtained with carbon tetrach loride,
4-methoxyphenol and piperonal. The type I spectrum of carbon tetrachloride  
underwent enhancement but there was no concomitant loss of Na2S20tt -  reducible 
455nm absorption, probably because carbon tetrachloride i t s e l f  gives rise to an 
absorption maximum at 454nm in Na2S20it-reduced microsomes (Reiner and Uehleke, 
1971). 4-Methowphenol gave no detectable interaction spectrum with control 
microsomes and l i t t l e  or no immediate spectrum with safrole microsomes. With 
phenobarbitone microsomes i t  gave a reverse type I (Schenkman e t , 1972b) 
spectrum w hilst the enhanced spectrum with safrole microsomes resembled a
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FIG. 7.6
Spectral Enhancement Produced by Benzene and some Alkyl benzenes
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Safrole microsomes were suspended in phosphate/glycerol buffer 
as per 7.2a. The fin a l cuvette concentration of each substrate
was 1.0 mM. Benzene 0-----0; Toluene A— A; Ethylbenzene • ------ •
n-Butyl benzene ■— ■; n-Hexyl benzene A— ±.
normal type I spectrum. The spectrum produced by piperonal in phenobarbitone 
microsomes and both its  in i t ia l  and enhanced spectrum with safrole microsomes 
resembled a type I spectrum but the wavelength o f the maximum was increased to 
about 408nm. Franklin (1971) reported that piperonal did not bind to 
phenobarbitone microsomes. A ll of the type I I  substrates u tilised  were inactive  
in displacing the 455nm absorption maximum.
f)  Some Factors Affecting the Rate of Displacement o f the 455nm Absorption
Maxi mum
A remarkable feature of the process of displacement was the very slow 
rate at which i t  occurred. The e ffect on this rate , o f displacing substrate 
concentration, g lycero l, isooctane extraction and the presence of non-displacing 
substrate was therefore examined. Displacement was monitored by following the 
progressive enhancement of the substrate (ethylbenzene) interaction spectrum.
Substrate Concentration and Glycerol Spectral enhancement proceeded 
more rapidly with increasing substrate concentration (Fig. 7.7) although when 
spectral change (aOD) was plotted as % of in it ia l  aOD, the differences in rate  
at d iffe ren t concentrations were much less marked. When measurements were made 
in the presence of glycerol the rate of enhancement was decreased: at substrate 
concentrations o f 0 .04, 0.40 and 2.00 mM the rate was 4 .2 , 3.1 and 2.1 times 
respectively, slower in the presence than in the absence o f glycerol when 
measurements o f aOD over the f i r s t  5 minutes were compared. Analysis o f values 
for " in it ia l  velocity" of enhancement at d ifferen t displacing substrate 
concentrations in the form of double reciprocal plots (Lineweaver and Burk , 
1934), yielded w e ll-fitt? n g  straight lines and indicated that glycerol was 
acting as a "non-competitive inhibitor" of the displacement process (Fig. 7 .8 ).
Under the conditions of these experiments, the minimum concentration of 
ethylbenzene required to e ffec t complete displacement was between 0.1 and 0.2mM
Fig. 7.7
Rate of Spectral Enhancement at Various Concentrations 
of Ethylbenzene Added to Safrole Microsomes
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For details of procedure see 7.2c . Microsomes were 
suspended in phosphate/glycerol buffer as per 7.2a.
Lineweaver-Burk Plot Showing Effect of Glycerol on the In it ia l ,  Rate 
of Spectral Enhancement Associated with Loss o f 455nm Absorption
Glycerol present (see 7.2a) k k ,,Vmax" = 0.080A/10 min.
Glycerol absent •— —•  " V ^ "  = 0.200 A/10 min.
100
(AOD/10 min)
x IQ-^i
in the absence, but around I.OmM in the presence of glycerol. These 
concentrations appeared to hold for preparations of safrole microsomes with 
quite widely varying apparent levels of the 455nm absorption maximum.
When displacement was incomplete, addition of Na2S20 if to the 
NADH-reduced sample might e l ic i t  an.increase of 10-50% in the residual 
455nm absorption. This contrasts with the minimal additional e ffect of 
Na2S20i,. on "intact" NADH-reduced safrole microsomes (see 7 .3 .1a ).
Isooctane Extraction: Although no in it ia l  type 1 spectral change was
generated on addition of up to 2mM of ethylbenzene to isooctane-extracted
safrole microsomes, extraction did not prevent the time-dependent
appearance of a "type 1" spectrum nor did i t  a ffec t the rate a t which
this spectrum underwent enhancement. In both extracted and unextracted
microsomes complete displacement of the 455nm absorption maximum was
effected and the aOD 'in  the extracted was smaller than that in themax
unextracted microsomes by an amount equal to the magnitude of the
AOD. . . .  i in the unextracted microsomes. Substrates inactive as in it ia l
displacers remained so a fte r isooctane extraction.
Presence of Non-Displacing Substrate: SKF 525A was added to safrole
microsomes a t a concentration in excess of that required to e l ic i t  the 
maximum type 1 spectral change in these microsomes. This treatment 
reduced by 70% the type 1 spectrum produced on addition of 1 mM 
ethylbenzene but did not prevent, or retard , the subsequent 
enhancement of this spectrum and complete displacement of the 455nm 
absorption maximum. No type 1 spectrum was generated on addition 
of 1 mM ethylbenzene to SKF 525A-saturated control microsomes.
7.3 .3 . Some Consequences of Formation and Displacement of the 455nm
Absorption Maximum
a) Effects on Cytochrome P450-C0, and Type I I  substrate Interaction
Spectra
Formation in v itro  of the 456nm absorption maximum from piperonyl 
butoxide was paralleled by inhib ition  of CO-binding to cytochrome P450 
(Philpot and Hodgson, 1971). To determine whether a sim ilar in h ib ition  
resulted from the interaction of safrole with cytochrome P450 in vivo, the 
CO-spectrum of safrole microsomes was measured before and a fte r  displacement.
Ethylbenzene (ImM) was added to safrole microsomes and the suspension 
immediately reduced with Na^O i*. The cytochrome P450-C0 spectrum of this  
suspension was compared with that of the same suspension but which had been 
incubated at room temperature with ethylbenzene (ImM) for 90 minutes prio r to 
reduction with Na2S20if . In 5 preparations o f safrole microsomes displacement 
of the 455nm absorption maximum resulted in increases of between 41 and 48% in  
the cytochrome P450-C0 spectrum.
The displacing substrate must be present in both cuvettes to show this  
effect fu lly . I f  i t  is present only in the sample cuvette, a type I I I  spectrum 
w ill be generated in the reference cuvette on reduction with Na2S20if , the 
455nm maximum of which w ill subtract from the 450nm maximum of the cytochrome 
P450-C0 spectrum in the sample cuvette.
The type I I  interaction spectrum of aniline in safrole microsomes did 
not undergo enhancement (see 7 .3 .2e ), but did so when ethylbenzene (ImM) was 
present in the microsomal suspension. The spectrum increased by 60-70% as 
compared with 41-48% in the case of the CO- spectrum. This additional 
increase probably derives from the known stimulatory e ffect of type I 
substrates on the magnitude of type I I  spectra (Leibman et al_., 1969), an 
effect which could be e lic ite d  to an equal extent in both safrole and control
microsomes with both displacing and non-displacing type 1 substrates.
b) Effects on the Cytochrome P450-Ethylisocyanide Spectrum
As an approach to determining whether qualitative changes in 
cytochrome P450, other than binding of the metabolite, occurred a fte r  safrole 
pretreatment, the ethyl isocyanide spectrum of safrole microsomes was 
examined before and a fte r  displacement of the 455nm absorption maximum.
In control microsomes at pH 7.6 the ra tio  between the two maxima of 
the ethyl isocyanide spectrum 430nm/455nm was 0.66 (mean of 3 observations). 
Dietary administration of safrole for 1 week brought this ra tio  to a value of 
1.21. A fter administration of safrole for 25 weeks, control and treated 
values were 0.73 and 1.40 respectively. This alteration of the ethyl isocyanide 
spectrum could be consistently demonstrated a fte r dietary administration of 
safrole but not when safrole was given by intraperitoneal in jection  
(150 mg/kg/day for 4 days). In this case, the level of the 455nm absorption 
maximum re la tive  to the (apparent) level o f cytochrome P450 was less than when 
safrole was given in the d ie t. However, i f  microsomes from rats treated by 
in jection were incubated in v itro  with safrole and NADPH, the resultant 
increase in the 455nm absorption maximum was paralleled by an increase in the 
ratio  430nm/455nm for the ethyl isocyanide spectrum from 0.8-0.9  to 1 .0 -1 .1 .
A fter displacement o f the 455nm absorption maximum, the 430nm/455nm ratio  
reverted from 1.21 to 0.76 (mean of 3 observations), a value close to that 
observed for control microsomes. This reversion was achieved purely by an 
increase in the 455nm maximum of the ethyl isocyanide spectrum. The total 
spectrum (430nm + 455nm) was increased by 31% a fte r displacement. The effec t 
of displacement of the 455nm absorption maximum on the ethyl isocyanide 
spectrum of safrole microsomes is illu s tra ted  in Fig. 7.5 .
For the reasons outlined in 7 .3 .3a , i t  is essential that the 
displacing substrate is present in both sample and reference cuvettes for the 
demonstration of these effects on the ethyl isocyanide spectrum.
c) Effects on the Apparent Level of Cytochrome b5
After displacement of the 455nm absorption maximum the cytochrome b5 
spectrum was decreased by 5-15% dependent on the amount of 455nm absorption 
displaced. These findings support the conclusion reached in 4.3g that the 
very high apparent levels of cytochrome b5 induced during chronic 
administration of safrole do not result simply from a contribution to the b5 
spectrum of the 427nm maximum of the type I I I  spectrum.
7.3 .4 Formation in v itro  of the 455nm Absorption Maximum
The formation in v itro  of a 455nm absorption maximum from 
piperonyl butoxide has been described in some detail by Franklin (1971,
1972 a ,b ). Most o f Franklin's findings could be confirmed using safrole  
and only a few additional observations are presented here.
a) Effects of D ifferent Pretreatments in vivo on the Rate of Formation 
in v itro  of the 455nm Absorption Maximum
Rates of formation of the 455nm absorption maximum (measured as 
described in 2.3) in microsomes from untreated rats and rats pretreated with 
phenobarbitone, safrole or 3-methylcholanthrene are given in Table 7 .5B. Two 
observations were of particu lar in terest. F irs tly , the specific increases in 
in it ia l  rate induced by each pretreatment exceeded by several fold the 
respective increases in the specific content of cytochrome P450 and secondly, 
w hilst the extent of the reaction ( i .e .  total AOD 455-490nm per incubation) 
was normally quite closely related to the in it ia l  rate , 3-methylcholanthrene 
pretreatment increased the extent more than the in it ia l  rate by a factor of 
approximately 2.5 (Table 7.5B).
In one.experiment, a small quantity of a preparation of human liv e r  
microsomes was available. Upon incubation with safrole and NADPH an increase 
in absorption at 455nm was observed and on subsequent reduction with 
Na2S20it , a type I I I  spectrum could be generated. Although quantitative  
measurements could not be undertaken, the rate of reaction appeared to be 
very low -  some 25-50% of that in untreated rat liv e r  microsomes.
TABLE 7.5
In V itro Formation of the 455nm Absorption Maximum: A. From Compounds 
Related to Safrole: B] Effect of In Vivo Pretreatments
Microsomes + Substrate
(Assay concentration 
0.5 mM)
In it ia l  Rate 
(aOD^ 55 ugonm/unit 
P450/hrJ §
Extent
(Total AOD^ss^gonm 
/u n it  P450) §
Control Safrole
Piperonyl butoxide
0 . 1 0
0.13 (130)*
0.0270
0.0410(148)
Phenobarbitone Safrole
Piperonyl butoxide 
Piperonal 
Eugenol 
Allylbenzene
0.26
0.39 (150) 
0 . 0 0  
0 . 0 0  
0 . 0 0
0 . 1 0 1 0
0.1380(137)
0.0000
0.0000
0.0000
Safrole Safrole
Piperonyl butoxide 
Piperonal 
Eugenol 
Allylbenzene
0.26
0.37 (142) 
0.11  
0 . 0 0  
0 . 0 0
0.0099 
0 . 1 2 1 0 (1 2 2 ) 
0.0045 (45) 
0.0000 
0.0000
Microsomes f^ In it ia l  Rate (AODif55_lt9onni/h r )  /u n it  P450 /mg microsomal
protein§
Extent § Extent/rate  
(per unit P450) 
X 100
Control 0.15 0.28 0.0017 1.13
Phenobarbitone 0.37 <247)u 1.51 (540) 0.0041 (241) 1.11
Safrole 0.43 (286) 0.72 (257) 0.0054 (317) 1.26
3-Methylchol­
anthrene
0.51 (340) 1.21 (432) 0.0153 (900) 3.00
t  For details of pretreatments see 2.2c 
§ Values represent means from 2 experiments
*  Figures in parentheses are values expressed as % of value for safrole
H " " " " " « » » " <1 M
b) Other Methylenedioxyphenyl and Related Compounds as Substrates for 
in v itro  Formation of the 455nm Absorption Maximum
The results of this experiment are summarised in Table 7 .5A. Neither 
of the compounds without an in tact methylenedioxy ring - eugenol and 
allylbenzene -  give rise to any increase in absorption at 455nm. Piperonyl 
butoxide supported a faster rate of reaction than did safrole w hilst piperonal 
gave rise to an increase in absorption at 455nm only in safrole microsomes and 
not in phenobarbitone microsomes.
c) Effect of Isooctane Extraction on in v itro  Formation of the 455nm 
Absorption Maximum
Abolition of the a b ility  to generate a type I spectrum by isooctane 
extraction, resulted in loss of the a b ility  of phenobarbitone microsomes 
either to form, or to bind, the species responsible for the 455nm absorption 
maximum. In safrole microsomes this a b ility  was reduced but not abolished, 
the rate being 50% and the extent 30% of that in unextracted microsomes 
(Table 7 .6 ). However, when safrole was added to the reaction mixture 30 
minutes prior to the addition of NADPH - i .e .  producing conditions under 
which displacement could occur.- the reaction rate was increased to 75% 
and the extent to 85% of that of the unextracted microsomes. When the 
displacing substrate naphthalene was added to the extracted safrole microsomes 
30 minutes prior to the addition of safrole and NADPH, the rate of reaction 
remained at 75%, but the extent was increased to 121% of that in the 
unextracted safrole microsomes.
TABLE 7-6
Effect of Isooctane Extraction on the In Vitro Formation of the.455am
Absorption Maximum
Microsomes * Substrate Additions In it ia l  
Rate f
Extent Extent/
RateXlOO
Phenobarbitone Safrole 0.8 mM 0.20H 0.0026 1.30
Safrole II II( 0.22 0.0032 1.45
Isooctane
Extracted
Phenobarbitone Safrole 0.8 mM 0.00 0 . 0 0 0 0
Safrole i i  i i 0.11 0.0010 0.91
ii Safrole 0.8 mM 30 min prior, 
to addition of NADPH 0.17 0.0027 1.59
ii
i ■ —  -
Safrole* 0.8 mMlNaipthalene 
0.5 mM added 30 min prior to 
safrole & NADPH 0.17 0.0040 2.35
*  For details of pretreatment see 2.2c 
t  For defin ition  see Table 7.5.
u Mean values: incubations performed in tr ip lic a te  on pooled microsomal 
preparations (2 rats per treatment group)
7.4 Discussion
A number o f substrates of cytochrome P450 are now known to give rise  
to species absorbing maximally, at 455nm (Franklin 1971, 1974; Schenkman 
et al_., 1972a;Werringloer and Estabrook, 1973) and a potent inh ib ition  of 
drug metabolism in v itro  accompanies the formation of such a species from 
piperonyl butoxide (Franklin, 1972a). A sim ilar effect in vivo was shown 
in Chapter 4 with safrole and, in consequence, some in v itro  studies have 
been performed to explore the nature of the interaction of safrole with 
cytochrome P450.
The addition of re la tiv e ly  low concentrations of certain substrates to 
microsomes from rats pretreated with safrole brought about a gradual 
disappearance of the 455nm absorption band which characterises the redox 
difference spectrum of these microsomes. Changes in magnitude of the 
455nm absorption maximum correlated closely with quantitative changes in  
the cytochrome P450-interaction spectrum of the added substrate. This, 
together with the appearance of a type I I I  spectrum (Philpot and Hodgson, 
1971) when untreated safrole microsomes were compared with the same 
microsomes a fte r substrate-induced abolition of the 455nm absorption 
maximum, supports the view that the 455nm maximum derives from a species 
bound to cytochrome P450 and suggests that the observed spectral changes 
represent the displacement of this bound species. In support of this  
conclusion, abolition of the 455nm maximum resulted in an increase o f up 
to 50% in the magnitude of the CO-spectrum of cytochrome P450, inh ib ition  
of CO binding being known to accompany formation in v itro  of the 455nm 
absorbing species from piperonyl butoxide (Phi 1 pot and Hodgson, 1971).
Nature of Metabolite Binding
The changes in the ethyl isocyanide spectrum of safrole microsomes 
indicate an e ffect of the bound metabolite rather than the synthesis o f a 
modified form of cytochrome P450 (Shoeman e t al_., 1969; Sladek and
Mannering, 1969) since they were reversible on displacement of the 
metabolite and since they could be produced in v it ro . Piperonyl butoxide 
e lic its  changes in the ethyl isocyanide spectrum sim ilar to those produced 
by safrole (Philpot and Hodgson, 1971/72; Skrinjaric-Spol ja r  et al_., 1971). 
Displacement increased only the 455nm maximum of the ethyl isocyanide 
spectrum. This is interesting since 3-methylcholanthrene pretreatment, 
which p re feren tia lly  increases the 455nm ethyl isocyanide maximum (Sladek 
and Mannering, 1969) and which apparently induces a high-spin form of 
cytochrome P450 (Waterman and Mason, 1972), resulted in the binding of a 
considerably greater amount, per unit of cytochrome P450, of the species 
responsible fo r the (safrole) 455nm absorption maximum. Possibly therefore, 
the safrole metabolite binds preferentia lly  to a high-spin form of 
cytochrome P450. Since characteristic changes in the spin state of 
cytochrome P450 accompany the binding of ligands (Cammer e t a l . ,  1966; 
Jefcoate e t al_. , 1969; Jefcoate and Gaylor, 1969), electron spin resonance 
spectroscopy should be valuable in investigating further the nature of the 
binding and displacement of the safrole metabolite.
Increased binding of the two ligands, CO and ethylisocyanide, 
attendant on abolition of the 455nm absorption maximum, implies that 
binding of the safrole metabolite involves a direct in teraction  with the 
haem iron of cytochrome P450. The concomitant increase in binding of the 
type I I  substrate aniline supports the same conclusion, the greater extent 
of this increase probably being attributable to the presence of the 
displacing type I substrate (Leibman et a K , 1969). This implied 
inhibition of an iline binding in safrole microsomes need not be contradicted 
by the observed increases in both the total binding (A0Dmax) and the 
a ff in ity  (K$) for aniline a fte r safrole pretreatment. These resu lts , 
calculated on a basis of equal CO-cytochrome P450 concentrations in both the
control and safrole microsomes (see 7 .3 .2a ), may be regarded as informative 
only of changes in that proportion of the cytochrome P450 in the safrole 
microsomes not involved in metabolite binding. In piperonyl butoxide 
treated microsomes, inhib ition of the type I I  binding of pyridine paralleled- 
the inh ib ition  of CO binding (Philpot and Hodgson, 1972).
Studies With biphenyl indicate that binding of the safrole metabolite 
also involves -  or at least affects -  the type I substrate binding s ite . 
Applying the argument put forward above, recalculation of the results to 
a basis of equal to ta l cytochrome P450 concentrations, assuming a P450 
concentration in the safrole microsomes 40% greater than that determined 
by the CO spectrum, shows that a fte r administration of safrole for 8 weeks 
the A0Dmax of both the high and the low a f f in ity  biphenyl interaction is 
greatly reduced, whilst the K$ does not d iffe r  greatly from the control.
This e ffe c t, analagous to non-competitive in h ib itio n , is consistent with 
an "occupation" of the biphenyl (type I )  binding s ite  in a proportion of 
the cytochrome P450 population and accords with the observed inh ib ition  of 
biphenyl 4-hydroxylase (Chapter 4) and the reported non-competitive 
inhibition of type I substrate metabolism produced by piperonyl butoxide 
(Franklin, 1972a; Friedman et al_., 1972).
For the formation in v itro  of the 455nm absorbing species from safro le , 
a requirement for spectrally apparent type I interaction with cytochrome 
P450 appeared absolute since isooctane extraction of phenobarbitone 
microsomes completely eradicated this a c tiv ity . Normal type I substrate 
metabolism, in contrast, is only s lig h tly  decreased by isooctane extraction  
(Leibman and Estabrook, 1971). Once formed, however, as in safrole  
microsomes, the 455nm absorption maximum was unaffected by isooctane 
extraction, suggesting that stable binding of the metabolite is not 
dependent on that fraction of the microsomal phospholipid associated with
the production of type I spectra: this s ta b ility  presumably derives from 
interaction with cytochrome P450 haem. Since isooctane extraction did not 
prevent the development, or decrease the magnitude of the displacement- 
associated type I spectrum, the bound metabolite may stab ilise  a specific  
s ite  which, on removal of the metabolite, is capable of interacting with 
certain type I substrates to produce an enhanced interaction spectrum.
The lack of e ffec t of high concentrations of the non-displacing substrate, 
SKF 525A, on displacement and the associated spectral changes, suggests 
that such a s ite  d iffe rs  from the "normal" type I s ite . However, any such 
difference(s) must be subtle to allow the enhanced interaction spectrum to 
resemble so closely a "normal" type I spectrum and to account for an 
observation that in safrole microsomes the binding of displacing and
f
non-displacing substrates was inhibited to a sim ilar degree.
I t  may be concluded that generation of the 455nm absorption maximum 
requires a spectrally detectable type I interaction of safrole with 
cytochrome P450 and that subsequent metabolite binding involves both a 
direct interaction with the haem and the type I substrate binding s ite . 
Since most type I substrates are chemically unsuitable for d irect haem 
liganding (Imai and Sato, 1967) the requirement for NADPH and 02 must.be 
in the generation o f a species su ffic ien tly  nucleophilic to undergo such 
interaction. Measurement of the absolute spectrum of cytochrome P450, 
which exhibits characteristic changes on interaction of substrates and 
ligands (Remmer ejb al_., 1969) might provide further evidence as to the 
nature of. the metabolite interaction.
Factors A ffecti ng Pisplacement
The most strik ing  difference between substrates active and inactive  
in displacing the bound metabolite was in chemical structure. Whilst a ll 
the active substrates were highly lip o p h ilic , several substrates equally,
or more lip o p h ilic  were inactive. However, without exception a ll the 
(type 1) inactive substrates were structurally more complex and s te rica lly  
"bulky" than the active substrates. The view th at, given a certain degree 
of lip o p h ilic ity , a c tiv ity  in displacing the bound metabolite is governed 
by molecular "size" is supported by observations with the series 
benzene-hexylbenzene and with the pair of compounds BHA and BHT. In the 
la t te r ,  the presence of an additional tert-bu ty l group in BHT - despite 
the attendant increase in lip o p h ilic ity  -  results in complete loss of 
a c tiv ity . The steric  dimensions of a tert-bu ty l group are greater than 
those of an unsubstituted benzene ring. A ctiv ity  in displacing the bound 
metabolite appears to be unrelated to the a ff in ity  (Ks) of the substrate 
fo r cytochrome P450. Thus, the inactive SKF 525A has an a f f in ity  some 
100-fold greater than that of most displacers and in the alkyl benzene 
series, a f f in ity  increases with increasing alkyl chain length (unpublished 
observations of K. Al-Galainy, 1973). However, i t  may be s ign ificant that 
benzene, which was an unexpectedly poor displacer, has an a f f in ity  some 
10-fold less than that of methyl- or ethylbenzene.
Although none of the type I I  substrates examined was particu larly  
lip o p h ilic , th e ir  in ac tiv ity  as displacers results more probably from 
th e ir  fundamentally d iffe ren t interaction with cytochrome P450. This is 
interesting since the bound metabolite appears to in teract with the type I I  
(haem) binding s ite  and since certain amphetamine derivatives which give 
type I I  interaction spectra can themselves give rise to 455nm absorbing 
species (Franklin, 1974). A common mechanism for the generation of 455nm 
absorbing species from both type I and type I I  compounds is possible since 
many type I I  substrates probably interact also with the type I binding s ite  
(Gorrod and Temple, 1973; Schenkman, 1970).
A ctiv ity  or in a c tiv ity  in displacing the bound metabolite thus appears 
to be unrelated to a b ility  or in a b ility  to give rise to a 455nm absorbing 
species. Of the active substrates only safrole can do so, whereas amongst 
the inactive substrates both piperonyl butoxide and SKF 525A can give rise  
to 455nm absorbing species. C learly , as implied by the isooctane studies, 
d iffe ren t interactions are involved in formation and displacement of these 
species. Some insight into the nature of the binding s ite  involved in 
displacement might be gained from dimensional analysis of molecular models 
of active and inactive substrates. Within the present resu lts , differences 
in rate of displacement between d iffe ren t substrates give no clear 
indication as to what constitutes a "best f i t "  in this respect
Mechanistic Considerations
The molecular events underlying the substrate-induced displacement of 
the 455nm absorption maximum and the accompanying spectral changes are 
unknown. The process cannot represent a simple replacement of the bound 
species by the displacing substrate since type I substrates could not 
"replace" an interaction with haem, since the accompanying spectral 
changes were type I  in nature and since displacement resulted in reversal 
of the inh ib ition  of CO and ethyl isocyanide binding to cytochrome P450.
The increase in CO binding never exceeded 50% and cannot d irec tly  account 
fo r the 200-350% increase in type I spectral change. Conceivably, a ll of 
the cytochrome P450 "unmasked" by displacement might be capable of 
forming the type I spectral complex as opposed to only the 12% (U llr ic h ,
1969) able to do so in normal microsomes. That CO its e lf  had no e ffec t 
on the magnitude of the 455nm absorption maximum suggests a high a f f in ity  
for the metabolite-haem interaction. However, when the relationship  
between displacing substrate concentration and rate of displacement was 
analysed as a double reciprocal p lo t, the intercept on the x axis,which might be 
regarded as "the concentration of substrate required to produce h a lf-
maximal rate of displacement", gave a value sim ilar to that of the Ks for 
many type I substrates -  an a f f in ity  some 100 times less than that fo r CO. 
This reinforces the view that displacing substrates act in d irectly  rather 
than by competition fo r a common binding s ite . Glycerol decreased the 
"Vmax" without affecting the "Km" for displacement which suggests that i t  
does not exert a d irec t e ffec t on the metabolite interaction: possibly its  
viscosity hinders access of the displacer to the metabolite interaction  
s ite . Any such e ffec t of viscosity could be examined with an "inert" 
agent such as polyvinyl pyrrolidine.
I f ,  as proposed by U llrich  and Schnabel (1973), the 455nm absorption 
maximum reflects the ligand interaction of a carbanion with cytochrome 
P450, disappearance of the maximum could represent the reprotonation of 
this species. Such a suggestion is energetically acceptable and could 
explain the length of time required for displacement since the hydrophobic
environment of the bound metabolite would not be conducive to rapid
\
reprotonation. Im p lic it in this proposal however, is an action o f the 
displacing substrate in prec ip itating , or greatly accelerating 
reprotonation, an action d if f ic u lt  to envisage other than as a substrate- 
induced conformational change resulting in increased hydrophilic ity around 
the bound metabolite. This proposal could be tested by the use of an 
appropriate fluorescent probe.
Significance o f Displacement
The displacement process described here has shown that safrole does 
not in teract "irreversibly" with cytochrome P450. Storage of safrole  
microsomes indicates that even without such external manipulation breakdown 
of the metabolite-cytochrome P450 complex precedes the destruction of 
cytochrome P450 i ts e l f .  The apparent storage s ta b ility  of cytochrome P450 
in safrole microsomes may thus be attributed to a restoration o f CO
binding attendant upon dissociation of the metabolite complex. The 
s ta b ility  o f the metabolite complex in vivo is more d i f f ic u lt  to assess 
since i t  is unknown whether or not its  formation represents a "dead end" 
in terms of metabolism. The 455nm absorbing species in safrole  
microsomes appeared to be re la tive ly  stable in the presence o f NADPH and 
02 suggesting that further mixed function oxidation does not contribute to 
its  breakdown: reprotonation of a carbanion would regenerate the parent 
compound. I t  w ill be necessary to determine the turnover rate of the 
metabolite complex in vivo before the potential in vivo significance of 
the displacement process can be assessed.
The relationship between the displacement process and rates of drug 
metabolism is unclear. An approach to this problem was made by measuring 
the in v itro  metabolism of biphenyl before and a fter biphenyl-mediated 
displacement of the bound metabolite. In this experiment an increase of 
more than 100% in the type I spectrum of biphenyl was accompanied by an 
increase of only some 10% in the rate of 4-hydroxylation of biphenyl.
Thus, substrate-induced displacement may not lead to a restoration of 
metabolic a c tiv ity . However, even i f  this is so, the behaviour of 
substrates e ither as displacers or non-displacers appears to be o f some 
importance in  view of the effects noted in Chapter 4 where, on chronic 
administration of safro le, the metabolism of biphenyl was impaired to a 
much greater extent than that of the non-displacing substrates, 
ethylmorphine and an iline . I t  is un likely, on structural grounds, that 
the endogenous, physiological substrates of cytochrome P450 would be 
active as displacers although this possib ility  merits investigation.
The observations reported in this chapter have been concerned with 
the interaction of safrole with cytochrome P450. However, the properties 
of the 455nm absorbing species generated from safrole d iffe r  in  some
respects from those reported fo r a number of other compounds. In
P
particu lar, the a b ility  of NADH, as opposed to NAIjN, to reduce the 
safrole-derived 455nm absorbing species might imply that binding of the 
safrole metabolite produces rather more fundamental changes in 
cytochrome P450. This might account for the considerable s ta b ility  of 
the safrole metabolite complex as compared with that formed, for 
from piperonyl butoxide (Lake and Parke, 1972) but i t  suggests that the 
phenomena described here may not be en tire ly  reproducible with 455nm 
absorbing species formed from other compounds.
The mechanism proposed by U llrich  and Schnabel (1973) suggests that 
many substrates of cytochrome P450 are potentially capable of giving rise  
to metabolite-cytochrome P450 complexes of the type apparently formed 
from safrole and recent reports indicate that this is so (Buening and 
Franklin 1974; Franklin 1974 a ,b ). Adverse effects might ensue in at 
least two d ifferen t ways from an interaction of this nature with 
cytochrome P450. F irs t ly , the impairment of drug metabolism resulting  
from the formation of re la tiv e ly  stable metabolite complexes may have 
important repercussions both fo r the metabolism.of the parent 
compound and of other substrates of the drug metabolising enzyme system. 
The possible significance of this situation in influencing the 
hepatotoxicity of safrole was considered in Chapter 4. These 
considerations could also be relevant in the case of a drug, chemically 
suitable for complex formation and administered in high doses fo r  
prolonged periods -  particu larly  in patients receiving multiple drug 
therapy. Secondly, as pointed out by U llrich  and Schnabel (1973), 
carbarn*ons formed from some compounds are unstable in the presence of 
oxygen: these might readily form peroxides which could lead to the
destruction of autoxidisable cell components. Clearly, therefore, 
further investigations of the nature of metabolite-cytochrome P450 
complexes and the factors influencing the ir formation and breakdown 
in vivo w ill be important.
CHAPTER EIGHT 
GENERAL DISCUSSION
General Discussion
Despite the frequency with which increased liv e r  weight and drug 
metabolising enzyme a c tiv ity  are encountered following the exposure of 
experimental animals to foreign compounds, the interrelationships  
between these phenomena and the production of liv e r in jury are 
incompletely understood. The present series of investigations suggests 
that a key factor influencing the production of both cytopathological 
and gross pathological changes by compounds causing liv e r  enlargement 
is the extent and the duration of the ir effects on drug metabolising 
enzyme a c tiv ity .
Significance of Enzyme Induction
Although the precise physiological role of the drug metabolising 
enzyme system remains uncertain, the importance of its  function in the 
metabolism of lip id -so luble  foreign compounds is generally accepted 
(Brodie 1962; Gelboin et al_., 1972) and, indeed, forms the basis fo r  
the interpretation of liv e r  enlargement accompanied by increased 
ac tiv ity  of these enzymes as representing an adaptive response. From 
the present resu lts , support for this interpretation derives not only 
from the apparently innocuous character of BHT, which produced 
persistent induction of the drug metabolising enzymes, but also from 
the converse situation , namely the ultimate development of 
pathological changes within the enlarged liv e r  when this was 
accompanied by only a transitory or weak induction of the drug 
metabolising enzymes, as in the case of safrole and Ponceau MX.
However, the concept of enzymic adaptation to chemical 
fluctuations in the environment has a broader basis than the changes 
e lic ite d  by foreign compounds in the ra t l iv e r . Thus, the maintenance
of homeostasis in a non-constant environment necessitatesf both at 
c e llu la r and tissue leve l, the continual regulation and adjustment of 
the myriad of metabolic processes occurring in the body. Such 
control operates ultim ately via changes in enzyme a c tiv ity . From 
early studies with bacteria i t  is known that an important regulatory 
mechanism involves the induction or repression of the synthesis of 
specific enzyme proteins mediated by changes in concentration of 
either th e ir  substrate or reaction product in catabolic and anabolic 
sequences respectively (Davis, 1961; Jacob and Monod, 1961). A w ell- 
known example is the induction of 3-galactosidase that follows the 
transfer of E.coli grown in a lactose-free medium to one containing this 
sugar as the sole carbon source. This response enables continued
•  r  '
survival under otherwise hostile conditions (Jacob and Monod, 1961). 
Comparable examples are, of necessity, less easy to identify  in 
m ultice llu lar organisms but several examples of substrate-mediated 
enzyme induction are well documented. A case in point is the 
induction of tryptophan pyrrolase which follows a tryptophan load in 
rats (Knox, 1962), whilst the transfer of rats from a mixed d ie t to one 
high in carbohydrate or protein results in the induction of 
carbohydrate (Fitch and Chaikoff, 1960) and protein (Schimke et a l .
1968) metabolising enzymes respectively. Induction of the drug 
metabolising enzymes following the intake of foreign compounds appears 
to be analagous. I t  d iffe rs  in being directed specifica lly  towards 
the removal from the body of substances of no nutrient value rather 
than to the u tilis a tio n  of nutrient materials, but in view of the 
rap id ity  with which lip id-soluble foreign compounds might otherwise 
accumulate within the body (cf Butler, 1958), such a function may 
be equally v ita l to the well being of the organism.
I t  is important to recognise, however, that owing to the low 
substrate specific ity  of the drug metabolising enzyme system, an 
increase in its  a c tiv ity  may a lte r  the rate of metabolism not only of a 
wide range of foreign compounds but also of certain physiologically 
active endogenous substances, notably steroid hormones and vitamin D 
(Brooks et al_., 1972; Hunter, 1974; Janz and Schmidt, 1974; Parke, 1972; 
Silver-, 1974). Moreover, drug metabolism is not always 
synonymous with drug detoxication: in a number of instances metabolites 
possess greater re ac tiv ity  than the parent compound and the hazard from 
such substances may be increased by prior exposure to enzyme inducing 
agents (De Matteis et a]_., 1974; G ille tte  e t a K , 1974; Mitchell e t a l . ,  
1973; Wright & Prescott, 1973)These considerations would indicate that 
although drug metabolising enzyme induction may be regarded as an 
adaptive phenomenon-in so fa r  as the inducing agent is concerned, there 
are situations in which i t  may not be en tire ly  without adverse 
consequences for the organism.
Significance of Liver Enlargement
Whilst i t  is well known that induction of drug metabolising 
enzymes is usually accompanied by enlargement of the liv e r , i t  is 
noteworthy that this change also accompanies the protein (Hurvitz and 
Freedland, 1968) and carbohydrate (Allen and Leahy, 1966; Bender e t a l . ,  
1972) mediated enzyme induction referred to above. During pregnancy 
and lactation in the ra t the maternal liv e r  enlarges and this e ffe c t, 
both morphologically and in terms of chemical composition, shares 
several features in common with the changes occurring in drug-induced 
liv e r  enlargement (Wilson e t al_., 1970). The extent of liv e r  
enlargement in nephrosis is proportional to the degree of albuminuria 
and presumably reflects a compensatory stimulation of hepatic albumin
synthesis (Lipmann et a K , 1952; Marsh and Drabkin, 1958). I t  seems 
reasonable to conclude, therefore, that in such situations 
enlargement of the liv e r  is primarily the result of an increased 
functional capacity (Goss, 1967). The observed temporal and dose- 
relationships between increases in drug metabolising enzyme a c tiv ity  
and liv e r  weight (Argyris and Magnus, 1968; G ilbert and Go!berg, 1965; 
Hoffman et a l . ,  1970, 1971; S e ife rt and Vacha, 1970) suggest that in 
the presence of enzyme induction and the absence of histopathological 
change, drug-induced liv e r  enlargement may also be considered prim arily  
as a consequence of increased functional capacity. The results of the 
present long-term studies with BHT are consistent with such a view. In 
fa c t, the absence o f histopathological change and the ready re v e rs ib ility  
of the liv e r  enlargement indicates that, although the precise nature of 
the stimulus remains unknown, the liv e r  growth produced by BHT cannot 
per se be regarded as an adverse effec t.
An enlarged but h isto logically  normal liv e r  may also result from 
exposure to compounds which do not cause an induction of the 
drug metabolising enzymes. In such circumstances there is no obvious 
hyperfunctional basis for the liv e r  response since there is no evidence 
that compounds producing this response are only those whose metabolism 
is mediated via enzyme systems other than the microsomal 
drug metabolising enzymes. The la t te r ,  on the contrary, are known to 
play an important role in the metabolism of several such compounds, e.g. 
safrole (Casida et al_., 1966); coumarin (Feuer, 1970; Gibbs et a l . ,
1971) and d ie ld rin  (Parke, 1968). Moreover, pathological changes in the 
liv e r  are known to occur following the chronic administration of a 
number of compounds producing liv e r  enlargement in the absence of drug 
metabolising enzyme induction (see Grasso et a K , 1974). I t  seems c lear,
therefore, that liv e r  enlargement in the absence of enzyme induction 
cannot be regarded as adaptive or hyperfunctional in the sense 
outlined e a rlie r .
The results obtained with safrole and Ponceau MX support this 
contention, for in both cases the dissociation of liv e r  enlargement 
from drug metabolising enzyme induction was paralleled by the 
appearance of histochemical changes indicative of cytological injury  
(Grasso et al_., 1974). S im ilarly, cytological evidence of damage 
involving mitochondrial changes was f i r s t  noted in the enlarged liv e r  
produced by d ie ldrin  at a stage where drug metabolising enzyme a c tiv ity  
had fa llen  to control levels (Hutterer et al_., 1969). I t  is also 
noteworthy that pathological changes do not develop in the enlarged 
liv e r  produced by 4-methylcoumarin -  a potent inducer of the 
drug metabolising enzymes (Feuer and Granda 1970; Feuer et al_., 1973) - 
whilst the reverse is true for the parent compound, coumarin.
Such results raise the possib ility  that the apparent in a b ility  of 
the liv e r  to increase -  or to sustain an increase in -  its  capacity for 
the metabolism of these compounds may be causally related to th e ir  
hepatotoxicity. Additional evidence that this may be so derives from 
dose-response studies with some inducers of the drug metabolising 
enzymes. In these studies (G ilbert and Golberg 1965; Golberg 1967; 
Hoffmann et al_., 1970, 1971), the degree of liv e r  enlargement and enzyme 
induction increased lin early  with the dose until a level of 
administration was reached above which no further increases occurred. At 
this point, the liv e r  concentration of the administered compound rose 
sharply and symptoms of to x ic ity  were observed. An analogy might be 
drawn between this situation and that obtaining a fte r the demise of the 
enzyme induction produced by safrole and d ie ldrin  or that resulting from
the in it ia l  absence or inadequacy of enzyme induction as in the case 
of coumarin and Ponceau MX. Such an argument was advanced by 
Golberg (1970) but to establish its  va lid ity  some comparative 
pharmacokinetic data fo r inducers and non-inducers of the drug 
metabolising enzymes, and some knowledge of the mechanisms underlying 
the absence or fa ilu re  of th is enzyme induction would be necessary.
I t  would also be useful to establish whether or not changes in the 
a c tiv ity  of extra-hepatic sites of drug metabolism paralle l the 
disturbance of the equilibrium between intake and excretion that may 
accompany the demise of the enzyme induction produced by safro le. I t  
may be, of course, that the changes -  or lack of changes -  in drug 
metabolising enzyme a c tiv ity  play no role in the pathogenesis of the 
lesions produced by the compounds in question, or that the primary 
biochemical lesion involves other enzyme systems. I t  w ill be of 
particular in terest in th is context to determine whether pathological 
changes develop when these compounds are administered a t levels below 
those necessary to produce liv e r  enlargement. Despite these 
uncertainties, however, the available evidence suggests that liv e r  
enlargement in the absence of drug metabolising enzyme induction may 
be indicative of incip ient hepatotoxicity and is to be contrasted 
with the 'hyperfunctional1 enlargement discussed e a r lie r . Moreover, 
i t  is evident that the biochemical and histochemical c r ite r ia  
employed in the present studies may provide a means of distinguishing 
between these two a t an early stage when both present h isto log ically  as 
enlarged but otherwise normal liv e rs .
The possible value of the measurement of induced changes in 
drug metabolising enzyme a c tiv ity  as an index of hepatotoxicity has 
recently been suggested (De Matteis et al_., 1974; Feuer e t al_., 1974) 
and the present results provide some additional support for th is view.
However, the biphasic response produced by safrole ■? and that 
reported for d ieldrin  (Hutterer et a l . ,  1969) -  emphasises that very 
short observation periods as advocated by De Matteis e t al_. and 
Feuer e t al_. may give rise to misleading results and clearly  
illu s tra tes  the fa llacy  of the assumption made by P la tt and Cockrill 
(1967) that the changes they observed a fte r 14 days would be 
representative of the changes occurring a fte r chronic administration. 
Furthermore, i t  is possible that the conclusions drawn in the preceding 
discussion may apply only to the ra t. Several agents known to produce 
sustained stimulation of drug metabolism in mouse liv e r , e.g. 
phenobarbitone and d ie ld rin , do give^rise to gross pathological 
changes in th is organ(Thorpe & Walker,1973; Wright e t al_., 1972).
r •
Although the metabolism of d ie ld rin , fo r example, is known to be 
q u a lita tive ly  d iffe ren t in the mouse and the ra t (Baldwin et a l . ,  1972), 
i t  remains to be seen whether the type of results obtained in the present 
study can be reproduced in other species less prone to the development of 
l iv e r  pathology than the mouse.
Hepatic Nodules
In addition to histopathological changes in the liv e r , including 
fa tty  change, hydropic degeneration and cell necrosis, both safrole and 
Ponceau MX gave rise to p ro life ra tive  lesions appearing grossly as 
hepatic nodules. Such lesions have been regarded by some pathologists 
as neoplastic (Bonser and Roe, 1970; Ikeda e t al_., 1966) but by others 
as hyperplastic (Grasso 1970; Grasso et al_., 1969). In this context i t  
is important to note that cell necrosis was observed prior to the 
appearance of the nodules induced by safrole and Ponceau MX. A paralle l 
might therefore be drawn between this situation and the induction of
cirrhosis by carbon tetrachloride in the ra t (McLean et al_., 1969;
H artro ft, 1964) in which case cell necrosis is evident several weeks, 
before the development of c irrho tic  nodules. In this experimental 
model the nodules vary in size but are uniformly distributed throughout 
a ll lobes of the liv e r  and accompanied by fib rosis . In contrast, the 
nodules induced by safrole and Ponceau MX were selectively sited in 
the major lobes, were few in number and were not usually accompanied by 
extensive fib ro s is . The reasons fo r the selective siting of these lesions 
are not known. I t  seems s ig n ifican t, however, that the cell degeneration 
produced by Ponceau MX and safrole was irregularly  distributed  
whereas in the case of carbon tetrachloride, cell necrosis occurs with
i
regu larity  in a ll lobules. These considerations suggest that the nodules
• f
induced by safrole and Ponceau MX represent a reactive hyperplasia and 
possess a pathological significance which is not dissim ilar to that of 
cirrho tic  nodules. As with c irrho tic  nodules in the human (W illis , 1967), 
the hyperplastic nodules in the ra t are prone to the development of 
neoplasia, although th is event appears to be rare in the case of Ponceau 
MX (Grasso e t 1975). The majority of the nodules appeared to be the 
result of controlled growth, both because of the uniform arrangement of 
the cells in cord-like structures resembling normal l iv e r , and because 
the m itotic a c tiv ity  appeared, in general, to be of the same order as that 
seen in untreated controls. Nevertheless, the heterogeneous enzyme 
histochemical appearance of the nodules suggests that they comprise a 
number of d iffe rin g  cell populations. The possib ility  cannot be 
excluded that the enzyme-deficient foci within the nodules may be in some 
way analagous with those observed a t an early stage in the livers  of rats 
treated with several established hepatocarcinogens (Goldfarb, 1973;
Kitigawa and Sugano, 1973; Scherer e t al_., 1972).
The significance of the biochemical changes observed in the 
nodules induced by safrole and Ponceau MX is not clear. In the e a rlie s t  
Ponceau MX nodules studied (56 weeks) however, the apparent inverse 
relationship between drug metabolising enzyme a c tiv ity  in the nodule and 
in the adjacent liv e r  is suggestive of a biochemically 'regenerative' 
role for the nodules. This would imply that the development of 
nodules represents a response not only to the total loss of functional 
units ( i .e .  the cell necrosis referred to above) but also to the 
reduced functional efficiency of the remaining units. Although no such 
inverse relationship was observed at weeks 66, 70 and 80, the fa ir ly  
consistently higher substrate metabolising capacity of the Ponceau MX 
nodules in comparison with the adjacent liv e r  is equally consistent
t
with a 'regenerative' function and contrasts with the very low levels  
of drug metabolising enzyme a c tiv ity  reported for a number of ra t H ver  
tumours (see below). I t  is noteworthy, however, that rapidly growing 
non-neoplastic liv e r  tissue e.g. in the neonate (see review by Done,
1964) or following partia l hepatectomy (Fouts et al_., 1961) is also 
characterised by reduced levels of drug metabolising enzyme a c tiv ity .
The im plication, therefore, is that the nodules (at least those induced 
by Ponceau MX) represent a fa ir ly  stable ( i .e .  non-dividing) ce ll 
population and this is supported both by the histological evidence 
discussed e a rlie r  and by the biochemical results which show l i t t l e  
change in the characteristics of the nodules in terms of th e ir drug 
metabolising enzyme a c tiv ity  between weeks 56-80 (see Tables 5 .4 -5 .6 ).
The above considerations must be tempered by the fact that when 
expressed on a per gram tissue basis, the substrate metabolising 
capacity of the nodules was not appreciably greater -  and in the case 
of the safrole nodules was in fact less than that of the adjacent l iv e r .
Moreover, certain components of the drug metabolising enzyme system
were present at very low levels in the nodules, resulting in a
departure from the normal quantitative interrelationships between 
rverife
d iffe ren t compounds of the system. Whether or not these quantitative  
abnormalities lead to qualita tive  differences in the manner in which 
foreign compounds are metabolised in the nodule has not been resolved 
I f  this were the case, i t  is possible that a lteration  of the 
metabolism of the nodule-inducing compound might resu lt in the 
increased production of a carcinogenically active derivative, thereby 
predisposing the nodule to the development of cancer. Another factor 
l ik e ly  to influence the drug metabolic capacity of the nodule is the 
blood supply i t  receives, for this w ill govern the b io ava ila b ility  
within the nodule of the agent responsible for its  induction. I t  
would be of in terest, therefore, to determine whether the blood 
supply to the nodules is atypical either in terms of total flow rate  
or in the ra tio  between its  venous and a rte ria l a fferent components 
For a better assessment of the functional significance of the nodules 
a method for gauging th e ir metabolic a c tiv ity  in vivo is c learly  
necessary. In this context a useful clue might be provided by 
2-acetyl aminofluorene (AAF) which binds to ce llu la r macromolecules 
only a fte r  two activation steps, one involving the drug metabolising 
enzyme system and the other occurring in the cytosol. Thus, nodule- 
bearing rats could be administered with suitably labelled AAF and 
nodular and non-nodular liv e r  subsequently analysed for covalently 
bound fluorene residues. The value of such an approach would, of 
course, be reduced i f  there were qualita tive  differences between 
nodule and adjacent liv e r  in th e ir metabolism of AAF.
I t  was not possible to make a direct comparison of the s a fro le -  
and Ponceau MX-induced liv e r  nodules with frankly neoplastic liv e r .  
However, as mentioned in 6 .1 , the hyperplastic liv e r  nodules induced 
by AAF have been implicated as d irect precursors of the malignant liv e r  
tumours produced by this compound. Such nodules differed from those 
produced by safrole and Ponceau MX both in the time of th e ir  
appearance (8-16 weeks v s .,45-65 weeks) and in th e ir  
biochemical and morphological characteristics. In both the nodular and 
the adjacent non-nodular liv e r  from AAF-treated rats , a ll components of 
the drug metabolising enzyme system were present a t markedly reduced 
levels -  expressed either on a per gram tissue or on a specific  
a c tiv ity  basis. The contrast between this situation and that
f _
obtaining in Ponceau MX-induced nodules,is .illu s tra ted  by Fig. 8 .1 . This 
apparent lack of d iffe re n tia l between nodular and adjacent non-nodular 
l iv e r  in the AAF-treated rats probably reflects the fact that in these 
animals, the liv e r  adjacent to the large nodules was i ts e lf  largely  
composed of microscopic areas of hyperplasia.
Existing publications indicate that drug metabolising enzyme 
a c tiv ity  in a number of tumour systems, including several so-called 
minimal deviation hepatomas, is either very low or absent (Adamson and 
Fouts, 1961; Brown e t al_., 1971; Hart et al_., 1965; Neubert and 
Hoffmeister, 1960). Thus the results obtained with the AAF-induced 
hyperplastic nodules appear to resemble those reported for neoplastic 
l iv e r . On the other hand, the high specific a c tiv ity  of several 
pathways of drug metabolism in the Ponceau MX nodules and the 
apparent preservation in the safrole nodules of the unusual 
interrelationships between components of the drug metabolising enzyme 
system typ ica lly  produced in 'normal* liv e r  by safrole, are in
251
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contrast with such results. Morphologically, the nodules produced 
by each of the compounds were sim ilar in so fa r as a ll were 
composed of re la tiv e ly  well ordered, enlarged hepatocytes. However, 
m itotic figures were prominent in the AAF nodules and in the male rats , 
the cells of those nodules contained enlarged vesicular nuclei.
Although th e ir  precise significance is uncertain, sim ilar nuclear 
changes are produced in ra t liv e r  by a number of hepatocarcinogens 
(Jackson 1974; R ouiller, 1964).
Overall, the results obtained might be construed as evidence that 
the liv e r  nodules induced by safrole and Ponceau MX and those induced 
by AAF are en tities  of fundamentally d ifferen t biological significance.
In particu lar, the difference in th e ir  respective times of appearance* 
both in absolute terms and in relation to the appearance of other 
pathological changes in the liv e r  (see Table 8 .1 ), support this  
construction. With regard to the biochemical results, however, i t  is 
recognised that measurements of absolute levels of enzyme a c tiv ity  may 
bear l i t t l e  re lation to the degree to which these nodular lesions 
deviate from normal liv e r  (Wu, 1967). A potentially more valuable 
approach would involve the study of metabolic regulation w ithin the 
nodules since loss of normal regulatory function is a characteristic  
of neoplastic tissue (P ito t, 1966). The inducib ility  of drug 
metabolising enzymes has been studied in a number of tumour systems. 
Conney and Burns (1963) demonstrated induction of azo-dye 
N-demethylase by 3-methylcholanthrene in Morris hepatoma but no such 
response could be evoked in primary azo-dye-induced hepatomas (Conney 
et al_., 1956). According to Hart et al_. (1965), phenobarbitone e lic ite d  
increases in drug metabolising enzyme ac tiv ity  in a series o f highly 
differentiated  hepatocellular carcinomas, although these increases 
were much smaller than in the surrounding liv e r tissue and the
metabolism of several substrates remained unaffected. I t  would be of 
in terest to extend this type of observation to the nodules induced by 
safrole and Ponceau MX and to compare the results so obtained with 
those o f paralle l observations on AAF-induced hyperplastic nodules and 
hepatocellular carcinomas. In the * pres en-t study, drug metabolising 
enzyme a c tiv ity  in the nodules was in fact measured in the presence of 
an effector o f the system, i .e .  the test compound. The possible 
significance of this might have been gauged by comparing levels of 
drug metabolising enzymes in nodules from rats maintained on the test 
compound un til immediately prior to determination of enzyme a c tiv ity ,  
with those in rats allowed a prior period of recovery on control d ie t.
However, a characterisation of the biochemical properties of the 
safrole-and Ponceau MX-induced nodules must c learly have a broader 
basis than studies on the drug metabolising enzyme system. Other 
aspects o f liv e r  function require investigation. Information on the 
regulation o f intermediary metabolism would be valuable particu larly  
since data of this type has been collected for a number o f tumour 
systems (see P ito t, 1966) and for the AAF-induced hyperplastic nodules 
(see Farber, 1973b). In the specific case of the la t te r ,  Epstein et 
a l . (1967) have reported that glycogen in the nodule cells is
re la tive ly  more stable both to.a 24 hour fast and to the
administration of glucagon than in the cells of the surrounding parenchyma 
On the other hand, Teebor and Seidman (1970) found that w hilst the 
specific a c tiv ity  of glucose-6-phosphatase was lower in 12-week nodules 
than in the surrounding liv e r , the percentage induction of a c tiv ity  
following a 24 hour fast or the administration of triamcinolone was very 
sim ilar in both tissues. In the interpretation of such results the
duration of the AAF pretreatment is lik e ly  to be a c r it ic a l factor.
A number of other known properties of the AAF-induced nodules 
might afford a basis for comparisons of these nodules with those 
induced by safrole and Ponceau MX. Thus, Epstein et a l. (1969/70) 
have reported that DNA in the cells of the nodules shows a number of 
abnormalities not present in DNA from the surrounding liv e r  parenchyma. 
S lifk in  et a l. (1972) found that cells from the nodules, in contrast to 
those in the adjacent parenchyma, could be successfully grown in v it ro . 
Transplantation of the AAF nodules is not possible until islands of 
malignancy can be seen histo logically  within the nodules (Farber, 1973b 
Reuber and Firminger, 1963): nothing is known of the 
transplantab ility  of the safrole and Ponceau MX nodules at any stage in  
th e ir development. F in a lly , i t  has recently been shown that a specific  
antigen is reproducibly associated with the liv e r  nodules induced by 
AAF but not with the'surrounding parenchyma or with pro liferating  
liv e r  tissue following partia l hepa'tectomy (Farber, 1974). Although 
the significance of this remains to be established, i t  would be of 
interest to determine whether any immunological changes are associated 
with the development of nodules in the livers of rats treated with 
safrole or Ponceau MX.
Despite the lim itations of the present study, the results 
obtained point to certain major differences in the characteristics of 
the liv e r  nodules induced by safrole and Ponceau MX and those induced 
by the hepatocarcinogen, AAF (see Table 8 .1 ). These differences ex ist 
not only a t the pathological and biochemical level but also in the 
behaviour of the nodules a fte r  withdrawal of the test compound. Thus, 
i t  is known that despite cessation of treatment, quite a high 
proportion of the early hyperplastic nodules induced by AAF progress 
to frank malignancy (Epstein e t aj_., 1967; Teebor and Becker, 1971).
TABLE 8.1
Summary of Hepatic Changes Produced by Safrole, 
Ponceau MX and AAF
Safrole/Ponceau MX AAF (Male)
Liver enlargement + -
Induction of drug 
metabolising enzymes + then - -
Histopathological.changes + +
Time o f appearance of 
nodules 45-65 weeks 8-16 weeks
Time of appearance in 
re lation  to other 
histopathological changes after/concurrent before/concurrent
Drug metabolising enzyme 
a c tiv ity  in nodules high low
Nuclear changes in nodules - +
M itotic figures in nodules rare frequent
Histology of nodules regular regular
On the contrary, the nodules induced by Ponceau MX - which in any case 
appear a t a much la te r  stage - do not appear to progress (Grasso et aU  
1975). No sim ilar studies on progression have been reported for safrole 
induced nodules but th e ir  s im ila rity  to the Ponceau MX nodules, both 
biochemically and pathologically, suggests that th e ir behaviour would 
resemble more probably these nodules rather than those induced by AAF.
Since pathological changes in the liv e r  are produced both by AAF 
and by safrole and Ponceau MX, the significance of these changes in the 
development of tumours is d if f ic u lt  to discern. However, i t  is known 
that, on cessation of administration, AAF-induced pathological changes 
(apart from the nodules) regressed whereas the nodules progressed to 
malignancy (Reuber, 1965). In this case therefore, the possib ility  
arises that malignant transformation may be independent of the other 
pathological changes produced. This appears less lik e ly  in the case of 
safrole and Ponceau MX. With these compounds, the early biochemical 
evidence of impaired functional capacity and the subsequent appearance 
of histopathological changes suggests that the ultimate development of 
nodules may represent a response to chronic, toxic liv e r  in jury. In 
such a situation i t  should be possible to establish a 'no-e ffect' level 
which would preclude the development of these nodules. Furthermore, 
i f ,  as appears to be the case, the development of nodules is a 
necessary prerequisite for the development of tumours, then the same 
'no -e ffect' level would also preclude the production of tumours.
Further experimental work is clearly required to establish more firm ly  
this proposed sequence of events. I f  this were established i t  would 
indicate that the neoplasia induced by safrole and Ponceau MX arises 
ind irectly  rather than as a consequence of 'chemical carcinogenesis' 
in the sense in which this term is commonly used. Such a d istinction  
in the mechanisms by which chemicals induce neoplasia is envisaged in
a recent publication from the W.H.O. (1974).
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Key to Tables
This section contains the data from the long-term feeding studies on 
which were based Figs. 3 .2 , 4 .2 , 5 .2 , 6.3 and 6.4 and Tables 3.3, 4 .3 ,
5.3 and 6.3. Included also are the data which formed the basis of 
Tables 4 .4 , 5.4 - 5.6 and 6.4 relating to the liv e r  nodules induced by 
safro le, Ponceau MX and 2-acetyl aminofluorene.
Unless stated otherwise, a ll values represent the mean and standard 
error o f the mean of observations on groups of 4 rats. Significant 
differences between values for control and treated groups are indicated 
as fo llow s:- a = p<0.05, b = p<0.01 and c = p<0.001. Values not so 
marked do not d iffe r  s ign ifican tly  a t the 5% (p<0.05) leve l. In Tables 
A6 -  A10, where values for liv e r  nodule tissue are compared both to 
values for adjacent, non-nodular liv e r  and for untreated control l iv e r ,  
the su ffix  ns is used to indicate means not d iffe rin g  sign ifican tly  from 
each other.
The following units are used throughout:-  
Body weight -  g 
Liver weight -  g
Relative liv e r  weight -  g liver/100  g body weight 
Succinate dehydrogenase - ymol INT reduced/g liver/minute  
Glucose-6-phosphate dehydrogenase - ymol NADP reduced/g l iv e r /  minute 
Ethylmorphine N-demethylase -  ymol formaldehyde produced/g liver/hour  
Aniline 4-hydroxylase - ymol 4-ami nophenol produced/g liver/hour 
Biphenyl 4-hydroxylase - ymol 4-hydroxybiphenyl produced/g liver/hour
7
continued o v e r le a f...
Biphenyl 2-hydroxylase -  nmol 2-hydroxybiphenyl produced/g liver/hour 
' NADPH-cytochrome c reductase - ymol cytochrome c reduced/g liver/m inute  
Cytochrome P450 -  nmol/g liv e r  
Cytochrome b5*- nmol/ g liv e r
455nm absorption maximum -  AOD 455-490nm/g liv e r  or /g  microsomal protein 
Microsomal protein -  mg/g liv e r  
Total liv e r  protein -  mg/g liv e r
/
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Measurements of Some Drug Metabolising Enzymes and Related 
Parameters at Intervals During the Chronic Administration 
of 2-Acetyl aminofluorene (AAF) to Male Rats*
WEEKS
1 8 16
Control 6.14 ± 0.31 10.28 ± 0.33 10.36 + 0.77
Liver Weight
AAF 4.98 ±
b
0.04 9.04 ± 0.50 17.93 +
b
1.92
Control 3.32 ± 0.04 2.86 ± 0.13 2.42 + 0.11
Relative Liver Weight
AAF 3.76 ±
b
0.06
c
4.28 ± 0.11 6.54 +
c
0.49
Control 45.8 ± 3.4 45.8 ± 0.5 42.4 + 3.4
Ethylmorphine N- 
demethylase AAF 39.9 ± 2.1
c
32.9 ± 1.2 24.4 +
b
2.6
Control 2.95 ± 0.29 2.54 ± 0 . 1 3 2.98 + 0.12
Aniline 4-hydroxylase
AAF 2.10 ±
a
0.12
b
1.96 ± 0.03 1.13 ±
c
0.13
Control 4.97 ± 0.42 4.41 ± 0.08 2.95 + 0.07
Biphenyl 4-hydroxylase
AAF 6.72 ±
a
0.30
a
4.85 ± 0.12 2.99 + 0.31
Control 0.21 ± 0.05 0.02 ± 0.00 0.02 + 0.00
Biphenyl 2-hydroxylase
AAF 0.29 ± 0.06
c
0.09 ± 0.00 0.09 +
c
0.01
Control 0.68 ± 0.03 1.25 ± 0.04 1.24 ± 0.06
NADPH-Cytochrome 
c reductase AAF 0.67 ± 0.04 1.21 ± 0 . 0 4 1.02 + 0.07
Control 19.0 ± 2.6 29.1 ± 2.3 34.8 + 2.1
Cytochrome P450
AAF 14.9 ± 2.0
b
17.5 ± 0.4. 14.2 +
c
0.8
Control 10.6 ± 0.7 13.5 ± 0.3 17.1 + 1.1
Cytochrome b5
AAF 14.3 ±
a
0.9 12.7 ± 0.3 14.2 +
a
0.6
'
Control 29.1 ± 1.5 31.3 ± 1.1 29.0 + 1.0
Microsomal protein
AAF 23.2 ±
b
0.5
b
25.6 ± 0.6 24.9 +
a
0.8
Control 5.52 ± 0.51 4.76 ± 0.37 4.44 + 0.11
Succinate dehydrogenase
AAF 5.31 ± 0.45 4.28 ± 0.07 3.04 ±
c
0.13
Control 244 ± 17 220 ± 3 209 + 4
Total protein .
AAF 218 ± 14
b
198 ± 4 178 +
b
5
See also Tables A10 and All
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TABLE All
Liver Weights o f Rats K illed  for Biochemical Studies 
on Liver Nodules (Tables A6-A10)
Liver Weight
Relative 
Liver Weight
Control 7.42 ± 0.78
a
2.17 ± 0.12
a
Safrole (wk. 85) 18.80 ± 3.83 8.02 ± 1.91
Control 7.97 ± 0.23
c
2.01 ± 0 . 1 7
c
Ponceau MX (wk. 66) 16.71 ± 0.96 6.49 ± 0.40
Control 7.80 ± 0.22
b
2.15 ± 0.07
b
Ponceau MX (wk. 70) 23.80 ± 3.47 8.25 ± 1.27
Control 8.71 ± 0.53
c
2.42 ± 0.16
c
Ponceau MX (wk. 80) 23.90 ± 2.99 10.31 ± 1.35
Control 11.17 ± 0.39
b
2.18 ± 0.04
c
AAF (Male wk. 22) 14.92 ± 0.85 5.67 ± 0.18
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